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Cardiac stem cells (CSCs) have been implicated as the most suitable source of stem cells for 
regenerating the diseased heart. However, diabetes is known to cause a progressive loss in the 
functional efficacy of CSCs. The mechanism behind this loss is unclear. MiRNAs are small, 
non-coding RNA molecules that regulate genes at the post-transcriptional level. In this study, I 
used a mouse model of type-2 diabetes to investigate if miRNAs are dysregulated in diabetic 
CSCs, and whether genetic manipulation of such miRNAs can provide novel insights into their 
pathophysiological role in improving the function of these cells in the diabetic condition.  
Sca-1+ CSCs were isolated from type-2 diabetic (n=6) and non-diabetic (n=6) db/db mice. 
Among 598 miRNAs evaluated by an n-counter miRNA expression assay, the expression 
profiles of 16 miRNAs were significantly altered in the diabetic condition. Among these 16 
miRNAs, miR-329 (1.7 ± 0.9 (P=0.01)), miR-376c (2.8 ± 0.8 (P=0.01)) and miR-495 (1.8 ± 0.6 
(P=0.02)) were significantly upregulated while miR-30c (0.4 ± 0.1 (P=0.03)) was significantly 
downregulated in diabetic CSCs. These miRNAs are involved in cell proliferation and survival. 
Mass spectrometry analysis predicted pro-apoptotic VDAC1 as a direct target for miR-30c and 
cell cycle regulator CDK6 as the direct target for miR-329, -376c and -495. Western blot 
analyses confirmed a marked increase in VDAC1 expression (3.2 ± 0.6 (P=0.01)) and a 
significant decrease in CDK6 expression (0.7 ± 0.1 (P=0.04)) in the diabetic CSCs. Moreover, 
luciferase assays confirmed VDAC1 as the direct target for miR-30c. An overexpression of 
miR-30c in diabetic CSCs showed a marked reduction in VDAC1 (0.7 ± 0.1 (P=0.03)) and 
cleaved caspase-3 (0.6 ± 0.1 (P=0.04)) protein expression, as well as reduced caspase-3/7 
activity (0.6 ± 0.1 (P<0.01)), suggesting that genetic manipulation of miRNAs could be 
beneficial in promoting CSC survival and function. Altogether, my results suggest that altered 
miR-30c expression may contribute to the reduced functional efficacy of CSCs in the diabetic 
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CHAPTER 1: INTRODUCTION 
The purpose of this thesis is to investigate the expression of microRNAs (miRNAs) in cardiac 
stem cells, as well as to demonstrate their pathophysiological role within these cells using a 
mouse model of type-2 diabetes mellitus (T2DM). In this section, a brief review of 
cardiovascular disease (CVD) will initially be described, followed by the current 
understanding of stem cells and their application as a viable treatment option for various 
diseases, including CVD. The characteristics of cardiac stem cells will then be discussed and 
compared to other stem cell subtypes in terms of their ability to promote cardiac repair and 
regenerate heart tissue. The effect of diabetes on cardiac stem cells will be highlighted as a 
limiting factor to their effectiveness as a therapeutic agent. The basic regulatory mechanisms 
associated with maintaining cardiac stem cell number and function will then be outlined. This 
will lead to the suggestion that manipulating the expression of molecular regulators such as 
miRNAs may be a better tool for maintaining the efficacy of cardiac stem cells, particularly 
for the purposes of reversing the deleterious effects of diabetes on these cells. Finally, the 
current understanding of miRNA will be described, as well as experimental evidences that 
have demonstrated their physiological and pathophysiological roles in cardiac stem cells, 
leading to the objectives and hypothesis of this study. I have previously published a review 
article that describes this background information in detail (Purvis et al., 2015). 
 
1.1 Cardiovascular disease 
1.1.1 Characterization and pathology 
Cardiovascular disease (CVD) is currently the leading cause of death in the world for both 
men and women and is responsible for approximately 31% of deaths each year (WHO, 2018). 
This disease encompasses a number of pathological conditions that affects the heart and its 
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primary blood vessels. In its most common form, CVD can cause a build-up of fatty deposits 
inside arteries in a condition known as artherosclerosis. This can lead to harmful blood clots, 
which damage organs supplied by the affected artery due to a lack of oxygen (Stocker and 
Keaney, 2003). CVD is deadly, because aside from causing direct damage to the heart, it can 
also cause complications with other well-known diseases, such as diabetes mellitus. When 
confounded with T2DM, CVD can cause pathological changes to the myocardium. Studies 
have shown that regardless of previous history, T2DM dramatically increases the incidence of 
myocardial infarction (MI), characterized by the sustained ischemia and subsequent loss of 
cardiomyocytes (Mendis et al., 2010; Haffner et al., 1998).  
Despite significant advances in the therapeutic treatment of CVD, the prevalence of heart 
failure continues to rise. A potential reason for this is that although CVD is traditionally 
treated by limiting scar formation or by preventing adverse remodelling, these methods do not 
account for the inevitable loss of cardiomyocytes that reduce cardiac function in CVD patients 
(Chiong et al., 2011; Zannad et al., 2009). It has become clear that this loss of 
cardiomyocytes can only be treated by replacing the damaged cells or regenerating the heart 
tissue. In recent years, stem cell therapies have been found to promote the regeneration of 
heart tissue and also improve cardiac function (Li et al., 2009; Caplan et al., 2006). This 
therefore indicates that the application of stem cells may be a novel option for the treatment of 
CVD. 
 
1.2 Introduction to stem cells 
1.2.1 Background, definition and general function 
Stem cells have gained considerable amount of interest as a viable treatment option for 
patients with CVD, especially those resistant to conventional therapies (Segers and Lee, 
2008). They can be defined as undifferentiated cell precursors that may give rise to different 
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cell types in the body (Li and Xie, 2005). These cells regularly function in a process known as 
self-renewal which involves a combination of proliferation and differentiation, ultimately 
leading to the production of multiple daughter cells with different cell fates (Kiger et al., 
2001).  
 
1.2.2 The specificity of different stem cell subsets 
Stem cells are known to exist in a variety of different tissues where they each have a distinct 
phenotype. Accordingly, they can be separated into certain subsets and classified based on 
their tissue specificity. Among the most commonly researched stem cells are embryonic stem 
cells (ESCs), mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs). These 
stem cells are typically identified based on specific antigenic markers, as detailed in Table 
1.1. ESCs can be identified by targeting Oct4 and Nanog markers, while MSCs and HSCs can 
be identified by targeting Cluster of differentiation 105 (CD105) and Cluster of differentiation 
90 (CD90), respectively (Rodrigues et al., 2017; Ullah et al., 2015; Matsuoka et al., 2001). 
 
Table 1.1. Common antigenic markers of different stem cells 
 ESCs MSCs HSCs 
Common markers Oct4, Nanog CD105, CD90 CD34 
 
ESCs are derived from the inner mass of the blastocyst and typically contribute to the 
formation of the embryo, which is known to undergo organogenesis in early development 
(Rippon and Bishop, 2004). ESCs are therefore pluripotent, meaning they have the ability to 
differentiate into many cells of the body (Rippon and Bishop, 2004). Interestingly, they also 
have beneficial implications in maintaining organ function, as studies have shown that ESCs 
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routinely differentiate into cell lines that promote the formation of new blood vessels (Caspi 
et al., 2007; Gepstein, 2002; Kehat et al., 2001). However, the clinical application of ESCs is 
often limited by pathological complications in the patient, leading to a greater demand for the 
use of alternative stem cells in stem cell therapy.  
MSCs are a multipotent type of stem cell that are defined by their ability to adhere to plastic, 
as well as their high expression of certain antigenic markers (eg. CD90 and CD105). They are 
able to differentiate into ectodermal, mesodermal and endodermal cells based on their age 
(Ullah et al., 2015). Early forming MSCs have been shown to have a predisposition to 
differentiate into chondrocytes, adipocytes and osteocytes, while this differentiation potential 
declines at higher passages (Ullah et al., 2015). They can also be isolated more easily 
compared to other stem cell subtypes as they derived from many tissues including blood, 
placenta, heart, skeletal muscle, adipose tissue and bone marrow (Meirelles et al., 2006). 
MSCs are able to migrate towards damaged tissue and replace the dead cells through self-
renewal (Ullah et al., 2015). However, it is difficult to generate adequate numbers of 
functional MSCs for therapeutic purposes. This is because these cells lose their capacity for 
differentiation very quickly over time as they are cultured in vitro (Ullah et al., 2015). MSCs 
also contribute to the formation of the microenvironment in the bone marrow, which 
indirectly enhances the development of HSCs.  
HSCs are derived from the mesoderm and give rise to mature blood cells in a process known 
as hematopoiesis (Gunsilius et al., 2001). During this process, HSCs are able to differentiate 
into both myeloid and lymphoid blood cell lineages in the embryo, as well as in the adult. In 
adults, these cells are commonly found in the bone marrow, and commonly used for the 
restoration of bone marrow in patients with weakened immune systems, as well as those 
afflicted with malignant diseases that have undergone chemoradiotherapy (Congdon, 1957; 
Lorenz et al., 1951). 
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Resident stem cells have also been successfully isolated from a variety of tissues including 
bone marrow, peripheral blood, brain, liver and reproductive organs using validated isolation 
techniques (Asahara, 2000). Although they have a similar capacity for self-renewal as other 
types of stem cells, their growth potential and response to their microenvironment varies 
depending on the tissue source (Raveh-Amit et al., 2013). Resident stem cells are unique 
compared to other stem cell types in that they are tissue specific. They therefore hold great 
potential for stem cell therapy due to the possibility of stimulating differentiation of an in vivo  
population without the need for transplantation (Mimeault and Batra, 2008). However, there is 
an ongoing debate as to which type of stem cell is the best for tissue regeneration (Raveh-
Amit et al., 2013).  
 
1.2.3 Stem cell niche and microenvironment 
Stem cells reside in anatomical locations called niches that are specialized to regulate their 
maintenance and repair. The niche creates a microenvironment that reduces both stem cell 
depletion and excessive proliferation (Scadden, 2006). It does this by receiving stimuli from 
other cells, as well as the extracellular matrix that activate or repress genes and transcriptional 
pathways. These interactions can augment the capacity of stem cells for self-renewal (Ferraro 
et al., 2010). The components of the niche are conserved even in the temporary absence of the 
stem cells which it is housing, allowing for the recruitment of exogenous stem cells to a pre-
existing niche site. The primary components of the stem cell niche include stromal cells and 
extracellular matrix that provide scaffolding support and anchor the stem cell, as well as blood 





1.2.4 Brief history of stem cell research 
The history of stem cell research has been complex, but rewarding. It is unclear when exactly 
the first stem cells were discovered. However, in 1978, Prindull and colleagues were reported 
to have identified a population of HSCs in human cord blood which were thought to be 
capable of forming colonies (Prindull et al., 1978). Shortly after this, Martin Evans was the 
first to identify pluripotent cells in mice blastocysts (Martin, 1981). These cells would later be 
known as ESCs, and this was the first time that stem cells were discovered in mice. Then in 
1998, James Thompson successfully isolated human ESCs and maintained their growth in 
vitro in efforts to develop the first human ESC cell line (Thompson et al., 1998). Following 
the discovery of MSCs in 1999, researchers found that the proliferation and differentiation of 
adult mouse stem cells could be manipulated to generate different types of cells such as bone, 
cartilage, fat, tendon and muscle (Pittenger et al., 1999). These initial findings lead to the 
development of many programs investigating the role of stem cell therapies as potential 
treatments for conditions such as Parkinson’s disease, muscular dystrophy, cancer and heart 
failure (Darabi et al., 2008; Wernig et al., 2008; Laflamme et al., 2007). Since then, ESCs 
have been found to successfully treat spinal cord injury (2010) and blindness (2012) (Stem 
cell timeline, 2015). This showed that by effectively harnessing their self-renewal capability, 
stem cells could thus be used as a tool for clinical applications.  
 
1.2.5 Therapeutic application of stem cells 
Stem cell therapy has been implicated as a viable treatment option for certain diseases, such 
as cancer and CVD (Goradel et al., 2017; Park et al., 2017). In addition, experimental 
evidences have strongly indicated the clinical use of stem cells in reversing the effects of 
neurodegeneration (Kim and Vellis, 2009). The transplantation of bone marrow has become 
the most widely used form of stem cell therapy to treat cancer (Karanes et al., 2008). It was 
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first introduced as a secondary treatment to attenuate the non-specific cytotoxic effects of 
conventional chemotherapy. This is due to the fact that bone marrow contains a pool of 
undifferentiated CD34+ HSCs (Table 1.1) that can migrate to the damaged site after 
transplantation (Copelan, 2006). Through self-renewal, these stem cells are able to re-
constitute many blood-forming and immune cells that are depleted in cancers such as 
leukemia and lymphoma, after chemotherapy (Copelan, 2006). However, this treatment has a 
major limitation, as it can cause acute graft versus host disease (GVHD) (Mielcarek et al., 
2003). GVHD is a disease in which immune cells of the donor damage host epithelial cells 
after allogeneic transplantation. It occurs in 35-50% of all HSC transplant patients and may 
lead to abdominal pain and liver failure (Jacobsohn and Vogelsang, 2007). 
The potential of stem cell-based therapies has also been researched in animal models of 
neurodegenerative diseases such as Parkinson’s, Alzheimer’s and Huntington’s diseases (Kim 
and Vellis, 2009). Parkinson’s disease is characterized by the depletion of dopaminergic 
neurons in the substantia nigra of the brain. Mouse embryonic and neural stem cells (NSCs) 
have been found to be capable of generating dopaminergic neurons after exposure to 
fibroblast growth factor 8 and sonic hedgehog proteins, indicating the potential of these stem 
cells in treating this disease (Lee et al, 2000; Kim et al., 2013). Moreover, the transplantation 
of NSCs in mice was found to attenuate the functional deficits in the central nervous system 
associated with Alzheimer’s and Huntington’s disease through neural cell replacement, 
neurotransmitter release, and production of neurotrophic factors (Kim and Vellis, 2009). In 
the case of Alzheimer’s disease, NSC transplantation has been found to rescue spacial and 
memory learning deficits by elevating expression of brain-derived neurotrophic factor, which 
is known to increase synaptic density in the hippocampus (Blurton-Jones et al., 2009).  
The bone marrow contains a high concentration of multipotent stem cells that can easily be 
acquired, and is therefore the most commonly used source of stem cells for clinical studies of 
heart failure. Bone marrow derived HSCs were the first adult stem cells discovered to 
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differentiate into cardiomyocytes after transplanting them into the infarcted hearts of mice 
(Leri et al., 2005). However, this effect has not yet been demonstrated in other animals (Leri 
et al., 2005; Murray et al., 2004; Balsam et al., 2004).  
Similar to HSCs, MSCs and ESCs have also been shown to differentiate into cardiomyocytes 
in vitro (Caplan et al., 2006), as well as to a much lower concentration in vivo (Miyahara et 
al., 2006). They therefore can be introduced into the diseased heart to re-constitute dead 
cardiomyocytes. This was shown after MSCs were injected into a swine model of MI 
(Schuleri et al., 2009). The MSCs underwent cardiomyogenesis and were found to express 
cardiomyocyte-specific markers, indicating that they differentiated into cardiomyocytes. They 
also attenuated LV remodeling, thus reducing the size of the scar (Schuleri et al., 2009). Other 
models of ischamic cardiomyopathy have shown that the injection of MSCs improves cardiac 
function, increases angiogenesis and reduces myocardial fibrosis (Li et al., 2009; Liu et al., 
2008; Nagaya et al., 2005).  
ESCs as previously mentioned are pluripotent and therefore have the potential to completely 
regenerate the myocardium after a heart failure. They have been found to improve LV 
remodeling and systolic function after transplantation in rat models of MI (Caspi et al., 2007; 
Cai et al., 2007). The transplantation of mouse ESCs into an infarcted sheep myocardium has 
also been found to elicit differentiation into cardiomyocytes and improve LV function 
(Menard et al., 2005). Despite these evidences, ESCs pose several potential threats to patients 
due to their allogeneic nature. They have been found to cause immunological rejection, as 
well as the formation of teratomas in mice tissue. Therefore these risks bring about significant 
concerns towards the use of ESCs in a clinical setting, especially for the treatment of heart 
failure patients in which the immune system is already compromized. 
Resident stem cells of the heart are now also being investigated for their ability to treat heart 
failure and improve cardiac function. Endogenous cardiac stem cells can be isolated and 
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expanded from the myocardium and epicardium of the heart (Bearzi et al., 2007). Although 
considerably less is known about the functions of these cells, there are strong indications that 
generating enough healthy cardiac stem cells to transplant back into patients with heart failure 
may be more beneficial than the use of other stem cell types. Our current understanding of the 
function of cardiac stem cells as well as its potential as a viable treatment option will 
therefore be explored in the next section. 
 
1.3 Cardiac stem cells 
1.3.1 Definition and general function 
The heart was originally thought of as a terminally differentiated, post-mitotic organ until the 
discovery of a population of endogenously expressed cardiac stem cells (CSCs) that were 
capable of generating cardiomyocytes and coronary vessels (Santini et al., 2016). CSCs are 
known as a specialized stem cell type which can be used for the purposes of organ 
regeneration, and reside in specialized niches in the myocardium of the heart. The structure of 
the niches are specifically designed to support the survival of the cells within the myocardial 
tissue (Leri et al., 2014). They are able to differentiate into adult cardiomyocytes, smooth 
muscle cells and endothelial cells, and in doing so regulate the physiological turnover of 
cardiac cells in the body (Nadal-Ginard et al., 2014). A pool of resident CSCs are known to 
be expressed endogenously within the myocardium and epicardium of the heart. This pool can 
be activated in response to an ischemic event, inducing their migration to the site of injury 






1.3.2 CSCs as best source of stem cells for cardiac repair 
Although stem cells from different origins have been used to repair damaged tissue in the 
past, recent studies have elicited an understanding that a specific stem cell subtype may confer 
a better regenerative response (Falanga, 2012). Compared to other stem cell subtypes, 
endogenous CSCs may therefore be a better option to regenerate heart tissue due to the fact 
that these cells are adapted to function in the specialized environment of the CSC niche. 
Moreover, unlike exogenous stem cells, CSCs are specifically programmed to differentiate 
into adult cardiomyocytes (Leri et al., 2005). Other stem cell types, such as bone marrow-
derived cells and ESCs have been reported to be capable of cardiogenesis. However, the 
differentiated cells which they produce often die within a short period of time after 
transplantation, or have limited functionality compared to resident cardiomyocytes (Laflamme 
and Murry, 2011). It is therefore plausible to assume that the therapeutic application of CSCs 
would allow for a more efficient re-constitution of heart tissue, and thus functional recovery 
of the heart compared to stem cells from other sources in the body.   
 
1.3.3 Selective markers for identification of CSCs 
CSCs can be selectively identified based on the expression of surface antigenic markers. The 
earliest known marker for these cells is Mesp1, a transcription factor that regulates 
cardiovascular cell fate. In the presence of the Wnt inhibitor, Dkk1, Mesp1 was found to 
downregulate genes that promote pluripotency, while upregulating the cardiac transcription 
factors, Nkx2.5 and GATA4 (Cyganek et al., 2013; David et al., 2008). Other markers that 
have previously been used to identify CSCs include multidrug resistance protein 1 and stem 
cell growth factor receptor (c-kit) protein (Messina et al., 2004). However despite early 
indications of their beneficial use for this purpose, the lineage and functional properties of c-
kit+ cells has recently come under scrutiny. In the developing heart, c-kit+ cells have been 
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found to primarily function as endothelial cells (Sultana et al., 2015). Moreover, it was 
reported that these cells retain their endothelial identity over time and undergo minimal 
differentiation into cardiomyocytes (Sultana et al., 2015; Berlo et al., 2014). This may 
indicate that c-kit is no longer suitable as a marker for CSCs. 
Stem cell antigen 1 (Sca-1) is now being used as the primary marker for identifying CSCs in 
mice and is known to constitute 70% of the remaining cells in the mouse heart after depletion 
of cardiomyocytes (Matsuura et al., 2014; Valente et al., 2014). Importantly, cell populations 
with high expression of Sca-1 (Sca-1+) have been shown to be inherently and functionally 
different to those with high expression of c-kit (Vicinanza et al., 2017). These Sca-1+ cells 
have also been shown to exhibit cardiac-specific and stemness characteristics such as a high 
proliferation capacity, which leads to an improvement in cardiac regeneration in mice (Li et 
al., 2017; Vicinanza et al., 2017). Moreover, these cells have a multipotent phenotype with 
the ability to differentiate into different cardiac cell lineages (Wang et al., 2014). These 
features suggest Sca-1 as an appropriate marker for identifying CSCs in mice. Antibodies 
specific for Sca-1 can thus be used to purify CSCs in a population of cardiac cells derived 
from mouse hearts. Nonetheless, the stem cell field is constantly evolving and new evidence 
provides new insights into the most suitable markers for these CSCs. It is evident that more 
research must be done to characterise the origin and functional nature of Sca-1 and other 
markers for these cells.  
 
1.3.4 Experimental evidence for transplantation of CSCs in regenerating heart tissue 
The therapeutic potential of CSCs is evident through the autologous transplantation of 
functional CSCs into the diseased heart (Purvis et al., 2015). This regenerative effect of CSCs 
involves two primary mechanisms: direct differentiation of the CSCs into cardiovascular cells 
or more commonly, secretion of paracrine factors which activate downstream regenerative 
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pathways (Nadal-Ginard et al., 2014). CSCs were initially found to exhibit this regenerative 
capability after autologous transplantation from healthy rat hearts into an infarcted 
myocardium (Zhang and Guo., 2018). Intramyocardial injection of CSCs promoted an 
increase in myocardial cell proliferation and improvements in exercise capacity, as well as a 
reduction in left ventricular end-diastolic volume in the rats with MI (Zhang and Guo., 2018). 
There was a significant increase in ejection fraction and myocardial proliferation, as well as a 
reduction in left-ventricular end-diastolic volume four weeks after transplantation into the left 
ventricle (Zhang and Guo, 2018).  
Moreover, the migration rate of CSCs to the damaged site has been found to increase as early 
as one week following injection into the heart (Ling et al., 2017). CSC transplantation has 
also been shown to be effective at improving cardiac function in the human heart. The clinical 
relevance of this transplantation was shown by Makkar and colleagues who demonstrated that 
transplantation of cardiosphere-derived stem cells promotes cardiac regeneration, reduces scar 
tissue and improves heart contractility in human patients with MI (Makkar et al., 2012). 
Although these evidences suggest that CSC transplantation may be a useful method for 
replacing dead cardiomyocytes, diabetes mellitus poses a threat to the effectiveness of CSC 
therapy as it is known to enhance stem cell aging and death (Katare et al., 2013; Rota et al., 
2006). 
 
1.4 Diabetes mellitus 
Diabetes mellitus is one of the most common non-communicable diseases in the world (WHO 
et al., 2018). It is characterized by an abnormal elevation in systemic glucose (hyperglycemia) 
due to either a deficiency in insulin production by the pancreas (type 1), or a reduced ability 
of cells to respond to the insulin that is produced (type 2) (Tripathi and Srivastava, 2006). 
T2DM is the more common of the two, accounting for over 90% of diabetic patients 
worldwide (Tripathi and Srivastava, 2006). In the heart, both type 1 and 2 diabetes mellitus 
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can causes abnormal alterations to the structure and function of the myocardium, manifesting 
in a condition called diabetic cardiomyopathy (DCM) (Boudina, 2010). 
 
1.4.1 Diabetic cardiomyopathy 
Unlike other diseases associated with CVD, DCM is caused by the development of diabetes, 
but is not confounded by coronary artery disease or hypertension (Boudina, 2010). DCM can 
limit the ability of the heart to pump blood by a number of mechanisms which include 
ventricular dilatation, myocyte hypertrophy, interstitial fibrosis and reduced systolic function 
of the left ventricle (Hayat et al., 2004). After evaluation of myocardial biopsies, apoptosis 
and necrosis has also been found to be elevated in diabetic subjects with heart failure, 
indicating that DCM also influences cell death (Hayat et al., 2004). Commonly used 
treatments for DCM include β-blockers, ACE inhibitors and Ca2+ channel inhibitors which 
help to reverse the cardiac remodelling associated with the disease, therefore improving left 
ventricle function (Hayat et al., 2004). Recently stem cell-based therapies have also been used 
to treat DCM, indicating the potential application of CSC therapy for regeneration of the 
diseased heart (Segers and Lee, 2008). 
 
1.4.2 Pathological effect of diabetes on CSCs 
Diabetes is known to adversely affect CSC function by increasing the amount of oxidative 
stress within these cells. This phenomenon has been demonstrated by Rota and colleagues 
who found a substantial increase in the expression of oxidative stress markers, nitrotyrosine 
and deoxyguanosine in resident CSCs located in diabetic mice (Rota et al., 2006). The 
oxidative stress in turn produces elevated levels of reactive oxygen species (ROS) which is 
known to disrupt mitochondrial, caspase and mitogen-activated protein kinase pathways that 
regulate important biological processes within the cell, leading to apoptosis (cell death) (Glass 
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et al., 2010). This was also supported by Katare and colleagues, who demonstrated that Sca-
1+ cardiac progenitor cells (CPCs) isolated from the hearts of diabetic mice have reduced 
activity of key enzymes in the pentose phosphate pathway, glucose-6-phosphate and 
transketolase (Katare et al., 2013). The suppression of these enzymes lead to apoptosis of 
CPCs in the diabetic mice by increasing the expression of advanced glycation end-products 
and suppressing the pro-survival proviral integration site for moloney murine leukemia virus-
1 (Pim-1)/B-cell lymphoma 2 (Bcl-2) signaling pathway (Katare et al., 2013). This may also 
explain why DCM can be characterized at the early stages of the disease by the 
downregulation of Pim-1 (Katare et al., 2011). Moreover, this finding correlated with a study 
showing that systemic delivery of Pim-1 into diabetic mice improved cardiac function and 
reduced cardiomyocyte apoptosis (Katare et al., 2011).  
Diabetes also reduces the proliferative capacity of CSCs. This is due to the fact that the 
accumulation of oxidative stress in the cell promotes senescence, a cellular aging process 
characterized by a decline in cellular function where a cell ceases to replicate (Rota et al., 
2006). Finally, diabetes was found to promote insulin-resistance in CPCs, and also 
dysregulate glucose metabolism by increasing the rate of glycolysis (Salabei et al., 2016). 
However, despite several studies demonstrating the harmful effects of diabetes on CSC 
number and function, the exact molecular mechanisms leading to the dysregulation of CSCs 
in the diabetic heart are still not fully understood. Nevertheless, certain regulatory molecules 
may prove beneficial in maintaining the functional viability of CSCs in the diabetic heart as 
they allow for the beneficial modulation of these cells. MiRNAs are one such molecule that 
has recently been investigated as a regulator for stem cell number and function. The 
appropriate application of miRNAs in a clinical setting may therefore regenerate damaged 





1.5.1 Definition and statistics 
MiRNAs are small (21-25 nucleotide), noncoding RNAs that are expressed in plants and 
animals and regulate gene expression at the posttranscriptional level (Wahid et al., 2010). 
They are differentially expressed in many different cell types in the body and are involved in 
a wide variety of cellular processes such as development, proliferation, differentiation and 
plasticity (Gangaraju and Lin, 2009). Thus far over 38,000 miRNAs have been characterized 
across all species. Each of these miRNAs has the potential to target hundreds of different 
genes (Count, M., 2018; Friedman et al., 2009). Moreover, 2200 miRNAs have been 
discovered in the human genome which can affect genes controlling important biological 
processes in the body (Hammond et al., 2015). Their differential expression has been shown 
to be useful in identifying diseases such as cancer, CVD and diabetes (Wang et al., 2015). In 
this way, the miRNAs can act as biomarkers to predict the onset of a certain disease. 
However, there is still a limited understanding of the role of these miRNAs within stem cells. 
 
1.5.2 Biogenesis pathway 
MiRNAs are believed to derive from either genetic or intronic material during splicing but are 
both encompassed in the same biogenesis framework (Ruby, 2007). Those derived from genes 
are transcribed in the nucleus by RNA polymerases (II and III) into primary transcripts called 
pri-miRNAs (Winter, 2009). A microprocessor complex consisting of the Drosha enzyme and 
the RNA-binding protein, DiGeorge criticial region 8 (DGCR8) process the transcripts into 
precursor (pre-) miRNAs (Rawal, 2014). MiRNAs derived from introns bypass this Drosha-
mediated processing and are directly converted into pre-miRNAs (Ruby, 2007). The pre-
miRNAs are transported through a nuclear pore into the cytoplasm by an exportin-5 
transporter protein, where they are further processed into a double-stranded mature miRNA 
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by the RNAse II enzyme, Dicer (Gangaraju and Lin, 2009). The mature miRNAs are 
unwound and incorporated along with argonaute proteins into an RNA-induced silencing 
complex (RISC). The RISC complex escorts the miRNA to conserved recognition sites on 
target messenger RNAs (mRNAs) which are either directly degraded by the miRNA or made 
dysfunctional through translational repression (Winter, 2009). These inhibitory pathways 
depend on complementary matching of the RISC complex to the target mRNA, which is 
mediated by associated argonaute proteins (Winter, 2009). The biogenesis pathway for 














































Figure 1.1. Schematic diagram depicting the biogenesis of microRNAs (miRNAs). The diagram outlines this process from the initial 
transcription of miRNA genes and processing of intronic miRNAs in the nucleus until its formation into double-stranded, mature 
miRNAs in the cytoplasm, and its eventual inhibition/repression of target mRNA. Arg = Argonaute proteins, RISC = RNA-induced 
silencing complex (Annotated from Purvis et al., 2015). 
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1.5.3 Physiological role in CSCs 
Due to their ability to target a wide variety of different genes, miRNAs have the potential to 
have an impact on a number of biological functions. The physiological roles of these miRNAs 
have been documented in certain stem cell subtypes, however relatively little is known about 
their role in CSCs (Purvis et al., 2015).  
 
1.5.3.1 MiRNAs regulate myocardial differentiation and proliferation of CSCs 
MiR-1 and miR-133 are two of the most commonly investigated miRNAs within stem cells, 
and have been shown to be involved in regulating the differentiation of ESCs. Takaya and 
coauthors used trichostatin A and a histone deactylase inhibitor to induce myocardial 
differentiation in mouse ESCs. They found that the expression levels of miRNA-1 and miR-
133 were reduced following this treatment, indicating that the ESCs successfully 
differentiated into CSCs. This outcome was also supported by a reduced expression of 
NKX2.5, a gene associated with cardiac differentiation (Takaya, 2009). Furthermore, the 
overexpression of miR-1 was found to inhibit CDK9 and HAND2 genes, which play roles in 
activating ventricular cardiomyocytes and activating cardiac-specific genes (Fig. 1.2) (Purvis 
et al., 2015; Takaya, 2009; Han et al., 2006). This suggests that miRNAs have the potential to 







Figure 1.2. Summary diagram depicting the cellular interactions of various miRNA subtypes and clusters with regard to their role of regulating the 
differentiation and proliferation potentials of cardiac stem cells (CSCs) and progenitor cells (CPCs). These miRNAs target specific transcription 
factors and cardiac genes (yellow circles) and inhibit their protein expression, causing a downstream effect on stem cell differentiation and 
proliferation (promotion is indicated by blue arrows and inhibition is indicated by the red arrows) (Annotated from Purvis et al., 2015). 
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The ability of miRNAs to regulate of stem cell function has been found to be dependent on 
the nature of their molecular targets. For this reason, there has been a disparity in the literature 
concerning the functional roles of miRNAs on CSC proliferation and differentiation. An 
example of this is the interplay between miR-1 and miR-133 on DLL1, a transcription factor 
which promotes the expression of cardiac mesoderm genes and suppresses the expression of 
nonmesoderm genes. MiR-1 was found to increase the differentiation of CSCs by inhibiting 
DLL1, while miR-133 inhibited this process (Ivey et al., 2008). Another study found that 
cardiac-specific miRNAs, miR-1 and miR-499 were found to be important for CPC 
differentiation. MiR-1 was found to inhibit the HDAC4 gene, while miR-499 was found to 
inhibit SOX6 gene (Fig. 1.2) (Sluijter et al., 2010). These genes are transcription factors that 
promote the differentiation of CPCs, which was prevented after blocking the actions of miR-1 
and miR-499 (Sluijter et al., 2010). 
There has also been evidence to suggest that other less common miRNA subtypes such as 
miR-204 and miR-669 also have the potential to promote CSC and CPC differentiation. The 
inhibition of miR-204 was found to increase the proliferation of CPCs without affecting cell 
viability or apoptosis. This was further supported by a subsequent downregulation of cardiac-
specific genes such as troponin TropT, β-MHC and C-actin (Fig. 1.2). Further bioinformatic 
analysis revealed that miR-204 targets ATF2, a transcription factor that elicited a similar 
increase in CPC proliferation after overexpressing it in these cells (Xiao, 2012). The roles of 
miR-669a and miR-669q were investigated in neonatal CPCs. When these miRNAs were 
overexpressed in mouse CPCs, there was a reduction in the differentiation potential of the 






1.5.3.2 MiRNAs promote angiogenic differentiation 
Certain miRNAs have also been found to target genes that regulate angiogenesis in CPCs. 
The overexpression of miR-1 has been found to have pro-angiogenic effects such as vascular 
tube formation and migration of CPCs, thus promoting angiogenic differentiation. This pro-
angiogenic potential of miR-1 was further demonstrated by inhibiting a negative regulator of 
apoptosis, sprouty-related EVH1 domain-containing protein 1 (SPRED1) (Mil et al., 2013). 
This role was also shown for miR-132 after discovering that the in vivo transplantation of 
saphenous vein derived cells, which readily secrete miR-132, into the infarcted myocardium 
of mice, resulted in the activation and vascular differentiation of endogenous CSCs (Katare et 
al., 2011). 
 
1.5.4 Pathophysiological role in CSCs 
Despite their ability to regulate physiological processes within the body, miRNAs can also 
have pathological consequences to the regular functioning of biological systems. This is 
generally attributed to the ability of such miRNAs to non-specifically target many different 
genes with a wide variety of functions (Purvis et al., 2015). In doing so, miRNAs can cause 
the unwanted activation of signaling pathways leading to cell death and disease.  
 
There is evidence to suggest that miRNAs may have a pathophysiological role in CSCs 
associated with apoptosis and necrotic cell death. In one study, CPCs were found to inhibit 
the critical apoptotic activator B-cell lymphoma 2 interacting mediator of cell death (Bim) 
after treatment with a miRNA cocktail consisting of miR-21, -24, and -221, leading to the 
enhanced survival of the progenitor cells. Furthermore, a marked improvement in the 
engraftment and survival of these cells was observed following the in vivo transplantation of 




Unlike the programmed form of cell death (apoptosis), necrosis is a premature form which 
results from enzymatic self-digestion and usually occurs in injured cells or dying tissue 
(Majno and Joris, 1995). Certain miRNAs have also been discovered to regulate the necrotic 
cell death of CSCs. For instance, CSCs that were exposed to oxidative stress and treated with 
a miR-155 precursor mimic, were found to target receptor interacting protein (RIP1), a protein 
required for the activation of necrotic death signaling pathways (Liu et al., 2011). Apoptosis 
and necrotic cell death are major contributors for the reduction in stem cell number after 
transplantation in patients with chronic morbidities such as diabetes (Moore et al., 2014; 
Katare et al., 2011). This may indicate the therapeutic use of such miRNAs that regulate these 
functions by improving the efficacy of stem cell therapy.  
 
1.5.5 Therapeutic use of miRNAs in CSCs 
Their well-documented capacity to regulate CSC function suggests that miRNAs may have 
the potential to have a positive impact on CVD. Although the evidence for this is limited, 
studies have supported the inclusion of certain miRNAs in CSC-based therapies. For instance, 
certain CSC-derived miRNAs such as miR-378 have been found to regulate genes that 
contribute to MI. The inhibition of miR-378 was found to improve the viability of Sca-1+ 
CSCs by enhancing the expression of connective tissue growth factor (CTGF), a promoter of 
cardiac tissue scarring and fibrosis (Kim et al., 2013; Shi-Wen et al., 2008). This indicates 
that the inhibition of miR-378 could improve CSC number and function in the ischemic heart, 
a notion that was further supported in the same study after finding that electrical stimulation 
of the CSCs led to a reduction in miR-378 expression and therefore cytoprotection against the 
effects of CTGF (Shi-Wen et al., 2008).  
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In contrast, other miRNAs such as miR-499 seem to regulate genes that protect the heart 
against CVDs by enhancing the self-renewal capabilities of CSCs into functional 
cardiomyocytes. MiR-499 translocates across gap junctions from cardiomyocytes onto 
structurally coupled CSCs in a cell-dependent manner, favouring their differentiation into 
adult cardiomyocytes by repressing the target genes, Sox6 and regulator of differentiation 1 
(Hosoda et al., 2011). This accounts for substantially higher expression levels of miR-499 in 
the differentiated cells compared to barely detectable levels in CSCs. Moreover, in vivo 
transplantation of CSCs expressing miR-499 into infarcted rat hearts promoted a more 
effective functional and structural recovery of the damaged heart compared to CSCs devoid of 
miR-499, indicating the beneifical role of miR-499 in improving cardiac function (Hosoda et 
al., 2011). 
The positive impact of certain miRNAs on CSC function suggests that these miRNAs may 
have the potential to counteract the harmful effects of diabetes on these cells. To understand 
this further, the expression of different miRNAs can be compared between diabetic and non-
diabetic CSCs to determine which miRNAs are altered in the diabetic condition. This altered 
expression can then be correlated with a potential pathophysiological role for these miRNAs 
within the CSCs. This role can be demonstrating by manipulating the expression of the 
miRNAs within the diabetic CSCs and observing how the altered miRNA expression effects 




1.6 Objectives and hypothesis  
The first objective of this project was to determine whether diabetes effects the expression of 
miRNAs within mouse and human CSCs. The outcome of this led to the second objective 
which was to demonstrate the pathophysiological role of the differentially expressed miRNAs 
in the diabetic CSCs. 
I hypothesized that certain miRNAs would exhibit a significant change in their level of 
expression in diabetic CSCs compared to non-diabetic CSCs in db/db mice, and that this 
effect of diabetes on miRNA expression could be translated to human CSCs. Furthermore, I 
hypothesized that genetic manipulation of these differentially expressed miRNAs would 




CHAPTER 2: GENERAL METHODOLOGY 
This chapter outlines the general methodology for the procedures and techniques that were 
most frequently used throughout this project. This includes the initial isolation of CSCs from 
mouse heart tissue, as well as downstream experiments such as flow cytometry, RNA 
extraction, q-PCR, protein extraction and western blot analysis. Although subsequent chapters 
of this thesis are more specialized, they also contain elements of these general techniques and 
are therefore referenced in this Chapter accordingly. 
 
2.1 Animal information 
The db/db mouse is an inbred mouse strain (C57BLKS/J) that is a useful animal model for 
T2DM (Burke et al., 2017). These mice develop an obese phenotype that predisposes them to 
diabetes at an early age due to a mutation in the leptin receptor gene (db) that regulates body 
fat (Mao et al., 2006; Chen et al., 1996). The diabetic db/db mice are extremely obese in 
appearance and can therefore be easily differentiated from the leaner non-diabetic mice. They 
also have been documented to develop other symptoms that mimic diabetes in humans such as 
hyperinsulinemia and hyperglycemia from six weeks of age (Burke et al., 2017; Kobayashi et 
al., 2000).  
The Katare laboratory holds a colony of db/db mice at the Hercus-Taieri Resource Unit in the 
University of Otago. These mice were transported as required for the extraction of heart tissue 
and eventual isolation of CSCs. The use of these mice was approved by the Animal Ethics 
Committee of the University of Otago (Reference No: 25/12). The mice were 8-10 weeks old 
at the time of tissue collection and were either diabetic or non-diabetic, reflected by an obese 
or lean appearance, respectively. Hyperglycemia was confirmed in all diabetic mice by 
measuring an increased glucose concentration in their urine. All animals were age and gender-
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matched and their hearts were collected and pooled together (4 hearts per sample) comprising 
the first set of diabetic (n=6) and non-diabetic CSC samples (n=6) that were analysed in 
Chapter 4.  
 
2.2 General plan for mouse CSC study 
Here, I will describe the plan (depicted in Fig. 2.1) used to fulfil the objectives of my study. 
After obtaining the mice, the CSCs were isolated and cultured in vitro. The CSCs were then 
purified before extracting total RNA and protein. The total RNA was used for a Nanostring 
expression profiling microarray, as well as for a q-PCR experiment that was subsequently 
performed for validation of Nanostring analysis data (described in Chapter 4, sections 4.2.1 
and 4.2.3). Next, total protein was used for western blotting analysis to confirm the target 
genes for the dysregulated miRNAs (described in Chapter 5, section 5.2.3). Validating the 
dysregulation of the miRNAs in the diabetic CSCs will indicate the effect of diabetes on 
miRNA expression, thus answering the first objective of the study. The second objective will 
be answered by performing functional experiments (described in Chapter 6, sections 6.2.3 and 
6.2.4) on the dysregulated miRNAs to determine their role in the diabetic CSCs.  
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Figure 2.1. Schematic flow chart outlining the general plan used for the mouse CSC study. The chart describes the isolation of CSCs to the extraction of 
total RNA and total protein, which were then processed in chapters 4, 5 and 6. Details of the plan used for culturing the CSCs is depicted in Figure 2.2. The 
extracted RNA was used for a Nanostring expression profiling microarray and q-PCR analysis. The extracted protein was used for target gene identification 
and western blot analysis. Functional experiments were also performed using the purified CSCs.  
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2.3 Culturing CSCs 
2.3.1 Initial cardiac cell isolation protocol 
A culture of CSCs was initially established using 24 diabetic and 24 non-diabetic age and 
gender-matched db/db mice. Based on previous data from the Katare lab and previous 
indications from other studies, these hearts were pooled to generate a sufficient number of 
CSCs for downstream experiments (Carlson et al., 2011). Each sample thus consisted of a 
pool of 4 mouse hearts, allowing for the comparative analysis of 6 diabetic and 6 non-diabetic 
CSC samples. The hearts were extracted from the mice and placed in sterile Hank’s Balanced 
Salt Solution (HBSS) isolation buffer (Table A1.1 in Appendix 1) on ice. This buffer 
maintains cellular pH and osmotic balance and provides essential inorganic ions. Previous 
publications from the Katare lab and others have shown that collagenase is optimal for 
isolating CSCs, while destroying other cell types in mouse heart tissue (Katare et al., 2013; 
Messina et al., 2004). A collagenase solution consisting of 30 mL sterile HBSS and 2% 
collagenase type II and IV (Worthington, USA, Table A1.1 in Appendix 1) was therefore 
prepared and incubated at 37°C for 20 minutes. The mouse hearts were placed in a 10 cm dish 
and the adipose tissue was removed. The hearts were then washed with sterile HBSS and 
chopped into smaller fragments using surgical scissors. These fragments were pipetted into a 
15 mL tube and the supernatant was aspirated. The fragments were further washed using 
sterile HBSS, and then placed in a T75 flask in which 15 mL of the pre-incubated collagenase 
solution was added.  
Collagenase is a protease which dissociates peptide bonds found in collagen and was thus 
used for digestion of the heart tissue. The heart tissue was digested at 37°C for 70 minutes on 
a cell shaker. The supernatant was collected in a new 50 mL tube on ice and 15 mL of the 
collagenase solution was pipetted onto the heart tissue in the T75 flask. The heart tissue was 
mechanically digested by strong, repetitive pipetting (x15), and the supernatant was again 
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collected in the 50 mL tube on ice. The cell suspension was then centrifuged at 1400 rpm for 
5 minutes. After aspirating the supernatant and re-suspending the cell pellet, 1 mL of 
Dulbecco’s modified eagle medium supplemented with 10% Ham’s F12 nutrient mixture 
(DMEM/F12, ThermoFisher, USA) growth medium was pipetted into the suspension. The 
media was also supplemented with 1% antibiotic-antimycotic (100X) (Thermo Fisher, New 
Zealand) to prevent contamination. The cell suspension for each sample was transferred into 
T25 flasks, supplemented with 4 mL growth media and incubated at 37°C for 60 minutes. The 
media in the flask was then aspirated and replaced with 5 mL of fresh media and incubated at 
37°C for 24 hours. From this time-point, the media was replaced every 2-3 days to remove 
cellular debris and maintain maximum confluency.  
The final samples that were obtained consisted of a population of non-specific cardiac cells 
that were presumed to contain a subset of CSCs. This cardiac cell population was initially 
grown within T25 flasks and passaged four times before being purified, as described in 
Chapter 3, section 3.2.3. 
 
2.3.2 Protocol used to achieve sufficient cell numbers  
The isolated cardiac cells were cultured and ultimately purified to obtain a pure CSC 
population. The cells were grown in either T25 or T75 cell culture flasks and incubated at 
37°C after being suspended in DMEM/F12 growth media (ThermoFisher, USA). Cells were 
monitored and passaged when they reached 80% confluency. The CSCs were grown as a 
primary cell culture. It was therefore important to have a clear plan of the steps involved in 
culturing CSCs in order to obtain appropriate cell numbers and ensure experiments are 
completed in a timely manner. For this reason, a schematic diagram was constructed outlining 
the different stages of CSC passaging from the initial isolation from mouse heart tissue to 
processing by RNA and protein extraction, as shown in Figure 2.2. The details of these steps 
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including passaging techniques, freezing cells and the purification procedure will be described 
in Chapter 3. 
Freshly isolated cardiac cells (P0) were initially plated in a single T25 flask. After seven days 
of culture to reach confluency, the cells were passaged to two T25 flasks at P1. These two 
flasks were cultured for four days until confluent, at which point one flask was further 
passaged to three T25 flasks at P2, while cells from the remaining flask were frozen to retain 
a stock of cells at P1. Two of the T25 flasks at P2 were scaled up to two corresponding T75 
flasks at P3, while cells from the remaining T25 flask were frozen to retain a stock of cells at 
P2. The cells in the T75 flasks at P3 were grown for seven days until confluent and then 
purified using the MACS purification procedure (Chapter 3, section 3.2.1). Cells from the 
remaining T25 flask were frozen at P3 (Fig. 2.2).  
The proportion of CSCs after purification was greatly reduced compared to the original total 
cell population; therefore the CSCs were plated into two T25 flasks at P4. The CSCs in each 
T25 flask were subsequently scaled up to a T75 flask at P5 after culturing them for seven 
days. An additional seven days of culturing allowed for the passaging of confluent T75 flasks 
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Figure 2.2. Schematic diagram outlining the cell culture experiments used within this study. This covers the initial isolation and purification of CSCs from mouse heart 
tissue to their eventual processing by RNA and protein extraction. The CSCs were processed at P6 by extracting protein for western blot analysis (WB) and extracting 
RNA for q-PCR. A proportion of cells were frozen at passage 1, 2, 3, and 6 in order to retain a stock for future use. This diagram shows the stages of culturing for one 
sample (non-diabetic/diabetic), however multiple diabetic (n=5) and non-diabetic (n=5) samples were cultured concurrently. T25 flasks are represented as small, blue 
rectangles, while T75 flasks are represented by larger, blue rectangles, and 6-well plates are represented by longer, green rectangle.  
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2.4 Flow cytometry 
Flow cytometry (FACS) was used to confirm the purity of the isolated CSCs from both mouse 
(Chapter 3, section 3.3.3) and human heart tissue (Chapter 7, section 7.3.2). The general 
procedure involves staining the cells with fluorophore-conjugated antibodies and analysing 
the expression of CSC surface markers.  
 
2.4.1 Staining of cells 
The CSCs in each sample were first trypsinized and counted using a hemocytometer. The 
CSC samples were then aliquoted to achieve the desired concentration (1 x 106 cells/mL) for 
each reaction. The samples were centrifuged at 1400 rpm for 5 minutes and re-suspended in 1 
mL of freshly prepared FACS buffer (Table A1.1 in Appendix 1). The 50 µL suspensions 
containing 5 x 104 cells were pipetted into polystyrene tubes (BD Biosciences, USA) along 
with 50 µL of a fluorophore-conjugated antibody solution (2.5 µL of antibody in 47.5 µL 
FACS buffer) and incubated in the dark for 30 minutes at 4°C. The monoclonal anti-mouse, 
Sca-1 antibody (Miltenyl Biotenic, Germany) was used to identify the mouse CSCs (Chapter 
3, section 3.2.1), while the monoclonal anti-human CD105, CD90 and Cluster of 
differentiation 34 (CD34) antibodies (eBiosciences, USA, Table A1.2 in Appendix 1) were 
used to identify the human CSCs (Chapter 7, section 7.2.3). Unstained/negative controls 
containing 50 µL of FACS buffer without cells were also included for each sample and 
subjected to the same incubation conditions. At the end of the incubation period, the tubes 
containing cells were washed twice with 2 mL of FACS buffer and then centrifuged at 1400 





2.4.2 Staining of compensation controls 
In FACS, the fluorescence from more than one fluorophore may be detected in the same 
channel of the flow cytometer if their emission spectra overlap. Fluorescence compensation 
can be used to remove this spill-over of fluorescence (Schwartz et al., 1998). The AbC anti-
mouse and anti-human bead kits (Thermo Fischer Scientific, USA) were used for 
compensation of mouse and human samples, respectively. This kit includes AbC capture 
beads that bind to mouse immunoglobulin, as well as negative beads that have no binding 
capacity. Binding of the two bead components with a fluorophore-conjugated antibody elicits 
a reaction whereby two distinct populations (positive and negative) of beads are created. This 
can be used to set the compensation parameters of the stained cells. The bead solutions were 
initially prepared by adding 2 drops of the AbC capture beads to separate tubes and then 
directly adding 2.5 µL of each respective conjugated antibody. The tubes containing beads 
were incubated in the dark for 15 minutes at RT, then washed twice with 3 mL of phosphate 
buffered saline (PBS) and centrifuged at 1400 rpm for 5 minutes at 4°C. The design for these 
tubes, as well as the fluorophores used is outlined in Table A2.1 and Table A2.2, respectively 
in Appendix 2.   
After the incubation period, the AbC capture bead pellets were re-suspended in 300 µL of 
PBS along with 2 drops of the negative capture beads (used as an unstained compensation 
control). Dead cells were also prepared as a positive compensation control for the PI channel. 
The cells in this sample were killed after incubation at -80°C for 24 hours. Just before 
analysing the samples, a 10 µL volume of 1 mg/mL Propidium Iodide (PI) (Life 
Technologies, USA) was added to the stained cell and bead samples, as well as the dead cell 





2.4.3 Data acquisition 
The Gallios flow cytometer (Beckman Counter Inc, USA) was used for data acquisition. At 
least 10,000 events within the gate of interest were acquired by the flow cytometer for each 
sample to ensure reliability of the data. The compensation parameters and flow cytometer 
voltages were set up to minimise spill over of samples in adjacent channels. Once the data 
was acquired for each sample, FlowJo 10.0 software (TreeStar, USA) was used for the 
analysis. The FSA (forward scatter area) and FSW (for scatter width) of the cell distribution 
was visualized and subjected to doublet discrimination. The compensation matrix was then 
created by gating the negative populations of cells in the channel containing the unstained 
sample. This involved identifying and excluding the population of dead cells from the PI 
channel. Fluorophore controls showed a similar spread of data as the unstained cells, 
indicating that the unstained samples could be used as controls for selecting positive cells for 
a particular marker. This compensation matrix was therefore applied to all positively stained 
cell samples to determine the proportion (%) of the respective markers in the CSCs (eg. Sca-1 
in Chapter 3, or CD105 in Chapter 7).  
 
2.5 RNA extraction 
Total RNA was extracted from diabetic and non-diabetic CSCs at different stages of the 
project using the established Qiagen protocol that has previously been used in the Katare 
laboratory (Rawal et al., 2016; Katare et al., 2011). The volumes of reagents used from the 






Table 2.1. Volumes of Qiagen reagents based on culture dish size 




Chloroform Isopropoanol Ethanol 
(75%) 
6-well plate 9cm2 900 µL 180 µL 450 µL 900 µL 
12-well plate 4cm2 400 µL 80 µL 200 µL 400 µL 
 
At the end of the experimental period, the media within each well was aspirated and the cells 
were washed using 1 mL of sterilized PBS. Next, Qiagen lysis buffer was added to the cells, 
which were subsequently incubated for 5 minutes at room temperature (RT). A cell scraper 
was used to manually detach and simultaneously lyse the cells in the flask. The resulting 
lysate was transferred to a fresh RNAse-free 1.5 mL collection tube to which chloroform was 
added and shaken vigorously for 15 seconds. This allows the chloroform to separate the RNA 
from protein and other cellular debris. Tubes were then centrifuged at 12,500 rpm for 15 
minutes at 4°C. The clear upper aqueous phase containing RNA was transferred to a new 
Eppendorf tube taking care not to disturb the protein precipitate (Coombs et al., 1999). 
Next, a volume of 100% ethanol equivalent to 1.5 fold of the initial lysis buffer was added to 
the Eppendorf tube and mixed by pipetting. This allows the RNA to be precipitated from the 
clear aqueous phase. Up to 700 µL of the aqueous phase was immediately transferred to an 
RNeasy Mini spin column fitted with a 2 mL collection tube and centrifuged at 10,000 rpm 
for 15 seconds at RT. This step was repeated until all the aqueous phase was passed through 
the column. After discarding the flow through in the collection tube, the RNA was washed 
with 700 µL of RWT buffer once and 500 µL of RPE buffer twice. Each time the column was 
centrifuged at 10,000 rpm for 15 seconds at RT and the flow through discarded. After the 
final wash, the column was placed in a new collection tube and centrifuged at full speed for 1 
minute to prevent any carry-over of RPE buffer. Finally, the column was placed in a 1.5 mL 
RNAse free collection tube, and RNA was eluted by addition of 30 µL of nuclease-free dH2O 
by centrifuging at 10,000 rpm for 1 minute. The RNA from each sample was quantified using 
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a Nanodrop spectrophotometer (ThermoScientific, USA) and the purity (260/280 absorbance) 
was also measured. A representative example of these measurements is shown below on RNA 
samples extracted from five diabetic and five non-diabetic mouse CSCs (Table 2.2). 
 
Table 2.2. RNA concentration and purity 
RNA sample Concentration 
(ng/µL) 
260nm absorbance 280nm absorbance 260/280 
(purity) 
Non-diabetic #1 52.70 0.067 0.034 1.971 
Non-diabetic #2 154.33 0.189 0.093 2.032 
Non-diabetic #3 52.45 0.064 0.033 1.939 
Non-diabetic #4 42.45 0.053 0.026 2.039 
Non-diabetic #5 64.80 0.081 0.041 1.976 
Diabetic #1 33.30 0.040 0.021 1.905 
Diabetic #2 101.60 0.127 0.062 2.048 
Diabetic #3 101.80 0.126 0.064 1.969 
Diabetic #4 170.45 0.218 0.106 2.057 
Diabetic #5 32.88 0.040 0.021 1.905 
 
 
2.6 q-PCR protocol and analysis 
The quantitative real-time PCR (q-PCR) is a commonly used procedure for determining 
molecular changes at the genetic level (Hugget et al., 2005). It was used in this project to 
determine changes in the expression levels of the miRNAs between diabetic and non-diabetic 
CSCs. The general protocol that was used for this technique is described below.  
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2.6.1 Reverse transcription (R.T) 
Reverse transcription of total RNA to complementary DNA (cDNA) was initially performed 
using miRNA-specific R.T primers. As described in the standardized ThermoFisher protocol, 
20 ng of total RNA is required for each q-PCR reaction. Samples with high RNA 
concentrations (>40 ng/µL) were diluted (1:10) to obtain working solutions of RNA. The 
RNA volumes were prepared in 0.2 mL PCR tubes and diluted with nuclease-free dH2O up to 
a volume of 5 µL. A master mix containing components of the TaqMan assay kit 
(ThermoFisher Scientific, USA) was prepared as indicated in Table 2.3. A 7 µL volume of 
R.T master mix and 3 µL of a miRNA-specific R.T primer (5X dilution) (ThermoFisher 
Scientific, USA) were added to the RNA samples, giving a total volume of 15 µL for each 
tube (Table 2.3). The samples were then incubated in a thermal cycler under the conditions 









Table 2.3. Solutions required for R.T samples 
Component  For 1 reaction 
(µL) 
RNA sample  5 
RT master mix reagents dNTPS (100mM) 0.15 
Multiscribe reverse transcriptase 1 
Reverse transcription buffer 
(10X dilution) 
1.5 
RNase inhibitor 0.19 
Nuclease-free dH2O 4.16 
miRNA-specific R.T primers (5X 
dilution) 
 3 
Total volume  15 
Table 2.4. Incubation settings for reverse transcription and PCR reaction 
A. Reverse transcription 
 Incubation temperature Incubation time No. of Cycles 
Step 1 16 °C 30 mins 1 
Step 2 42 °C 30 mins 1 
Step 3 85 °C 5 mins 1 
B. PCR 
 Incubation temperature Incubation time No. of Cycles 
Step 1 95 °C 10 mins 1 
Step 2 95 °C 15 sec  
40 60 °C 1 min 
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2.6.2 Polymerase chain reaction (PCR) 
Next, the cDNA products corresponding to each RNA sample were amplified with the PCR 
reaction. After pipetting 1 µL of each cDNA sample into a 96-well PCR plate in triplicate, 
6.25 µL of a PCR premix solution (Takara, Japan) was added to each well, along with 4.75 
µL of nuclease-free dH2O. This was followed by adding 0.5 µL of a miRNA-specific TM 
primer (20 X dilution) (ThermoFisher Scientific, USA), giving a total volume of 12.5 µL for 
each well (Table 2.5). Negative controls were also prepared alongside the experimental 
samples in order to test for the quality of the cDNA products and TM primers. The cDNA 
samples were then amplified by incubation in a PCR machine (ThermoFisher Scientific, 








2.6.3 Data analysis 
In order to determine the relative fold changes of each target miRNA, the raw q-PCR data was 
analysed using cycle at threshold (Ct) values as a measure of expression (Schmittgen and 
Livak, 2008). Ct values are defined as the number of PCR cycles at which a set fluorescence 
threshold is achieved. The data was analysed by first calculating the mean of the three 
replicate Ct values for each RNA sample. A ΔCt was then calculated for each target miRNA 
Table 2.5. Solutions required for PCR samples 
Component For 1 reaction (µL) 
R.T-reaction 1 
PCR premix 6.25 
Nuclease-free dH2O 4.75 
miRNA-specific TM primer (20X 
dilution) 
0.5 
Total volume 12.5 
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by subtracting the mean Ct of the endogenous control, U6 small nuclear ribonucleoprotein 
(U6) from the mean Ct of the target miRNAs in each sample. Finally, a ΔΔCt was determined 
for each miRNA by subtracting the mean ΔCt of the non-diabetic samples from the mean ΔCt 
of both non-diabetic and diabetic samples. The ΔΔCt values were used to calculate the 
relative fold changes for the diabetic and non-diabetic CSC-derived RNA samples using the 
following formula:  
 
Mean fold changes were determined for all target miRNAs in each sample and a two-tailed 
unpaired t-test was performed to determine the statistical significance (P<0.05) for the 
differences in expression of each target miRNA between diabetic and non-diabetic CSC-
derived miRNA samples. The standard error was also calculated for each reaction to account 
for data variability. 
 
2.7 Protein extraction and quantification 
2.7.1 Protein extraction 
 Total protein was extracted to conduct western blot analysis. For this, CSCs were trypsinized 
and centrifuged to form a pellet in 1.5 mL centrifuge tubes on ice. The cell pellet was re-
suspended in 1 mL of the radioimmunoprecipitation assay (RIPA) lysis buffer, which was 
supplemented with protease inhibitors to prevent protein degradation during the extraction 
process. Cells were lysed by repeat-pipetting and aggressive syringing with a 1 mL syringe 
fitted with a 30G needle. The RIPA lysis buffer was prepared (Table A1.1 in Appendix 1) at a 
pH of 7.4, then incubated for 20 minutes at RT, and centrifuged at 14000 rpm for 30 minutes 
at RT to allow for protein separation from the other cellular components. The resulting protein 
supernatant was collected and stored at -80°C. 




2.7.2 Bradford assay for protein quantification 
A Bradford colorimetric assay (Sapan et al., 1999) was used to determine protein 
concentration in this study. A serial dilution of 0 – 2 mg/mL was made using bovine serum 
albumin (BSA), as shown in Table 2.6. 
 
The Bradford reagent contains a Coomassie dye that binds to the protein causing a progressive 
colour change in the solution from brown to blue depending on the protein concentration (Sapan 
et al., 1999). Thus, the serial dilutions were observed as a progressive colour gradient from 
brown to blue for 0 – 2 mg/mL of BSA. A 1 µL volume of each protein suspension was then 
diluted in 999 µL of Bradford reagent. Finally, 100 µL of the solution containing BSA and 
protein dilutions were pipetted in triplicate in wells of a clear 96-well plate. The optical density 
of each well was measured in a spectrophotometer at a 595 nm wavelength. After subtracting 
the mean optical densities (OD) of the negative control (0 mg/mL of BSA) from that of the 
BSA and protein, a reference standard curve graph was constructed using Graphpad Prism 
software (Fig. A3 in Appendix 3). The gradient and thus effectiveness of the standard curve 
was determined from the R-squared statistical measure of linear regression. This indicates the 
proportion of variance between different concentrations of BSA and the resulting optical 
densities, and is evaluated between 0 and 1.0. An R-squared value of 1.0 indicates that no 
Table 2.6. Serial dilutions for Bradford assay 
BSA concentration 
(mg/mL) 
BSA volume from 2 mg/mL 
stock (µL) 
Volume of Bradford reagent 
(µL) 
0 0 1000 
0.4 20 980 
0.7 35 965 
1.0 50 950 
1.3 65 935 
2.0 100 900 
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variance exists between the variables. The protein concentrations in each sample were then 





2.8 Western blot protocol and analysis 
Western blot analyses were used as to determine the link between specific miRNAs and their 
target genes. The aim of this was to demonstrate the functional role for the changes in the 
expression of miRNAs in the diabetic CSCs.  
 
2.8.1 SDS-PAGE gel electrophoresis 
The total protein was denatured by incubation at 95°C for 5 minutes after dilution with 2X 
loading buffer (Table A1.1 in Appendix 1) containing 30% mercaptoethanol at a 1:1 dilution. 
Thirty micrograms of total protein and 6 µL of Precision Plus Kaleidoscope Protein Standard 
(Bio-Rad, NZ) were loaded on a 12% SDS-PAGE gel (Table A1.1 in Appendix 1). Gel 
electrophoresis was run at 100V for 20 minutes, and then 150V for approximately 60 minutes 
to separate the proteins based on size and charge. The gel was run until the protein samples 











2.8.2 Protein transfer 
The protein was then transferred from the gel to a polyvinylidene difluoride (PVDF) 
membrane pre-soaked in methanol using a transfer sandwich cassette. The cassette consisted 
of two pieces of fibrous pad, two pieces of filter paper, and a PVDF membrane, arranged as 







Figure 2.3. Diagram depicting the transfer sandwich cassette that was used in the western blot 
procedure after gel electrophoresis. This allows for the transfer of protein from the SDS-PAGE 
gel (dark blue rectangle) to the PVDF membrane (dotted line) as the current travels from the 
cathode to the anode. Diagram adapted from Liang et al., 2013. 




The membrane was initially cut according to the size of the gel and then activated by soaking 
in 100% methanol for 30 seconds, followed by incubation in transfer buffer for 3 minutes. 
The transfer sandwich was assembled by first placing a fibrous pad onto the cathode side of 
the cassette, followed by filter paper and then the gel (Liang et al., 2013). The membrane was 
then carefully placed over the gel and smoothed out with a roller to remove air bubbles 
between the gel and the membrane. The second filter paper was then placed on the membrane 
followed by the second fibrous pad, and then clamped shut. The sandwich was then placed 
into the cassette which was topped up with 1 L of transfer buffer. Transfer was done at 90V at 
4°C for 90 minutes. In order to confirm whether the proteins have been successfully 
transferred onto the membrane, a Ponceau stain was performed. The membrane was soaked in 
red Ponceau reagent for 1 minute with gentle shaking, then soaked in dH2O until the reagent 
was washed away. The protein bands in each lane could be visualized on the membrane after 
taking an image using a Syngene PXi gel imaging system (Atkinson, USA) (Fig. A4 in 
Appendix 4).  
 
2.8.3 Blocking and probing with the antibody 
After washing the membrane three times in Tris-buffered saline with tween 20 (TBS-T) 
(Table A1.1 in Appendix 1) for 10 minutes each, the membranes were incubated with 5% 
BSA in 10 mL of TBS-T for 60 minutes at RT with gentle shaking to block the binding of 
detection antibody to non-specific proteins. This is followed by probing the membrane with 
primary antibody which was diluted in 10 mL of blocking buffer according to the 
manufacturer’s protocol. The membrane was incubated for 18 hours at 4°C with gentle 
shaking. After this incubation period the primary antibody was collected and stored (at -20°C) 
for re-use. The membrane was then washed three times in TBS-T for 10 minutes each with 
gentle shaking. A secondary antibody that is specifically reactive to the rabbit/mouse host 
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species of the primary antibody was then prepared at a dilution of 1:3,000 in blocking buffer 
and added to the membrane. The membrane was incubated at RT for 60 minutes, then washed 
three times in TBS-T for 10 minutes each. 
 
2.8.4 Detection of chemiluminescent signals 
After the final wash, the membrane was blotted dry to remove excess washing buffer and 
placed on a clear plastic film on the Syngene PXi gel imaging tray. Two West Pico ECL 
reagents: SuperSignal solution and Peroxide solution (Thermo Fischer Scientific, USA) were 
prepared at a 1:1 dilution to detect the chemiluminescent signals (Imaizumi et al., 2002). A 1 
mL volume of this mixture was applied onto the membrane to completely cover it. The tray 
was closed to incubate the membrane in the dark for 5 minutes at RT to allow for the reaction 
of peroxidase with luminol substrate. The membrane was then sealed in the plastic film and 
correctly positioned in the Syngene machine. Chemiluminescent images were captured using 
the software for later analysis (shown in Chapter 4, section 4.3 and Chapter 6, section 6.3) 
using the ImageJ program. The density of each protein band could be determined by inverting 
the colour scheme, and then using a function of ImageJ to calculate the area of the band. The 
relative proportion of a specific protein on the membrane could therefore be calculated by 
dividing the density of the specific protein by the density of a reference (housekeeping) gene 
(eg. β-actin). The membrane was then either further processed by adding a second primary 
antibody (for a reference or other specific gene), or dried by dipping the membrane in 100% 
methanol for 15 seconds, then left to dry between paper towels overnight. 
 
2.9 Statistical methodology 
In this project, I have used a number of statistical measures to demonstrate both the reliability 
and variance in the data. A two-tailed unpaired t-test was used to determine whether changes 
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in miRNA or gene expression between diabetic and non-diabetic groups were statistically 
significant (P<0.05). The standard error of the mean was calculated for each data set by taking 
the square root of the standard deviation divided by the sample size. These standard errors are 
depicted as error bars on the histograms in the following chapters. The sample sizes and 
number of biological repeats for each experiment were determined from previous literature in 
the field (Galimov et al., 2016; Hu et al., 2014).  
A one-way ANOVA was also included in experiments which were repeated three times. This 
was used to determine the variance between repetitions in each data subset where the same 
samples were used. An ‘F’ value was calculated for each subset and compared to a statistical 
‘Fcrit’ value. If the F value is larger than the Fcrit, the null hypothesis which states that there 
is no significant difference between each repetition can be rejected (Ardelean, 2017). These 
values can thus be used as a measure of consistency between the repetitions of each 
experiment. Finally, the Kruskal Wallis H test was implemented as a non-parametric 
statistical measure of consistency in experiments with low (n=3) sample numbers. This test 
similarly determines if the null hypothesis is rejected by comparing the calculated ‘H’ value 
to the statistical ‘Hcrit’ value. If the H value exceeds the Hcrit value, there is a significant 









CHAPTER 3: ESTABLISHING A CULTURE OF 
PURIFIED MOUSE CSCS 
 
3.1 Introduction 
In this chapter, I will discuss the theory and techniques involved in establishing a culture of 
CSCs from mouse heart tissue. The results of this Chapter are particularly important in terms 
of the overall project as many downstream experiments were heavily dependent on the purity 
and viability of the CSCs that were obtained. I will start by outlining the aims and objectives 
of this section, followed by the background information necessary for understanding the 
growth and purification of CSCs. I will then describe the methodology associated with 
establishing a CSC culture, as well as a brief discussion on the qualitative and quantitative 
data that was obtained during this process. 
 
3.1.1 Aims and Objectives  
The aim of this section of the project was to establish a culture of purified CSCs from diabetic 
and non-diabetic db/db mouse heart tissue. 
 
3.1.2 The principle of cell culture   
Cell culture is a technique that is commonly used to grow cells in a controlled, artificial 
environment (in vitro) while simulating the in vivo physiological conditions of the cell. In 
vitro cell culture is one of the most valuable methods to investigate the biological functions of 
mammalian cells (Oyeleye et al., 2016). These cells can be obtained from a variety of tissues 
using a method designed for cell digestion and disaggregation (Oyeleye et al., 2016). There 
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are several methods of culturing mammalian cells in vitro depending on their normal 
physiological growth conditions. The method that I used in this study involves culturing an 
adherent monolayer of cells in a flask that can be serially monitored using light microscopy. 
The proliferation capacity of these cells is maintained by supplementing them with growth 
media containing nutrients and growth factors (Gospodarowicz and Moran, 1976). 
This type of cell culture has also been used to investigate the self-renewing capabilities of 
stem cells. MSCs and ESCs have routinely been grown as adherent monolayers, which can 
then be differentiated into more specialized cells such as chondrocytes, osteocytes, adipocytes 
and cardiomyocytes by adding a differentiation medium (Almalki and Agrawal, 2016; 
Yamamoto et al., 2003). I used this approach in my study to culture CSCs and investigate 
their self-renewing capabilities in the diabetic condition. 
 
3.1.3 Passaging CSCs in vitro  
After their initial isolation from organs or tissue, stem cells are commonly plated into suitable 
flasks or containers in preparation for culturing. An advantage of culturing stem cells 
compared to other cell types is that they have a higher proliferation potential, resulting in a 
faster and more efficient growth curve. In this case, a small number of isolated CSCs can be 
grown and expanded to yield an exponentially greater number of these cells over time, 
indicating that a relatively smaller amount of heart tissue is required as a starting point. 
However, this can also pose problems for the viability of the cells: 
Due to their high capacity for proliferation, the number of stem cells increases dramatically 
over just a few days by spreading out across the surface of the flask. For this reason, the cells 
soon exhaust the available surface area and become overcrowded or ‘confluent’. This has 
several negative implications with regards to cell viability as the high confluency reduces the 
capacity of the cells for proliferation, and also may lead to cell death (Brezden and Rauth et 
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al., 1996). Passaging is a technique that is used to increase the available surface area used by 
the cells which acts to sustain their growth over longer periods of culture (Masters and Stacey, 
2007). In my project, passaging was extremely important for promoting the expansion of the 
CSCs in vitro whereby the cells were either scaled up to a larger flask, or divided into 
multiple same-sized flasks to maintain cell growth.  
 
3.1.4 Purification of CSCs  
A population of non-specific cardiac cells can easily be obtained from the chemical digestion 
of heart tissue. However, in order to isolate the CSCs from other material within this cardiac 
cell population, they must be separated by a process called ‘purification’. 
There are a variety of different techniques that can be used for purifying CSCs. Field flow 
fractionation (FFF) is one common purification method which utilizes gravitational forces to 
separate stem cells based on their size and morphology (Roda et al., 2009). However, 
although this method is efficient, it is not specific because stem cells are not easily 
differentiated based on size. Affinity-based purification methods such as fluorescence-
activated cell sorting (FACS) overcome these limitations by using specific antibodies that 
bind to stem cell surface markers (Zhu and Murthy, 2014). In FACS, the antibodies are tagged 
with fluorescent dyes to sort the cells in a suspension based on fluorescence and light 
scattering. However, a disadvantage of this technique is that it requires expensive equipment 
and produces a low cell yield (107 cells) (Putnam et al., 2003). 
Molecular tagging with magnetic beads is another affinity-based method commonly used for 
stem cell purification. Magnetic-activated cell sorting (MACS) is highly specific and 
produces a greater cell yield (1011 cells) compared to other purification methods (González-
González et al., 2011; Thiel et al., 1998). It utilises a variety of specific antigenic markers that 
are expressed on the surface of stem cells which can be targeted using magnetically labelled 
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antibodies. MACS has also be used to purify CSCs and CPCs, and will therefore be used to 
purify CSCs in my study (Vicinanza et al., 2017; Xiao et al., 2016). 
Sca-1 (Stem cell antigen-1) is a well-known murine antigen that is expressed on the surface of 
mouse CSCs as well as other stem cell subtypes in mouse tissue (Wang et al., 2014; Wang et 
al., 2009). It was originally only used as a marker for MSCs and HSCs, however in 2003 a 
population of Sca-1+ cells was also found in the myocardium of adult mice (Oh et al., 2003). 
These Sca-1+ cells were unique as they were negative for other stem cell markers such as 
CD45, CD34 and c-kit (Oh et al., 2003). They were also reported to exhibit similar 
telomerase activity to that observed in the newborn heart, suggesting they have stem cell-like 
properties. Moreover, there was no telomerase activity detected from Sca-1- cells in the same 
population (Oh et al., 2003). The Sca-1+ cells were also found to migrate towards an infarcted 
mouse myocardium following intravenous administration (Liu et al., 2013). This finding in 
combination with the observed ability of these cells to fuse to the injured myocardium and 
differentiate into healthy cardiomyocytes, suggested that Sca-1 could be considered as a 
suitable marker for the identification and purification of functional CSCs derived from mouse 
heart tissue (Liu et al., 2013; Oh et al., 2003).  
 
3.1.5 Cryopreservation of CSCs 
As with all stem cells, CSCs can be exposed to contaminants causing unexpected cell death 
and also attain senescence after several passages (Hu et al., 2014). In order to retain a stock of 
freshly isolated CSCs over a long period of time, cryopreservation can be used. This involves 
the suspension of CSCs in a cryoprotectant solution followed by immediate exposure to 
extremely low temperatures to freeze the cells. The cryoprotectant maintains the structural 
and functional properties of the cell while limiting any enzymatic and chemical reactions that 
may cause damage due to the freezing conditions (Bakhach, 2009). As such, this method can 
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be used to store CSCs in either liquid nitrogen (-196 °C) or temperatures exceeding -80 °C for 
up to 2 years (Hosoda et al., 2017). It has also been shown to preserve the proliferative 
capacity, cardiac differentiation and angiogenic capabilities of the CSCs after re-initiating 
growth of the cells from at least one month of exposure at -80 °C (Jackson et al., 2017). In 
this project, certain experiments were performed on the same samples at different time points 
and therefore cryopreservation at -80 °C was routinely used to retain a stock of each purified 
CSC sample for future experiments. 
 
3.2 Methods 
3.2.1 MACS purification protocol 
After isolating the CSCs from mouse heart tissue (using the protocol outlined in Chapter 2, 
section 2.3.1), the CSCs were purified using MACS (Miltenyi Biotec) (Fig. 3.1). This 
technique initially involves immunolabeling the cells with the Sca-1 antibody, followed by 
the application of magnetically labelled microbeads. This magnetic labelling allows for the 
retention of Sca-1+ cells after passing the total cell population through a magnetic field.  
 
3.2.1.1  Magnetic labelling 
A volume of approximately 5 mL per sample of DMEM/F12 media was stored at 4 °C for 30 
minutes prior to starting the experiment. Non-specific cardiac cells from each diabetic (n=6) 
and non-diabetic (n=6) sample were then pelleted as described in Chapter 2, section 2.3.1. 
The pellets from each sample were re-suspended with 1 mL of the pre-cold DMEM/F12. The 
number of cells from each sample were counted using a hemocytometer (Table A5 in 
Appendix 5). The cells were then transferred into 2 mL microcentrifuge tubes (1 x 107 
cells/tube) and centrifuged at 1400 rpm for 10 minutes. The supernatant was aspirated from 
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each sample and the cells were re-suspended with 90 µL of the pre-cold DMEM/F12 (107 
cells/90 µL).  
A volume of 10 µL/ 107 cells containing 30 µg anti-Sca-1-FITC (Miltenyi Biotec, Australia) 
was added to each sample, mixed well, and incubated at 4 °C for 10 minutes. The cells were 
then washed by adding 1 mL of pre-cold DMEM/F12 directly into the tubes and centrifuged 
at 1400 rpm for 10 minutes. The supernatant was aspirated from each tube and the cells were 
re-suspended with 80 µL of the pre-cold DMEM/F12 (107 cells/80 µL). A volume of 20 µL/ 
107 cells of anti-FITC microbeads (Miltenyi Biotec, Australia) was added to each sample, 
mixed well, and incubated at 4 °C for 15 minutes. The cells were then washed again by 
adding 1 mL of pre-cold DMEM/F12 media, and centrifuged at 1400 rpm for 10 minutes. 
After the supernatant was aspirated, the cells labelled with the Sca-1 antibody were re-
suspended in 500 µL of pre-warmed DMEM/F12. In preparation for magnetic separation, an 
MS column was placed in the magnetic field of a MiniMACS separator. 
 
3.2.1.2  Magnetic separation 
The MS column within the magnetic field was initially washed with 500 µL of pre-warmed 
DMEM/F12 such that the media passes into a 15 mL tube positioned below the MACS 
separator, as shown in Figure 3.1. The 15 mL tube was then discarded and replaced with 
another 15 mL tube. A cell suspension was then added to the column followed by 500 µL of 
DMEM/F12. The flow-through solution collected contains cells which are negative for Sca-1.  
The MS column was removed from the MACS separator within the magnetic field and placed 
within a new 15 mL tube. A 1 mL volume of DMEM/F12 was added to the column and a 
plunger from a syringe was used to immediately flush out the fraction of cells that are 
magnetically labelled and positive for Sca-1. The magnetic separation procedure was repeated 
for each sample which were then centrifuged at 1400 rpm for 10 minutes. The samples were 
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then added to 4 mL of DMEM/F12 media and plated in a fresh T25 flask and incubated at 37 











Multi stand magnet 
Figure 3.1. Magnetic activated cell sorting apparatus. The MS column is shown placed 
within the MACS separator (green), with a 15 mL collection tube directly below. The 
MACS separator is within the magnetic field formed from its association with the multi 




3.2.2 Flow cytometry protocol 
In order to confirm that the purified cells are Sca-1+ CSCs, FACS was performed for the 
detection of the Sca-1 marker using diabetic and non-diabetic samples. Cells were prepared 
for FACS as described in Chapter 2, section 2.4. The tubes that were prepared consisted of 
one unstained sample, one dead sample (stained with 3µM PI), two experimental samples 
containing live CSCs (one diabetic, one non-diabetic), and one sample containing 
fluoresceinisothiocyanate (FITC)-conjugated CD40 beads. The FITC beads were used as a 
control to account for spill-over of the fluorescent signal between flow cytometer channels.  
Monoclonal anti-mouse, FITC-conjugated Sca-1 (10 µL of 30 µg anti-Sca-1-FITC/107 cells, 
Miltenyl Biotenic, Germany, Table 1.2A in Appendix 1) was used as the primary antibody for 
the CSCs. The samples were processed by the flow cytometer and analysed according to the 
protocol outlined in Chapter 2, section 2.4.3. 
 
3.2.3 Passaging CSCs  
Following purification, the CSCs were passaged in order to maintain optimal growth of the 
cells for long periods of time. This technique was frequently used to transfer the cells into a 
larger flask to provide greater surface area for optimal growth; or ‘split’ to create duplicate 
samples, as outlined in Chapter 2, section 2.3. The old media was aspirated from the T25 flask 
and the cells were washed with 2.5 mL of pre-warmed phosphate-buffered saline (PBS). After 
aspirating the PBS solution from the flask, 2.5 mL of the TrypLE dissociation reagent was 
pipetted into the flask. The flask was gently rocked so as to completely cover the cell layer 
with the dissociation reagent. The flask was then incubated at 37 °C for 3 minutes, then gently 
tapped to dissociate the remaining cells which were confirmed by observing them under a 
light microscope. When ≥ 90% of the cells were detached, 5 mL of pre-warmed DMEM/F12 
media was added to the flask and dispersed over the cell layer surface several times. If ≤ 90% 
55 
 
of the cells were detached, the flask was re-incubated for 1-2 minutes until dissociation was 
observed. The cell suspension was then transferred to a 15 mL tube and centrifuged at 1400 
rpm for 5 minutes. The cell pellet was then re-suspended in 1 mL of media and either pipetted 
into a larger flask or split at a ratio of 1:2 into same-sized flasks, along with the appropriate 
volume of media. A 1:2 split ratio has been documented in other studies to allow for optimal 
CSC growth (Monsanto et al., 2017).  
 
3.2.4 Freezing CSCs  
The isolation and expansion of CSCs in vitro consumes a substantial amount of time and 
resources. Therefore, in order to save time for future experiments and avoid the isolation 
process, it is imperative to have a stock of extra CSCs at each passage number. The CSCs 
corresponding to each sample can be frozen at -80 °C and be thawed and re-initiated when 
needed. The CSCs were frozen by suspending them in a MSC freezing medium (Millipore, 
Darmstadt, Germany). After the samples were pelleted, 1 mL of freezing medium was used to 
freeze one T25 confluent flask. The freezing medium was mixed gently within a cryogenic 
tube, and incubated at -20 °C for 1 hour. It was then transferred to a -80 °C storage container 
to ensure viability for up to 2 years.  
When required for further experiments, the cells were thawed by placing the cryogenic tubes 
directly into a 37 °C water bath for 2-3 minutes or until the ice melted. The cells were then 
slowly pipetted into individual 15 mL tubes containing 9 mL of pre-warmed DMEM/F12 and 
centrifuging at 1400 rpm for 5 minutes. The pellet was then re-suspended in 1 mL of pre-
warmed DMEM/F12 and incubated at 37 °C for 24 hours. The DMEM/F12 media was then 
replaced and the sample observed carefully under the microscope to ensure the cells are 





3.3.1 Morphology of cells after initial isolation 
Immediately following isolation, these cells were observed as a dense monolayer of 
suspended cells and debris (Fig. 3.2A). After 24 hours of incubation at 37°C, the majority of 
the debris was washed away with DMEM/F12 media, leaving a small proportion of spherical 






























Figure 3.2. Phase contrast images taken from observing early cardiac cells under a light microscope. 
The cells are shown immediately after isolation from diabetic mouse heart tissue and subsequent 
plating into a T25 flask. They are initially observed as a dense monolayer of cardiac cells and tissue 
debris (A, Scale bar = 125 µm, 4x magnification), but soon form a spherical shape after incubation 
(B, Scale bar = 50 µm, 10x magnification), before attaching to the flask and branching out into their 









Further replenishment of the cells with fresh growth media following another 24 hour 
incubation washed away any dead, floating cells while simultaneously providing fresh 
nutrients for those that survived. Within the next 48 hours, the cells appeared to stretch out 
into an elongated, spindle shape with multiple branches extending across the surface of the 
flask. Similar to MSCs, the CSCs contained large nuclei that were bright and reflective under 








Figure 3.3. Phase contrast image taken from observing cardiac cells under a light microscope. The 
cells are shown at six days after their initial isolation from diabetic mouse heart tissue. Cell 
morphology shifts from a spherical shape to an elongated, spindle shape as cells branch out and 




The morphology of the cells resembled a mesenchymal phenotype and there were no apparent 
morphological differences between cells derived from non-diabetic and diabetic origins. As 
the cells branched out and grew larger, they simultaneously proliferated through cell division, 
thus gradually becoming confluent. They also started to interconnect with branches of 
neighbouring cells, which seemingly acted to accelerate their proliferation (Fig. 3.3). 
Approximately one week after their initial isolation, cells became 80-90% confluent, during 
which they were trypsinized and plated into two further T25 flasks to accommodate their 
rapidly increasing cell number. 
 
3.3.2 Morphology of Sca-1+ CSCs after MACS purification 
Following the purification of the CSCs by MACS, the number of CSCs were quantified for 
each sample. The total number of cells was markedly reduced by 4-5 fold following 
purification by magnetic sorting. The Sca-1+ CSCs that were plated into new flasks were 
similar in morphology to the previously observed cardiac cells after 24 hours of incubation 
(Fig. 3.4A). Morphologically, the Sca-1+ CSCs had a greater cross-sectional area (Fig. 3.4B) 












Figure 3.4. Phase contrast images taken from observing purified CSCs under a light microscope. 
The cells were isolated from diabetic heart tissue and are shown at 24 hours (A) and one week 








The CSCs were grown in DMEM/F12 culture media and incubated at 37 °C for 
approximately 10 days following purification until the cells became 80-90% confluent (Fig. 
3.5). At this stage the CSCs could be further processed for functional studies by extracting the 










Figure 3.5. Phase contrast image taken from observing purified CSCs under a light microscope. 
The cells were isolated from diabetic heart tissue and are shown at 10 days after MACS 
purification. The cells are shown at 80% confluence which is an appropriate level for 




3.3.3 Flow cytometry of Sca-1+ CSC samples 
The Katare laboratory has consistently measured the purity of Sca-1+ CSCs purified using the 
MACS technique (Katare et al., 2013). However, to confirm this myself I performed FACS 
on one diabetic and one non-diabetic CSC sample. Around 20,000 cells were measured in 
each sample. The percentages of live cells were consistent among both non-diabetic (98%, 
Fig. 3.6A) and diabetic (97%, Fig. 3.6A). More than 80% of the cells expressed Sca-1 in both 
CSC samples. A representative FACS quantification histogram depicting the proportion of 










Figure 3.6. Data taken from the FACS analysis of a non-diabetic CSC sample after MACS purification. The proportion of live and dead 
cells in the sample is shown on the left (A). Dead cells are positive for PI and are thus shown on the graph as PI+ cells. The proportion of 




Establishing a culture of viable CSCs was vital as it provided a framework for downstream 
experiments in order to investigate their expression and functional characteristics in the 
diabetic condition. After isolating the CSCs from both diabetic and non-diabetic db/db mice, 
the morphology, purity and growth conditions of the CSCs were confirmed by comparing the 
results to other studies as described below. 
 
3.4.1 Qualitative results of the CSCs 
All diabetic and non-diabetic CSCs exhibited a morphology that was similar to the MSC 
profile. This was supported by studies reporting the resemblance of heart-derived Sca-1+ 
progenitor cells to a mesenchymal phenotype (Oh et al., 2004; Valente et al., 2014). These 
cells are also notably distinct from the HSC or endothelial progenitor cell profile commonly 
found in Sca-1- cells derived from the heart (Oh et al., 2004; Valente et al., 2014). 
Furthermore, MSCs derived from bone marrow and adipose tissue are known to form a 
homogenous population of elongated spindle-shaped cells with an abundant cytoplasm and 
large nuclei after passage 3 (Li et al., 2015). This characterisation was also consistent with the 
CSCs observed in this study after passage 1, suggesting the isolated cells possess stem cell-
like features. There were no observable morphological differences between diabetic and non-
diabetic CSCs, however a detailed ultrastructural analysis was not performed. Thus far, there 






3.4.2 Growth rate of the CSCs 
There was no change in the growth of the CSCs for the first 9-10 passages. However, in 
subsequent passages there was a noticeable decline in growth rate which was assumed to be 
attributed to cell senescence. This may be due to dysfunctional telomeres or genotoxic 
stresses that promote DNA damage, thus causing irreversible arrest of the cell cycle (Takai et 
al., 2003; Rodier et al., 2009). Senescent cells are also known to have a large, flat 
morphology which resembled the CSCs in my study above passage 10 (Fig. A6 in Appendix 
6) (Rodier et al., 2011). As the CSCs have a similar phenotypic profile to MSCs, it is 
plausible that they undergo the same loss of cell division that is associated with senescence 
after long periods of cell culture (Turinetto et al., 2016). Interestingly, the diabetic CSCs did 
not exhibit any difference in growth rate or growth pattern and were comparable to the non-
diabetic CSCs. This finding contrasts with another study reporting the production of ROS in 
diabetic CPCs, leading to telomeric shortening and irreversible growth arrest (senescence) 
(Rota et al., 2006). However, there were disparities in the type of diabetes as Rota et al. used 
type-1 diabetic mice, whereas I used T2DM mice in my study. This is supported by the fact 
that the apoptotic effect of ROS can vary depending on the age of the animal (Tasat et al., 
2003). Nevertheless, there is very limited evidence for the effect of ROS on CPCs and CSCs 
in vitro. 
 
3.4.3 Purity of the CSCs  
Within the context of this project, stem cell purity can be defined as a measure of the total 
proportion of stem cells within a population that contain a high expression of specific and 
well-recognized antigenic markers (Yuan et al., 2011). As previously mentioned, Sca-1 is 
known as a marker for the identification CSCs and was thus used to measure the purity of 
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these cells. The proportion of Sca-1+ cells were considerably high in both the diabetic and 
non-diabetic sample. 
Despite there being no quantifiable threshold for Sca-1 as a measure of CSC purity, studies 
have indicated that there is a correlation between Sca-1 expression and the CSC phenotype. 
CSC colonies that are isolated from mouse heart tissue containing a high proportion of Sca-1 
(91%) exhibit functional properties that are consistent with the heart-derived stem cells 
originally identified by Takamiya and coauthors (Takamiya et al., 2011). Pure Sca-1+ CSCs 
were able to attenuate the size of infarcted heart tissue, while preserving ventricular function 
and capillary density after transplantation in a mouse model of MI (Takamiya et al., 2011). 
These CSCs were also found to directly differentiate into cardiomyocytes, as well as 
expressing other pluripotent stem cell markers such as Nanog and telomerase reverse 
transcriptase (Takamiya et al., 2011). To further support this correlation, CSC colonies with 
significantly lower levels of Sca-1 (17%) isolated from the same hearts exhibit a substantially 
reduced differentiation potential compared to those with greater Sca-1 expression (Takamiya 
et al., 2011). These evidences, along with the increased expression of Sca-1+ cells in the 
FACS analysis suggests that the CSC population was pure. 
In this chapter I have shown how the Sca-1+ mouse CSCs were isolated from diabetic and 
non-diabetic mice, and purified. I have also outlined the culturing methods used to generate 
sufficient numbers of CSCs for downstream experiments. In the following chapter, I will 
address the first objective of my project by demonstrating how diabetes may alter miRNA 







CHAPTER 4: DIFFERENTIAL REGULATION OF 
MIRNAS IN DIABETIC MOUSE CSCs 
 
4.1 Introduction 
This chapter will focus on demonstrating the differential effects of diabetes on miRNA 
expression in the CSCs isolated from diabetic mice. I will first describe the objective, 
followed by a brief background outlining the theory and rationale of the techniques that were 
used. I will then outline the methodology and results of these experiments, followed by a brief 
discussion of the observed data and its relevance with literature in the field. 
 
4.1.1 Aims and Objectives 
The primary aim for this chapter is to identify whether diabetes causes dysregulation of 
miRNAs derived from mouse CSCs. The second aim is to validate this altered miRNA 
expression through q-PCR and western blot analysis. 
 
4.1.2 Diabetes causes dysregulation of miRNAs 
Diabetes has been demonstrated to cause altered miRNA expression throughout the body in 
both mice and humans (Assmann et al., 2017; Shantikumar et al., 2012). This differential 
expression has been reported in various tissues including skeletal muscle, liver, adipose tissue 
and cardiomyocytes (Fomison-Nurse et al., 2018; Rawal et al., 2017; Shantikumar et al., 
2012). Zampetaki and coauthors identified the abnormal expression of thirteen miRNA 
subtypes in the plasma collected from 80 diabetic individuals compared to healthy volunteers 
over a 10 year observation period (Zampetaki et al., 2010). While the mechanism behind this 
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effect is poorly understood, certain studies have shown that the elevated glucose and hypoxia 
associated with diabetes may alter important proteins that are involved in miRNA synthesis 
(Rahimi et al., 2014). 
To my knowledge, it is not known whether diabetes also affects miRNA expression within the 
CSCs. Therefore, in this section of the project, I aim to determine the differential expression 
pattern of miRNAs in the diabetic CSCs. The outcome of this objective is important as it 
provides implications towards the pathophysiological roles of miRNAs in regulating CSC 
function. 
 
4.1.3 Nanostring microarray can measure differential miRNA expression in diabetic 
CSCs 
Expression profiling has been suggested to determine the level at which the miRNAs are 
expressed, indicating whether a patient is likely to have a disease (Liu et al., 2008). This 
technique has also been extensively performed in stem cell research to determine the effect of 
miRNAs on their biological function. Microarrays are a common method for expression 
profiling that can be used to determine changes in DNA and RNA expression (Govindarajan 
et al., 2012). A genetic microarray consists of a collection of microscopic spots that are 
attached to a glass slide or chip containing target DNA fragments. Fluorescent markers 
attached to specific DNA probes are hybridized to the target DNA fragments through 
complementary sequence binding. A computer can then record the fluorescence emitted from 
the DNA fragments after passing the slide through a laser beam which can be used to 
determine gene expression. This process is sensitive and specific for the simultaneous 
identification of multiple DNA fragments, and can be used to determine differences in the 
expression levels of mRNA/miRNA and protein between healthy and disease states 
(Govindarajan et al., 2012).  
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In this project, a Nanostring microarray was used to determine whether there is a difference in 
the expression profile of miRNAs in diabetic CSCs. The primary advantage of the Nanostring 
microarray is that while most conventional microarrays have a relative measurement of DNA 
that represents mRNA or miRNA expression, the Nanostring microarray measures the 
absolute quantity of the DNA in the cell or tissue extract. This allows for more reliable and 
accurate data, which is crucial as the Nanostring microarray forms the backbone of this 
project and therefore influences important downstream results.  
 
4.2 Methods 
4.2.1 Nanostring microarray  
Six diabetic and six non-diabetic CSC samples (isolated from 24 diabetic and 24 non-diabetic 
db/db mice, respectively) were used for the Nanostring microarray. For each sample, four 
mouse hearts were pooled together (n=6 samples in both diabetic and non-diabetic) to 
generate a sufficient number of CSCs that could be grown and passaged in vitro. After 
purifying the Sca-1 positive CSCs using the MACS protocol (Chapter 3, section 3.2.1), total 
RNA was extracted (detail protocol in Chapter 2, section 2.5) and sent to Nanostring 
Technologies (Life Sciences, Seattle, U.S.A.). An ncounter mouse miRNA expression assay 
kit was used to isolate the miRNAs from the total RNA in each sample through ligation with 
specific, corresponding oligonucleotide tags. For each sample, 100ng of total RNA was added 
to the miRNA-tag ligation reaction and then diluted to a 1:10 concentration to produce 10ng 
of RNA for the miRNA-tag sample.  
These miR-tag samples were then hybridized with 598 random miRNA-specific DNA probes. 
Each probe was arranged in pairs, consisting of a reporter probe, which emits fluorescence; 
and a capture probe, which immobilizes the miRNAs for data collection (Fig. 4.1A). Specific 
miRNA-probe complexes were formed as a result of the hybridization and immobilized on a 
12 sample nCounter cartridge. Excess probes were removed from the complexes and a GEN2 
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digital analyzer (Fig. 4.1B) was then used to image the fluorescent miRNA-probes, quantify 
the number of miRNAs in each sample and group them according to their relative expression 
pattern (Fig. 4.1C). A set of six positive control probes were also included in the reaction 
which had consistent expression across all RNA samples, except one diabetic sample (Fig. 
4.2). This was determined from a Pearson correlation coefficient (R2) of above 0.95. The one 
diabetic sample with a low R2 value indicated an inhibition of miRNA-tag ligation and was 





















Figure 4.1. The primary steps involved in the Nanostring microarray reaction starting with 
hybridization of the miRNAs to reporter and capture DNA probes (A). The colour-coded fluorescent 
reporter probe is used to identify complementary miRNAs upon binding to the capture probe. The 
capture probe binds to and immobilizes the miRNAs before imaging. The samples are then imaged 
and quantified using the GEN2 digital analyzer (B), and the fluorescent bands corresponding to 














4.2.2 Bioinformatic analysis  
4.2.2.1 Predicted effect of differentially regulated miRNAs on CSC function 
To confirm the reliability of the differentially regulated miRNAs within the CSCs, the 
function of the miRNAs must also be considered. As such, the alterations in miRNA 
expression that were demonstrated by the Nanostring analysis must also be validated by 
measuring the expression of corresponding ‘target’ genes. To do this, the miRPath 
bioinformatic tool (DIANA TOOLS (Vlachos et al., 2012)) was initially used to identify 
which of the differentially regulated miRNAs are associated with self-renewal/proliferation, 
the main function of CSCs. Seven miRNAs that were shown to either promote or inhibit cell 
proliferation by targeting genes within these signaling pathways were therefore selected for 
molecular validation by q-PCR (Chapter 4, section 4.2.3). 
  
Figure 4.2. Graph indicating the Pearson Correlation Coefficients (R2) that were calculated for 
positive control samples in the normalization phase of data collection across all RNA samples in 
the Nanostring microarray. Samples 1-6 are total RNA extracted from diabetic CSCs, while 
Samples 7-12 are total RNA extracted from non-diabetic CSCs. One diabetic RNA sample was 
excluded from data analysis due to a low R2 value. 
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4.2.2.2 Identification of target genes 
MiRNA-target prediction databases are presently the most common method for the 
identification of miRNA target genes. These databases were therefore used to identify targets 
for the most substantially and significantly altered miRNAs among those validated by q-PCR. 
Four separate prediction databases (microT-CDS (Paraskevopoulou et al., 2013), miRDB 
(Wong and Wang, 2015), microRNA.org (Betel et al., 2008) and TargetScan (Agarwal et al., 
2015)) were used to identify common target genes for the candidate miRNAs. The selected 
targets were validated by performing western blot analyses (Chapter 4. section 4.2.4) to 
determine the total protein expression of these genes within the diabetic and non-diabetic 
CSCs.  
 
4.2.3 q-PCR of candidate miRNAs  
A quantitative real-time PCR (q-PCR) was used to demonstrate the reliability of the 
dysregulated miRNAs from the Nanostring microarray. q-PCRs can measure the relative 
differences in DNA and RNA expression at the molecular level (Morey et al., 2006). The 
changes in miRNA expression that were observed in the Nanostring analysis were validated by 
real-time PCR analysis for the top seven miRNAs (six upregulated, one downregulated). 
Following the protocol in Chapter 2 (section 2.2.6), total RNA from 10 CSC samples (five 
diabetic, five non-diabetic) that were previously sent to Nanostring Technologies were reverse 
transcribed to cDNA using stem loop primers specific to the candidate miRNAs. I previously 
demonstrated that 20 ng of miRNA was sufficient for the reverse transcription of RNA into 
cDNA, and thus this amount was used to calculate the appropriate volume of RNA sample for 
each reverse transcription reaction (Rawal et al., 2017). The PCR reaction was performed in 
triplicate and repeated twice to obtain a more reliable outcome for the expression of miRNAs 
within the CSCs, as well as to identify any technical errors in the procedure. The q-PCR data 
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was analysed by using the cycle at threshold (Ct) quantification method as described in Chapter 
2, section 2.6.3. This analysis was used to determine molecular fold changes for each miRNA 
subtype within the diabetic and non-diabetic CSCs.  
 
4.2.4 Western blot analysis  
Bioinformatic analysis predicted two common target genes (GSK3-β and MEF2C) for the 
four most significantly altered miRNAs (detailed in the results below). Western blot analysis 
was performed to determine whether the expression of these genes in the diabetic CSCs 
correlated with the altered expression profiles of the corresponding miRNAs. Total protein 
was extracted from four diabetic and four non-diabetic CSCs and probed for Mouse 
monoclonal anti-GSK3-β (NovusBio, 1:1000) and Mouse monoclonal anti-MEF2C 
(NovusBio, 1:1000) against the GSK3-β and MEF2C genes, respectively using the western 
blot protocol detailed in Chapter 2, section 2.7.  
 
4.3 Results 
4.3.1 Diabetes induces dysregulation of miRNAs in CSCs 
Raw data was obtained from the Nanostring microarray for 598 miRNA subtypes in the diabetic 
and non-diabetic CSCs. To provide a reference for comparative analysis, the raw expression 
values of the miRNAs in the diabetic CSCs were further normalized to those in non-diabetic 
CSCs. For this, the mean of the non-diabetic expression values of each sample was first 
calculated. Fold changes for each miRNA subtype were then calculated by dividing the miRNA 
expression value in each diabetic sample by the mean miRNA expression value in the non-
diabetic samples. The mean fold change for each miRNA subtype was calculated and a two-
tailed t-test was performed to determine the statistical significance of these fold changes (Table 
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4.1). MiRNAs were selected on the basis of significant fold change (P<0.05) in the diabetic 
CSCs compared to non-diabetic CSCs. Among the 598 miRNAs tested, 16 miRNAs (as listed 
in Table 4.1), showed significant dysregulation in the diabetic CSCs. Among the 16 miRNAs, 












Fold change in 
diabetic CSCs 
P value 
miR-382 1.46 ± 0.57 2.40 ± 0.17 1.64 ± 0.59 0.001 
miR-376c 1.40 ± 0.39 3.90 ± 0.68 2.79 ± 0.78 0.005 
miR-329 1.97 ± 0.81 3.39 ± 0.61 1.72 ± 0.87 0.010 
miR-1983 1.20 ± 0.26 2.29 ± 0.35 1.91 ± 0.44 0.012 
miR-495 1.26 ± 0.27 2.32 ± 0.35 1.84 ± 0.60 0.016 
miR-28 1.09 ± 0.16 1.74 ± 0.21 1.60 ± 0.44 0.022 
miR-30c 1.16 ± 0.25 0.46 ± 0.08 0.40 ± 0.26 0.025 
miR-99b 1.03 ± 0.09 1.33 ± 0.10 1.29 ± 0.14 0.026 
miR-125b 1.13 ± 0.19 1.56 ± 0.11 1.38 ± 0.22 0.029 
miR-19a 1.31 ± 0.29 2.02 ± 0.30 1.54 ± 0.42 0.036 
miR-106b 1.10 ± 0.17 0.60 ± 0.07 0.55 ± 0.18 0.037 
miR-125a 1.31 ± 0.35 1.63 ± 0.12 1.24 ± 0.37 0.037 
miR-126 2.17 ± 0.86 4.83 ± 1.49 2.23 ± 1.72 0.041 
miR-804 1.03 ± 0.09 1.32 ± 0.11 1.28 ± 0.14 0.043 
miR-365 1.05 ± 0.10 1.39 ± 0.11 1.32 ± 0.15 0.045 
miR-132 1.07 ± 0.14 1.88 ± 0.35 1.76 ± 0.38 0.045 
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4.3.2 Dysregulated miRNAs were predicted to regulate CSC function 
Analysis using the miRPath bioinformatic tool showed that 7 out of the 16 significantly 
altered miRNAs were predicted to regulate signaling pathways associated with proliferation 
and self-renewal, including the wingless-type (WNT), vascular endothelial growth factor 
(VEGF), hedgehog, janus kinase-signal transducer and activator of transcription (JAK-
STAT), focal adhesion and phosphoinositide 3-kinase-protein kinase B (PI3K-AKT) 
pathways. Within these pathways miR-329, -495, -376c, -19a, -365 and -804 were predicted 
to inhibit cell proliferation, while miR-30c was the only miRNA that was predicted to 
promote cell proliferation (Table 4.2). Interestingly, the effect of these miRNAs on 
proliferation correlated with their altered expression profiles in the diabetic CSCs. Among the 
seven miRNAs analysed, those that were predicted to inhibit proliferation (miR-376, -329, -
495, -19a, -804 and -365) were upregulated (Tables 4.1 and 4.2), while the only miRNA that 
was predicted to promote proliferation (miR-30c) was downregulated in the diabetic CSCs 
(Tables 4.1 and 4.2). Since proliferation and self-renewal are the major functions of all stem 
cells (including CSCs), this data suggested that seven miRNAs could regulate CSC function. 





Table 4.2. Predicted effect of miRNAs on cell proliferation 
Signaling pathway miRNAs promoting cell 
proliferation 
miRNAs inhibiting cell 
proliferation 
WNT   miR-376c 
VEGF  miR-329, -495, -19a 
Hedgehog  miR-30c  miR-376c, -19a, -365 
JAK-STAT  miR-329, -495, -19a, -365 
Focal adhesion miR-30c miR-365, miR-804 
PI3K-AKT miR-30c miR-376c, miR-365 
T2DM  miR-329, -495, -19a 
 
 
4.3.3 q-PCR analysis partially validated the Nanostring data 
Out of the seven miRNAs analysed, only four (miR-495 (16.39 ± 1.81 vs 1.14 ± 0.17, 
P<0.001), -329 (12.85 ± 2.28 vs 1.52 ± 0.49, P<0.001), -376c (13.01 ± 2.61 vs 2.30 ± 1.01, 
P=0.002) and -30c (0.29 ± 0.05 vs 1.07 ± 0.12, P=0.006)) replicated the changes observed in 
the Nanostring analysis (Fig. 4.3).  
In contrast, miR-365 (1.41 ± 0.11 vs 1.42 ± 0.49, diabetic vs non-diabetic, P=0.99), miR-19a 
(1.67 ± 0.51 vs 1.25 ± 0.26, diabetic vs non-diabetic, P=0.47) and miR-804 (1.24 ± 0.24 vs 
1.24 ± 0.28, diabetic vs non-diabetic, P=0.99) showed no statistical difference in expression 
pattern in the diabetic CSCs compared to the non-diabetic CSCs (Fig. 4.3).  
Although it was originally considered to be more specific than other microarrays, the 
Nanostring microarray produced false-positive results. Furthermore, the miRNAs which were 
known regulators of CSC proliferation and differentiation (miR-1, -133, -378, -499, -204, and 
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-669) were not among the significantly changed miRNAs in the study. This indicates the 
necessity to validate this Nanostring data using q-PCR and western blot analysis. With their 
dysregulated expression partially validated by q-PCR, miR-329, -376c, -495 and -30c were 
thus chosen as candidate miRNAs for western blot analysis. However, specific gene targets 
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Figure 4.3. Quantitative q-PCR bar graph and scatter plot depicting 
significantly altered miRNAs from Nanostring microarray within 
non-diabetic (n=5) and diabetic CSCs (n=5). MiRNAs -495, -329, -
376c and -30c were significantly regulated in the diabetic CSCs. Data 
are means ± SEM. A two-tailed t-test was performed to determine 
significant data (** = P<0.01). 
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4.3.4    GSK3-β and MEF2C predicted as common targets for four selected miRNAs 
Four online bioinformatic prediction tools (microT-CDS, miRDB, microRNA.org, 
TargetScan) were used to predict gene targets for the four candidate miRNAs validated by q-
PCR. These bioinformatic analyses provide an indication of genes that may potentially acts as 
targets for the miRNAs across all cell types, however experimental validation is required to 
confirm them as targets within the CSCs. Across all four miRNA-target prediction databases, 
the glycogen synthase kinase-3β (GSK3-β) and myocyte specific enhancer-2C (MEF2C) 
genes were identified as the most frequent targets of miR-329, -376c, -495 and -30c. GSK3-β 
was predicted as a target for all four miRNAs, while MEF2C was predicted as a target for 
miR-329, -376c and -495 (Table 4.3). They were therefore chosen as appropriate gene targets 
for a functional validation study using western blot analysis. 
 
Table 4.3. Genes across four miRNA-target prediction databases 
Target gene microT-CDS miRDB microRNA.org TargetScan 
















Furthermore, using miRPath, GSK3-β and MEF2C were also predicted to regulate signaling 
pathways associated with cell proliferation. Two of the prominent signaling pathways that are 
involved with promoting cell proliferation are the PI3K-AKT and mitogen-activated protein 
kinase (MAPK) signaling pathways; both of which were found to contain GSK3-β and 
MEF2C. The MAPK pathway showed significant results (P=0.02) for the expression of the 
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four candidate miRNAs. The following diagrams depict the predicted interactions of the 
miRNAs on both the genes in regulating cell proliferation. GSK3-β acts as a target for miR-
329, -376c, -495 and -30c within the PI3K-AKT signaling pathway (Fig. 4.4A), while 
MEF2C was found to act as a target for miR-329. -495 and -376c within the MAPK signaling 
pathway (Fig. 4.4B). Both signaling pathways also suggested that GSK3-β and MEF2C may 








Figure 4.4. As depicted in the miRPath bioinformatic tool, the PI3K-AKT (A) and MAPK (B) 
signaling pathways lead to cell cycle progression (cell proliferation). In the PI3K-AKT signaling 
pathway, phosphoinositide 3-kinase (PI3K) activates phosphatidylinositol-3,4,5-bisphosphate (PIP3), 
which increases the expression of the tumor-suppressors, cyclin-dependent kinase inhibitor 1 (p21) 
and cyclin-dependent kinase inhibitor 1B (p27). This leads to the activation of cyclins and cyclin-
dependent kinases, which promote the cell cycle. In MAPK signaling, transforming growth factor β 
(TGFβ) activates apoptosis signal-regulating kinase 1 (ASK1), which leads to the activation of the 
dual enzymes, mitogen-activated protein kinase kinase 3 (MKK3) and mitogen-activated protein 
kinase kinase 6 (MKK6). This increases the expression of the tumor suppressor, p38, which activates 
the cell cycle promoter, MEF2C. The four candidate miRNAs (miR-329, -376c, -495 and -30c) were 
found to target one or both of the two target genes (GSK3-β, MEF2C) within these pathways. The 
GSK3-β and MEF2C genes are highlighted in yellow within each pathway. The black, dashed arrow 
indicates stimulation, while the red dotted line indicates miRNA inhibition. 
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4.3.4 GSK3-β and MEF2C protein expression did not change in diabetic CSCs 
An inversely proportionate difference in the protein expression of GSK3-β and MEF2C in the 
diabetic CSCs could functionally validate the change in expression of miRNAs -329, -376c, -
495 and -30c that were observed in the Nanostring microarray and q-PCR data. However, 
despite being predicted as suitable targets by four miRNA-target prediction databases, 
western blot analyses showed no change in the expression pattern of both GSK3-β and 
MEF2C in the diabetic CSCs (Fig. 4.5). This outcome revealed that, at least for the purposes 
of this study, the method of predicting target genes for miRNAs by using miRNA-target 

































 Figure 2. mRNA expression of target genes, GSK3-β and Mef2C in diabetic and non-diabetic CSCs. 
Representative MEF2C immunoblot
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Figure 4.5. Representative immunoblots and western blot quantification data (bar graph and scatter 
plot) (C) of GSK3-β (47kDa) (A) and MEF2C (51kDa) (B) target gene expression in diabetic (n=4) 
and non-diabetic CSCs (n=4). β-actin (42kDa) was used as an endogenous control for each gene. Data 





4.4.1 Summary of results 
In this Chapter, I have shown for the first time that diabetes induces dysregulation of miRNA 
expression in CSCs. This was demonstrated using the Nanostring microarray which showed 
that 16 out of 598 miRNAs investigated exhibit significantly altered expression profiles in the 
diabetic CSCs. With the aid of bioinformatic tools to correlate the altered expression of these 
miRNAs with the main function of CSCs (self-renewal and proliferation), 7 of the 16 
miRNAs were found to be predicted to target genes that led to this outcome. Among those 
that were predicted to regulate CSC function, the q-PCR validated only four miRNAs (miR-
329, -376c, -495 and -30c). Bioinformatic analysis predicted GSK3-β and MEF2C as suitable 
common targets for the four validated miRNAs. However, western blot analysis did not show 
any changes in both GSK3-β and MEF2C expression in the diabetic CSCs, suggesting the 
paucity of the prediction software in my experimental setup.  
 
4.4.2 Nanostring microarray and q-PCR experiments 
The Nanostring microarray has several advantages compared to other more conventional 
microarrays. It is extremely specific due to the inclusion of unique oligonucleotide tags, as well 
as a pair of reporter and capture probes that bind to each miRNA in the reaction. After 
hybridisation with the probes, the miRNAs are labelled with a colour-code to increase the 
likelihood of detection (Malkov et al., 2009). Another advantage is that the Nanostring 
microarray measures miRNA expression without the need for amplification, unlike in 
traditional microarray analysis. This eliminates enzymatic bias that occurs in other microarrays 
when amplifying DNA (Geiss et al., 2008). Furthermore, it contains a more reliable 
quantification procedure in that the absolute number of each specific miRNA is counted, 
providing a more accurate dataset compared to those derived from methods where miRNAs are 
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expressed as a relative amount (Llorens et al., 2013). This aspect is especially important in my 
study because it is concerned with determining differences in absolute expression of miRNAs 
between two different conditions.  
Despite these advantages, among the seven miRNAs chosen, only four (miR-329, -376c, -495 
and -30c) were replicated to exhibit similar expression differences by q-PCR analysis. Although 
the fold changes between nanostring analysis and q-PCR were not similar, the trend in the 
significantly altered miRNAs was the same. It is also noteworthy that nanostring analysis counts 
the absolute miRNA levels, whereas q-PCR counts the relative change in the miRNA 
expression levels. Hence it is not surprising that the fold changes look different. Therefore, 
although the reproducibility of the Nanostring microarray has been praised over other 
techniques (Veldman-Jones et al., 2015), my study has revealed that the Nanostring data must 
be validated by other means to produce the most reliable results. The three miRNAs (miR-19a, 
-804 and -365) that could not be validated using this method may reflect the unforeseen 
inaccuracy of the Nanostring microarray, although limitations of the 95% confidence of the 
two-tailed t-test may have also contributed. Nevertheless, the four miRNAs (-495, -376c, -329 
and -30c) that were validated by q-PCR were regarded as reliable due to their highly statistically 
significant differential expression that matched with their original Nanostring expression 
profiles in the diabetic CSCs. 
 
4.4.3 Candidate miRNAs on stem cell function and the diabetic heart 
While the roles of the differentially expressed miRNAs (-329, -376c, -495 and -30c) have been 
well established in various forms of cancer (Kang et al., 2016; Yang et al., 2014), only minimal 
evidence is available for their role in multipotent stem cells. MiR-495 and miR-329 have been 
demonstrated to regulate the differentiation of human MSCs and ESCs (Li et al., 2017; Cha et 
al., 2016; Lee et al., 2014, Yang et al., 2013), while miR-376c and miR-30c have been shown 
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to regulate the differentiation of mouse and human NSCs (Sun et al., 2016; Liu et al., 2014). 
To my knowledge there is no evidence for the role of these miRNAs in CSCs. However, their 
predicted effect on cell proliferation (Table 3) can be compared to other studies that have 
investigated their self-renewing capabilities in various cell lines (Sun et al., 2016; Jin et al., 
2013; Xiao et al., 2013). Furthermore, the pathophysiological roles of these miRNAs can be 
further understood by determining whether their differential expression in the diabetic CSCs 
(Table 2) correlates with their impact on the diabetic heart.  
 
4.4.3.1 MiR-30c 
Among the candidate miRNAs, miR-30c is the only miRNA that is known to be highly 
expressed in the heart (Cheng et al., 2007). It is also associated with DCM as demonstrated by 
Raut and colleagues, who showed that miR-30c binds to and targets cell division control protein 
42 (CDC42), p21-activated kinase 1 (PAK1) and cell tumor antigen p53 in cardiomyocytes of 
diabetic rats (Raut et al., 2016; Raut et al., 2015). These genes have been found to promote 
myocardial fibrosis and hypertrophy, and therefore lead to cardiac dysfunction (Ye et al., 2013; 
Care et al., 2007). This suggests that miR-30c is beneficial in preserving cardiac function during 
diabetes, correlating with the downregulated expression of this miRNA in the diabetic CSCs 
(Table 2). 
MiR-30c was also the only candidate miRNA that was predicted to promote cell proliferation 
(Table 3). The effect of miR-30c on proliferation is antagonistic in cancerous conditions with 
various studies showing miR-30c to reduce proliferation in cancer cell lines (Jia et al., 2011; 
Irani and Hussain, 2015). However, in non-cancerous cells such as NSCs, Sun and colleagues 
demonstrated that miR-30c overexpression promotes proliferation by reducing the expression 
of semaphoring 3A (SEMA3A), a protein involved in promoting neurogenesis (Sun et al., 
2016). In the heart, Liu et al. showed that miR-30c overexpression promotes myocardial cell 
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proliferation by inhibiting the transcription factor, GLI2 within the Hedgehog signaling 
pathway (Liu et al., 2016). Notably, this was also one of the signaling pathways in which 
miR-30c was predicted to promote proliferation using the bioinformatic analysis (Table 3). 
This therefore supports the predicted effect of miR-30c on the proliferation of CSCs.  
 
4.4.3.2 MiR-329 
MiR-329 was upregulated in the diabetic CSCs (Table 2). This is supported by studies that have 
demonstrated a pathological role for miR-329 in the diabetic heart. Wang and colleagues 
demonstrated that miR-329 overexpression in mouse endothelial cells inhibits the expression 
of CD146, a promoter of cell proliferation and angiogenesis (Wang et al., 2013). This was 
further supported by Welton et al., who showed that knocking down miR-329 increases arterial 
endothelial cell proliferation, as well as neovascularization and blood flow recovery after 
femoral artery ligation in a model of critical limb ischemia (Welton et al., 2014).  
Bioinformatic analyses predicted that miR-329 inhibits cell proliferation (Table 3). Evidence 
for this has been demonstrated by a study from Yang and colleagues who showed that miR-
329 can inhibit the proliferation of neuroblastoma cells by targeting lysine-specific 
demethylase 1 (KDM1A) (Yang et al., 2014). In addition, using glioma cells, Xiao and 
colleagues identified the transcription factor, E2F1 as the direct target for miR-329. E2F1 is a 
promoter of the AKT signaling pathway, which is a known activator of the cell cycle (Xiao et 
al., 2013). Growth factor receptor-bound protein 2 (GRB2) was also identified as another 
direct target for miR-329 in pancreatic cancer cells. The overexpression of GRB2 reduces the 
anti-proliferative and apoptotic effects of miR-329 in these cells (Wang et al., 2016). These 




The role of miR-495 in the diabetic heart is unclear, as studies have shown conflicting evidence 
as to whether this miRNA is beneficial or pathological to cardiac function. Therefore, there is 
no conclusive evidence to support the upregulation of miR-495 that was observed in the diabetic 
CSCs (Table 2). One study found that miR-495 knock-down increases endothelial cell 
proliferation, as well as neovascularization and blood flow recovery in mice with ischemia 
(Welton et al., 2014). Conversely, Clark and Naya demonstrated that miR-495 overexpression 
promotes the proliferation of rat cardiomyocytes by targeting the transcriptional coactivator and 
cell cycle inhibitor, CITED2 (Clark and Naya, 2015). One reason for this differential effect may 
be that the role of miR-495 in the heart is species-dependent as the studies showed it to be 
beneficial in the mouse heart, but pathological in the rat heart.  
Bioinformatic analyses also predicted miR-495 to inhibit cell proliferation (Table 3). This is 
supported by a study from Chen and colleagues who found that miR-495 overexpression, as 
well as knock-down of the miR-495 target gene, CDK6, causes cell cycle arrest and inhibition 
of cell proliferation in glioblastoma multiform cells (Chen et al., 2013). In another study, Chu 
and colleagues showed that miR-495 inhibits the proliferation of lung cancer cells by 
targeting metastasis-associated protein 3 (MTA3) (Chu et al., 2013). However, because miR-
495 has mostly been studied in cancer cell lines, it is unclear whether this anti-proliferative 
effect can be translated from cancer tissue to healthy tissue. MiR-495 is also known to inhibit 
stem cell differentiation. In particular, this role has been identified by inhibiting the target 
genes,  DNMT3A methyltransferase and SOX9 transcription factor in mouse ESCs and 




Compared to the other candidate miRNAs, considerably less information is known about the 
role of miR-376c in the diabetic heart. The predicted effect of miR-376c inhibiting cell 
proliferation was also not supported by the literature. On the contrary, certain studies have 
indicated that miR-376c promotes proliferation. Fu and colleagues showed that miR-376c 
overexpression increases the proliferation of trophoblasts by targeting activin receptor-like 
kinase 5 (ALK5) and activin receptor-like kinase 7 (ALK7) receptors (Fu et al., 2013). In 
contrast, Jin and colleagues showed that miR-376c overexpression inhibited cell proliferation 
and invasion in osteosarcoma cells (Jin et al., 2013). However, as with other miRNAs, miR-
376c has differential effects on non-cancerous cells as shown by Kureel and colleagues, who 
showed that miR-376c overexpression inhibited the differentiation of osteoblasts (Kureel et al., 
2018). Based on this, my study has provided the first evidence that diabetes increases the 
expression of miR-376c in CSCs. 
 
4.4.4 Predicted target gene expression in diabetic CSCs 
Bioinformatic analysis predicted GSK3-β and MEF2C as suitable targets for the candidate 
miRNAs. Both GSK3-β and MEF2C have been demonstrated to regulate the proliferation, 
differentiation and survival of stem cell subtypes (Esfandiari et al., 2012; Li et al., 2008). 
However, western blot analyses showed no change in total protein expression of these genes 
between diabetic and non-diabetic CSCs (Fig. 4.5). These results differed from several other 
studies which indicate that the expression profiles of GSK3-β and MEF2C are altered in diabetic 
mice and rats (Feng et al., 2008; Eldar-Finkelman et al., 1999).  
One explanation for these results is that the expression of these genes are tissue-specific in the 
diabetic condition. This tissue-specificity has been indicated by a reduction in GSK3-β 
expression in human skeletal muscle, but no change in expression in adipocytes after 
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troglitazone treatment (Ciaraldi et al., 2006). It was also supported by Patel and colleagues who 
demonstrated that GSK3-β knock-down in mice led to a greater improvement in glucose 
tolerance and insulin signaling in skeletal muscle compared to other tissues such as the liver 
(Patel et al., 2008). GSK3-β primarily acts by inactivating glycogen synthase, an enzyme that 
limits the effects of diabetes by converting glucose to glycogen (Saltiel, 2001). The extent to 
which GSK3-β regulates glucose metabolism may therefore reflect its differential expression 
in other tissues.  
Despite being a common method for target identification, recent analysis of the miRNA-target 
prediction software has revealed that this method relies on a computational prediction and 
therefore may not always produce experimentally validated results (Witkos et al., 2011). It is 
noteworthy that the prediction software is primarily used as a starting tool for further analysis. 
Nevertheless, this may indicate that in order to validate the change in expression of the 
candidate miRNAs, another form of validation must be designed that is specific for the 
experimental samples used in this study. In the following chapter, I will argue that due to the 
complexity of the protein interactions and variability in growth conditions of the CSCs in vitro, 
the researcher must identify certain target genes within their own experimental CSC samples 





CHAPTER 5: IDENTIFICATION AND 
VALIDATION OF MIRNA TARGETS 
 
5.1 Introduction 
In Chapter 4, the western blot analysis of GSK3β and MEF2C failed to show any change in 
expression in the diabetic CSCs, despite being predicted as miRNA targets in multiple protein 
databases. It also indicated that the bioinformatic prediction software may not be as reliable as 
once thought, and a more accurate technique for miRNA target identification was required. In 
this Chapter, mass spectrometry was used as a tool for the identification of miRNA target 
genes. Once appropriate target genes have been selected, they can be confirmed as direct 
miRNA targets by luciferase assays. If these techniques proved to be successful, western blot 
analysis could then be repeated for the new miRNA target genes in diabetic and non-diabetic 
CSCs. This in turn would address the first objective of the project. Evidence for the 
advantages of these techniques will first be described, followed by the corresponding 
protocols that were performed. The data will then be analysed and compared to the relevant 
literature. 
 
5.1.1 Aims and Objectives 
The primary aim of this chapter was to identify the direct target genes for the miRNAs which 
showed altered expression in the diabetic CSCs in order to validate the functional efficacy of 
the altered miRNAs. The second aim was to validate the expression of these genes in the 




5.1.2 Conventional techniques for identifying miRNA targets 
Due to the fact that the primary function of miRNAs is to regulate gene expression, 
appropriate target genes must first be identified in order to functionally validate the changes 
observed in the diabetic CSCs. There are a number of existing techniques that have been used 
for this purpose. Gene expression analysis has been applied by correlating the differential 
expression of miRNAs with subsequent target mRNA degradation after transfection in cell 
lines (Lim et al., 2005). Alternatively, RISC components such as argonaute proteins can be 
tagged with an epitope and co-immunoprecipitated along with target mRNA in cells by using 
an antibody against the epitope. The precipitates can then be analysed by a microarray to 
identify miRNA targets (Beitzinger et al., 2007).  
The most common method for identifying miRNA targets is through the use of bioinformatic 
tools and target-based prediction software. Although there have been advances in the accuracy 
of computational algorithms within these databases, there are still a high number of false 
positives resulting from inaccurate sequence matching (Oh et al., 2017; Oliveira et al., 2017; 
Pinzόn et al., 2017; Min and Yoon, 2010). Evidence for this limitation was notably found in 
my study (Chapter 4, section 4.3.5) where the GSK3β and MEF2C genes, that were predicted 
to be direct targets for the dysregulated miRNAs in diabetic CSCs, showed no change in total 
protein expression. Quantitative proteomics is a biochemical approach towards miRNA target 
identification that is recently gaining a lot of interest due to its high sensitivity and 
effectiveness. This method relies on mass spectrometry to assess and quantify peptides in an 
experimental sample, and then correlate the results with advanced sequencing databases (Ma 





5.1.3 Mass spectrometry 
Mass spectrometry (MS) is a technique that measures the chemical compositions of 
substances by ionization. The ions can be sorted and separated according to their mass and 
charge by a mass spectrometer. MS has been routinely used to characterise molecules by 
determining their mass, isotopic signature or chemical structure (Biemann, 1963). It can also 
be applied towards the characterisation of proteins of interest whereby the proteins are 
enzymatically digested into peptides and then fractionated into ions (Wysocki et al., 2005; 
Trauger et al., 2002). The isobaric tags for relative and absolute quantitation (iTRAQ) method 
can be used to label the resulting peptides and quantify them based on the signal intensities of 
the fractionated ions. These signal intensities correspond to the relative abundance of a 
peptide in a sample population (Wiese et al., 2007). Peptide mass fingerprinting can then be 
used to identify an unknown protein in the sample by correlating the mass-to-charge ratios of 
the ions with protein databases that contain sequencing information (James et al., 1993). 
Recent evidence for the use of this technique for the characterization and identification of 
miRNA target genes is very convincing (Ma et al., 2015). For this reason, I used MS in my 
study to determine the appropriate target genes for the differentially regulated miRNAs in the 
diabetic CSCs.  
 
5.1.4 Luciferase for validating miRNA targets 
The genes identified from mass spectrometry must then be confirmed as direct targets by 
performing a luciferase assay. This assay is commonly used to study gene expression in 
mammalian cells at the transcriptional level. Each luciferase assay contains a specific 
oxidative luciferase enzyme that enables the emission of light from the organisms that express 
them. For instance, the firefly luciferase assay utilizes a specific luciferase enzyme in fireflies 
to convert luciferin into oxyluciferin. The energy released by this reaction (shown below) 
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comes in the form of light, and is proportional to the amount of luciferase in the assay 
(Nguyen et al., 1988).  
 
Luciferin + O2 + ATP                                           Oxyluciferin + CO2 + AMP + PPi + LIGHT 
 
The assay can be used in conjunction with MS for identifying target genes. The regulatory 
(3’) region of the specific, identified gene is cloned in an expression vector (plasmid) 
downstream to a luciferase gene and introduced into cells. When the cell is lysed, the 
luciferase enzyme is exposed to oxygen. The luciferin substrate can then be added to the cell 
to produce light (luminescence) which can be measured using a luminometer. The 
luminescence produced is proportional to the expression of the gene of interest that was 
cloned with luciferase (Nguyen et al., 1988). As such, I utilized a firefly luciferase reporter 
assay in my project to determine the expression of a predicted target gene of one of the 
differentially regulated miRNAs.  
The identification of miRNA targets is vital for confirming the differential expression of the 
candidate miRNAs (-495, -376, -329 and -30c) that were partially validated by q-PCR. 
Contrary to my previous attempts involving the use of prediction software, here I used a more 
specific proteomic technique (MS) to predict the target genes for the differentially regulated 








5.2.1 Mass spectrometry (MS) protocol 
5.2.1.1 Sample preparation 
I performed the sample preparation for MS with help from Dr. Torsten Kleffman (Department 
of Biochemistry, University of Otago). Total protein was initially extracted from diabetic 
(n=5) and non-diabetic CSC samples (n=5) and quantified by performing a Bradford assay 
(Chapter 2). The normal recipe for RIPA lysis buffer was modified for MS, in which the SDS 
was used at a lower concentration (0.02% for MS compared to 0.1% in the regular RIPA 
buffer) and Triton was excluded to limit the amount of detergent in the protein suspensions. 
The total protein samples were processed by a filter-aided sample preparation (FASP, 
Wiśniewski et al., 2009). The procedure for this was modified for compatibility with 
downstream iTRAQ labelling. The protein samples were loaded into 0.5 mL ultrafiltration 
units (10 kDa cut-off) and buffer-exchanged into 8 M urea in 0.25 M triethylammonium 
bicarbonate (TEAB). The samples were then washed and purified by centrifuging three times 
at 14,000 x g at 20 °C for 15 minutes each, reducing the volume of the samples down to 20 
µL each time. The washing step reduces the presence of detergents and nucleic acids in the 
samples that can produce excessive background signal in the mass spectrometer. The protein 
concentration was measured in aliquots of each sample by performing a Bradford assay 
(Chapter 2, section 2.7.2). The proteins in each sample were then digested into smaller 
peptides by adding trypsin (1 µg trypsin / 20 µg of protein) on-filter for 24 hours at 37 °C. An 
additional aliquot of trypsin was added to each sample and incubated for 4 hours at 37 °C, 
before transferring the filter content of each sample into new tubes. The peptides were 
labelled with iTRAQ reagents (8plex iTRAQ kit, Sigma-Aldrich, Germany) and pooled 
according to the manufacturer’s instructions.  
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Peptides of the pooled iTRAQ labelled samples were subjected to off-gel isoelectric focusing 
(IEF) using an Agilent OFFGEL Fractionator (Agilent Technologies). Isoelectric focusing 
separates the peptides in each sample by subjecting them to an electric field along a pH 
gradient. As the peptides migrate from the anode to the cathode, they eventually stop when 
they lose their charge. This separates the peptides into stationary bands called ‘fractions’ 
(Gundry et al., 2010). The samples in this project were fractionated into 24 fractions along a 
pH gradient (pH 4-10) according to the manufacturer’s instructions. The fractions were 
concentrated using a centrifugal vacuum concentrator and analysed in duplicates by nanoflow 
liquid chromatography-coupled LTQ Orbitrap tandem mass spectrometry (Tripletof 6600). 
The nanoflow liquid chromatography ionises the peptides into a small heated capillary within 
an electric field to produce charged droplets. The ions can then be characterized according to 
their mass-to-charge ratio (MS/MS spectra) by the mass spectrometer (Gundry et al., 2010).  
During the nanoflow liquid chromatography, half of each fraction was loaded onto a trap 
column and separated on a packed emitter tip column through an acetonitrile gradient (5-35%) 
in aqueous 0.2% formic acid for 45 minutes, followed by an increase to 99% over 10 minutes. 
The mass spectrometer was operated in MS mode at 60,000 resolution (400 m/z) and eight 
data-dependent MS/MS scans were performed on the ions. The first four scans were 
performed as collision induced dissociation (CID) scans on the strongest four precursors for 
peptide identification. CID allows for fragmentation of the ions by colliding them with neutral 
molecules (eg. nitrogen) (Parcher et al., 2018). The next four scans were performed as high 
energy collision induced dissociation (HCD) scans of the same four precursors for reporter 
ion quantification. The fragmented ions were thus detected and quantified in the mass 




5.2.1.2 Peptide mass fingerprinting using SWATH acquisition 
The MS data was analysed by peptide mass fingerprinting in order to identify differentially 
regulated miRNA targets. The SWATH (Serial window acquisition of theoretical spectra) 
acquisition containing Peakview 2.0 and MarkerView 1.2 analyses software (SCIEX, 
Australia) was used for this purpose. The MS/MS spectra of 2000 randomly selected peptides 
were imported into PeakView and converted into SWATH files containing specific peptide 
tags. PeakView expresses the MS/MS spectra of each peptide as ‘peaks’ based on the 
intensity of their mass-to-charge ratio. The data was then imported to MarkerView which 
displays the quantified peaks in a scatter plot. The principal component analysis function was 
used to calculate a logarithmic (Log10) fold change signifying the relative difference in the 
MS/MS spectra of each peptide in the diabetic and non-diabetic samples. This data could then 
be sorted based on statistical significance by performing a two-tailed t-test on the MS/MS 
spectra of each peptide. Peptides were only selected if they exhibited a Log fold change 
within a selected range (-0.3 < x < 0.3) as well as a P value below 0.05. The MS/MS spectral 
data of each selected peptide could then be converted into peptide sequences by importing 
their SWATH peptide tags into FASTA software (EMBL-EBI, UK). The sequence of each 
peptide was then searched in the National Centre for Biotechnology Information database 
(ncbi.nlm.nih.gov/proteins) to determine the entire genome sequence of the corresponding 
gene. The identities of these genes were verified by importing the genome sequences into the 
STRING database. In this way, a list of genes were identified in the original experimental 






5.2.1.3 Correlating results to bioinformatic tools and literature 
The identified genes were searched in five well known bioinformatic databases (TargetScan, 
miRanda, RNA22, microRNA.org and miRDB) to determine which have been predicted as 
targets for the differentially regulated candidate miRNAs (miR-329, -376c, -495 and -30c). 
Two target genes, voltage-dependent anion-selective channel 1 (VDAC1) and cyclin-
dependent kinase 6 (CDK6) were finally selected based on two criteria:  
1. The magnitude of the fold change of a corresponding peptide determined from mass 
spectrometry analysis  
2. The number of bioinformatic databases that have predicted the genes as targets for the 
differentially regulated miRNAs 
 
5.2.2 Luciferase assay protocol 
A luciferase assay was performed to determine whether the VDAC1 gene identified from MS 
analysis is a direct target for miR-30c. VDAC1 is a 31 kDa protein that forms a channel 
through the outer mitochondrial and plasma membranes. The channel at the outer 
mitochondrial membrane allows for the entry and exit of small hydrophilic molecules into the 
mitochondria, while the channel in the plasma membrane allows for the diffusion of 
substances that regulate cell volume (Baumgarner et al., 2009; Baker et al., 2004). 
Plasmids containing a 3’UTR region of the VDAC1 and CDK6 genes were first transformed 
into and extracted from bacteria, and then quantified using a Nanodrop Spectrophotometer. 
The 3’UTR region of CDK6 was included as a negative control due to the fact that it was not 
a predicted target for miR-30c. Next, one non-diabetic CSC sample was cultured in T25 flasks 
at P8. Once confluent, the cells were counted using a hemocytometer and seeded into 16 wells 
of a white 96-well plate (1 x 104 cells / well) at P9. The cells were then incubated for 24 hours 
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at 37 °C. The CSCs in each well were co-transfected with either miR-30c or scrambled mimic 
as well as either of the 3’UTR plasmids of each gene in quadruplicate, according to Table 5.1. 
The miR-30c/scrambled mimic were added to each well at a concentration of 10 µM, while 
the 3’UTR plasmids were added at a concentration of 250 nM along with the standard dilution 
of RNAiMAX lipofectamine reagent for a 96-well plate (Table 5.1). 
 
 
The miR-30c precursor (sequence in Appendix 7) or scrambled mimic was first diluted by 
adding 0.5 µL of the mimic to 25 µL of serum-deprived DMEM/F12 media. A 1.5 µL volume 
of lipofectamine reagent was also diluted in 25 µL of serum-deprived DMEM/F12 media and 
added to the diluted miR-30c/scrambled mimic. The mixture was then incubated for 5 minutes 
at RT, and then added to each corresponding well of the 96-well plate. The 3’UTR plasmids 
consisting of the VDAC1, CDK6 or Renilla control was subsequently added to the wells at a 
volume of 1.5 µL before incubating the plate for 48 hours at 37 °C.  
The Luc-Pair Duo-Luciferase assay kit (GeneCopoeia, USA) was then used to perform the 
luciferase assay. The kit contains two luciferin substrates (Luc Sub I and II) which are 
oxidized by the firefly luciferase enzyme. The 96-well plate containing the CSCs was allowed 
to equilibrate to RT and the growth media was aspirated. Twenty microlitres of 10-times 
diluted luciferase lysis buffer was added to each well. The plate was then incubated on an 
 
Table 5.1. Volumes and concentrations of reagents for luciferase assay 
Reagents Concentration per well Volume per well (µL) 
Lipofectamine RNAiMAX reagent  1.50  
DMEM/F12 media for 
lipofectamine dilution 
 25 
Renilla control 3’UTR plasmid 775 ng/µL 0.32 
VDAC1 3’UTR plasmid 704 ng/µL 0.36 
CDK6 3’UTR plasmid 519 ng/µL 0.48 
MiR-30c/scrambled mimic 10 mol/L 0.50 





orbital shaker for 15 minutes to mix the solution. FLuc (Firefly) and RLuc (Renilla) working 
solutions were prepared by adding 10 µL of Luc Sub I and II (100X) to 1 mL of Luc Buffer I 
and II, respectively. The solutions were then mixed well by inverting the tubes and then 
incubated in the dark for 5 minutes at RT. After the incubation period, 100 µL of FLuc 
solution was added to each well of the 96-well plate and mixed by pipetting up and down 
using a multi-channel pipette. The tubes were then incubated in the dark for 5 minutes at RT 
and luminescence was measured using a luminometer. After recording the luminescence 
values, 100 µL of RLuc solution was added to each well. The solution was mixed by pipetting 
and incubated in the dark for 5 minutes at RT, luminescence was measured as described 
above. The ratio of luminescence emitted from the Firefly and Renilla luciferase enzymes in 
the CSCs transfected with either miR-30c or scrambled mimic was then calculated from 
which a fold change was determined for the expression of the 3’UTR of VDAC1 and CDK6. 
A two tailed t-test was performed to determine the significance of these fold changes. 
 
5.2.3 Western blot analysis protocol for identifying target genes 
Once the target genes were identified, western blot analysis was performed for functional 
validation at the protein level. Western blots were performed as described in Chapter 2, 
section 2.8. Following the transfer of proteins, membranes were incubated with a mouse, 
monoclonal anti-CDK6 antibody (1:1000, Cell Signaling Technology, U.S.A, 40kDa, Table 
A1.2 in Appendix 1) and a rabbit, polyclonal anti-VDAC1 antibody (1:1000, abcam, 
Australia, 31kDa, Table A1.2 in Appendix 1). Goat, anti-mouse or mouse, anti-rabbit 
antibody (1:3000, ThermoFisher, USA, Table A1.2 in Appendix 1) were subsequently used as 
secondary antibodies for anti-CDK6 and anti-VDAC1, respectively. A rabbit, polyclonal anti-
α-tubulin antibody (1:1000, abcam, Australia, 50kDa, Table A1.2 in Appendix 1) was also 
used to identify the α-tubulin gene, which was used as a loading control. Western blots were 
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repeated three independent times for each antibody, and quantified by densitometry using 
ImageJ software (NIH, USA). 
 
5.3 Results 
5.3.1 Target proteins were identified by Mass Spectrometry 
Among the 2000 peptides evaluated by mass spectrometry, there were 435 (22%) that were 
significantly dysregulated in diabetic CSCs. Among these, 197 peptides (45%) were 
significantly upregulated and 238 peptides (55%) were significantly downregulated in the 
diabetic CSCs.  
From this list, the 16 most significantly upregulated (fold change > 1.5 in diabetic CSCs) and 
16 most significantly downregulated (fold change < 0.8 in diabetic CSCs) peptides were 
selected for bioinformatic analysis. Bioinformatic analysis was used to determine which of 
these peptides constitute appropriate miRNA targets. In this analysis, five miRNA-target 
prediction databases (TargetScan, RNA22, miRanda, microRNA.org, miRDB) were searched 
to determine which of the 32 significantly dysregulated peptides were likely to bind to the 
candidate miRNAs (miR-329, -495 and -376c and -30c). The results revealed that 10 
significantly dysregulated peptides (8 downregulated, 2 upregulated) constituted proteins that 




Table 5.2. Significantly differentially expressed MS peptides as miRNA targets 
Target proteins Fold change (diabetic vs 
non- diabetic CSCs) 
Candidate miRNAs 
predicted 
Number of databases 
Downregulated     
KPNB1 0.39 (P<0.001) miR-376c 1 (TargetScan) 






2 (miRDB, RNA22) 
3 (TargetScan, miRDB, 
miRanda) 
1 (TargetScan) 



















2 (TargetScan, miRanda) 





2 (TargetScan, miRanda) 
2 (miRanda, 
microRNA.org) 











2 (TargetScan, miRanda) 
 
1 (TargetScan) 
Upregulated     






VDAC1 1.67 (P<0.01) 
 





Table 5.2. Table describing the significantly altered target proteins from the MS analysis. The target proteins are 
separated based on whether they are upregulated or downregulated in the diabetic CSCs. Significance was determined 
by a two-tailed t-test. Bioinformatic miR-target prediction databases were used to identify the target proteins that are 
predicted to be regulated by the candidate miRNAs. A larger group of dysregulated MS peptides are shown in 
Appendix 11. KPNB1 = Importin subunit 𝛽1, CDK6 = Cyclin-dependent kinase 6, GCC2 = Grip and coiled-coil 
domain-containing protein 2, SARNP = SAP domain-containing ribonucleoprotein, GUCY1B1 = Guanylate cyclase 
soluble β1, DNAJB4 = DnaJ homolog subfamily B member 4, TPT1 = Translationally controlled tumor protein 1, 
CMPK1 = Cytidine/Uridine monophosphate kinase 1, MBNL2 = Muscleblind-like splicing regulator 2, VDAC1 = 
Voltage-dependent anion-selective channel 1.  
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Two of these proteins (CDK6 and VDAC1) were selected for western blot analysis using two 
criteria: 
1. The number of databases that identified an association between miRNA and protein 
2. The correlation between the differential expression of the miRNAs and protein in 
diabetic CSCs 
The cell cycle promoter, CDK6 was predicted to be a target for miR-329, -495 and -376c in 
four databases combined (miRDB, RNA22, miRanda and TargetScan). Out of all peptides 
analysed, this was the most number of databases where a peptide was identified as a predicted 
target for the candidate miRNAs. The downregulation of CDK6 in the diabetic CSCs (fold 
change of 0.44 ± 0.12) also correlated with the upregulation of miR-329, -495 and -376c in 
the original Nanostring microarray (Chapter 4, section 4.3.1). This protein was therefore 
selected as the most appropriate target for validating the altered expression profiles of miR-
329, -495 and -376c in the diabetic and non-diabetic CSCs.  
VDAC1 was predicted to be a target for miR-30c in two databases (RNA22 and 
microRNA.org). In addition, the upregulated expression of VDAC1 in the diabetic CSCs (fold 
change of 1.67 ± 0.11) also correlated with the downregulated expression of miR-30c in the 
original Nanostring microarray. VDAC1 was also the only significantly upregulated peptide 
that was predicted to be the sole target for miR-30c. For these reasons, VDAC1 was selected 
as the most appropriate target for validating the altered expression profile of miR-30c in the 
diabetic and non-diabetic CSCs. 
Among the 2000 randomly selected peptides assessed by mass spectrometry, those 
corresponding to the CDK6 and VDAC1 genes were also among the most substantially and 
significantly (P<0.05) altered in the diabetic CSCs. The significantly altered expression 
profiles of CDK6 and VDAC1 are summarized in Table 5.3, along with the relevant 





The characteristics of CDK6 and its relation to stem cell function are well documented 
(Laurenti et al., 2015; Scheicher et al., 2015), however not much is known about the 
functional consequences of VDAC1 dysregulation in CSCs. Furthermore, the role of miR-30c 
is not well defined in CSCs. For these reasons, VDAC1 was selected for a luciferase assay to 
confirm this protein as a direct target for miR-30c, before examining the role of miR-30c in 
diabetic CSCs by performing functional experiments. 
 
5.3.2 Luciferase assay confirmed VDAC1 as the direct target of miR-30c  
The luciferase assay was performed to confirm if VDAC1 is a direct target for miR-30c as 
indicated by the MS data. Mean expression data was calculated for 3’UTR of VDAC1 in the 
CSCs transfected with miR-30c and scrambled mimic which was expressed as a percentage of 
the VDAC1 expression in the scrambled control after normalisation. As shown in Figure 5.1, 
transfecting cells with the miR-30c precursor mimic significantly reduced the luminescence of 
the VDAC1 3’UTR (0.62 ± 0.18, P < 0.01). This supports the MS data and bioinformatic 
analysis and provides the first evidence that VDAC1 is a ‘direct’ target for miR-30c. The 
inclusion of the CDK6 3’UTR as a negative control showed a non-significant increase (1.34 ± 
Table 5.3. Target genes chosen using mass spectrometry from those significantly regulated 
in diabetic CSCs 
Target gene miRNAs 
predicted 
Bioinformatic databases Fold change in diabetic CSCs 




miRDB, RNA22, miRanda, 
TargetScan  
0.44 ± 0.12 (P<0.001) 
 




0.36, P = 0.54) in the expression of the 3’UTR of CDK6 in the CSC transfected with the miR-
30c precursor mimic further validating my technique and results as CDK6 is not a predicted 















































Figure 5.1. Quantitative data showing reduced luciferase activity of Luc-VDAC1-3’UTR 
construct (0.62 ± 0.18, n=3, P<0.01) compared to scrambled (control) in a non-diabetic CSC 
co-transfected with 10µM miR-30c precursor mimic and VDAC1 plasmid. The Luc-CDK6-
3’UTR was used as a negative control. Data are means ± SEM. Significance (** = P<0.01) 
is illustrated by a two-tailed t-test. n.s. = not significant. 
Luciferase activity in CSCs transfected with 
VDAC1 and miR-30c precursor mimic 
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5.3.3 Western blot analysis validated VDAC1 and CDK6 as functional targets of the 
candidate miRNAs 
To functionally validate the expression of VDAC1 and CDK6 proteins in the diabetic CSCs, 
western blots were performed (Fig. A8.1 in Appendix 8). A two-tailed unpaired t-test showed 
a significant downregulation of CDK6 protein expression in diabetic CSCs (0.73 ± 0.10, n=4, 
P = 0.04) compared to in non-diabetic CSCs (1.00 ± 0.17, n=4) (Fig. 5.2A). A one-way 
ANOVA also showed no significant difference between repetitions in either non-diabetic (P > 
0.05, F = 1.46 x 10-12, Fcrit = 3.49) or diabetic groups (P > 0.05, F = 0.63, Fcrit = 3.49). This 
therefore provides evidence to suggest a functional validation for the upregulated expression 
profiles of the miRNAs (miR-329, -376c and -495) in the Nanostring microarray. A two-
tailed unpaired t-test also showed a significant upregulation of VDAC1 protein expression in 
the diabetic CSCs (3.16 ± 0.58, n=4, P < 0.01) compared to the non-diabetic CSCs (1.00 ± 
0.22) (Fig. 5.2B), thereby suggesting a functional validation for the downregulated expression 
of miR-30c in the diabetic CSCs. Similarly, the one-way ANOVA showed no significant 
difference between repetitions in either non-diabetic (P > 0.05, F = 5.5 x 10-16, Fcrit = 4.26) or 











































C D K 6  e x p r e s s io n  in  d ia b e t ic


























Figure 5.2A. Representative immunoblot and quantitative data showing the 
significant downregulation of CDK6 in diabetic CSCs vs non-diabetic 
CSCs (0.73 ± 0.10 vs 1.00 ± 0.17, n=4, P<0.05, repeated three times). Data 
measured as percentage of CDK6 protein compared to α-tubulin 
endogenous control. Data are means ± SEM. Significance (* = P<0.05) was 
determined from a two-tailed t-test.  














V D A C 1  e x p r e ss io n  in  d ia b e t ic























Figure 5.2B. Representative immunoblot and quantitative data showing 
the significant upregulation of VDAC1 in diabetic vs non-diabetic CSCs 
(3.16 ± 0.58 vs 1.00 ± 0.22, n=4, P<0.01, repeated three times). Data 
measured as percentage of VDAC1 protein compared to alpha tubulin 
endogenous control. Data are means ± SEM. Significance (** = P<0.01) 













5.4.1 Summary of results 
In this chapter, mass spectrometry predicted CDK6 as a common target protein for miR-329, -
376c, -495, while VDAC1 was predicted as a direct target protein for miR-30c. VDAC1 was 
subsequently confirmed as a direct target for miR-30c using the luciferase assay. The results 
of the assay showed that there was a significant reduction in the expression of the 3’UTR 
construct of VDAC1 in CSCs transfected with the miR-30c precursor mimic compared to the 
scrambled control. Western blot analyses showed that CDK6 was significantly downregulated 
in diabetic CSCs, correlating with the upregulated Nanostring profiles of miR-329, -376c and 
-495. Conversely, western blots showed VDAC1 to be significantly upregulated in the 
diabetic CSCs, correlating with the downregulated Nanostring profile of miR-30c. These 
western blot analyses therefore validated the dysregulated expression of the candidate 
miRNAs in the Nanostring microarray and q-PCR. To my knowledge, this is the first 
evidence to show that VDAC1 is the direct target for miR-30c.  
 
5.4.2 Mass spectrometry analysis 
Among the peptides that were found to be dysregulated in the diabetic CSCs by mass 
spectrometry, 22% were significantly altered (P<0.05). This was slightly higher than the 
percentages of significant peptides (12% and 14%) found in other studies using mass 
spectrometry for target miRNA identification (Ou et al., 2014; Bargaje et al., 2012). As 
mentioned in the results, CDK6 and VDAC1 were determined to be the most suitable target 
genes for the candidate miRNAs. The altered expression profiles of both CDK6 and VDAC1 
in the diabetic CSCs correlated with the expression patterns of the candidate miRNAs that 
were predicted to target each gene (Chapter 5, section 5.3.1). This suggested that CDK6 and 
VDAC1 total protein may exhibit a similar expression pattern in the diabetic CSCs compared 
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to their respective mass spectrometry profiles. Interestingly, GSK3-β and MEF2C genes 
which were originally predicted as targets for the miRNAs by bioinformatic analyses, were 
not among the peptides identified by mass spectrometry.  
 
5.4.3 Known functional roles of VDAC1 and CDK6  
In the mitochondria, VDAC1 is a component of the permeability pore complex (PTP) that is 
responsible for the release of mitochondrial products such as cytochrome C which triggers 
apoptotic cell death (Baumgartner et al., 2009). In this process, apoptotic proteins specifically 
interact with VDAC1, causing oligomerization and subsequent opening of the channel (Abu-
Hamad et al., 2009). VDAC1 also allows for the diffusion of calcium ions into the 
mitochondria, which causes calcium overload and an accumulation of ROS, leading to 
apoptosis through caspase activation (Chen et al., 2009). VDAC1 is also known to regulate 
mitochondrial membrane potential, depending on the open/closed conformation of the 
channel. The channel has a closed conformation at membrane potentials above 30 mV and is 
cation-selective, while it is anion-selective at lower membrane potentials (Rostovtseva et al., 
2006). Evidently, a primary function of VDAC1 is to promote apoptosis (Abu-Hamad et al., 
2009; Shoshan-Barmatz et al., 2009). Functional assays and additional western blots were 
performed in the next chapter (Chapter 6, section 6.3.2, 6.3.3 and 6.3.4) to demonstrate the 
pro-apoptotic effect of VDAC1.  
CDK6 is a 40 kDa serine threonine kinase that is involved in stimulating the G1/S phase of 
the cell cycle by binding to and activating the cell cycle-dependent genes, cyclin D1, 2 and 3 
(Meyerson and Harlow, 1994). It therefore mainly acts to promote cell proliferation by 
stimulating cell cycle progression. CDK6 is generally located in the nuclei of proliferating 
cells, but has also been found in the cytoplasm (Mahony et al., 1998). Another study has 
suggested that CDK6 may also contain an intrinsic quality control function in terms of the life 
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cycle of the cell. Moreover, overexpression of CDK6 can lead to the accumulation of the 
apoptotic proteins, p53 and retinoblastoma-like protein 2 (p130) and increased sensitivity to 
UV-irradiation. This suggests that CDK6 may trigger a negative feedback mechanism to limit 
the proliferation of damaged or dysfunctional cells (Nagasawa et al., 2001).  
 
5.4.4 Specific miRNAs regulate VDAC1 and CDK6 
There is no known literature thus far describing the existence of VDAC1 or CDK6 within the 
CSCs. Nevertheless, studies have shown that these genes are regulated by miRNAs in other 
cell types. For instance, in a mouse model of Parkinson’s disease, miR-7 was found to prevent 
the release of cytochrome C from the PTP by binding to and inhibiting VDAC1. This led to 
the generation of ROS and subsequent apoptosis of the mouse primary neurons. It also 
implicated a neuroprotective role for miR-7 in Parkinson’s disease in which mitochondrial 
dysfunction is a known contributor (Chaudhuri et al., 2016). Similarly, miR-29a improved 
neuronal cell survival in mice through the inhibition of VDAC1. This correlated with the 
development of ataxia in the same mice following miR-29a knockdown through upregulation 
of VDAC1 (Roshan et al., 2014). 
There has been evidence that miRNAs target CDK6 to regulate cell proliferation. Wu and 
colleagues showed that miR-129 reduced proliferation through the direct inhibition of CDK6 
in lung epithelial derived cells in mice (Wu et al., 2010). In another study, Sun and colleagues 
showed that miR-34a inhibits CDK6 in an adenocarcinomic human epithelial cell line and 
suggested that this could prevent tumour metastasis through the targeted inhibition of CDK6 
(Sun et al., 2008). MiR-34a is of particular relevance to my study as it has been found to be 
activated in the diabetic heart, as well as in diabetic CPCs (Fomison-Nurse et al., 2018). 
Interestingly, among the dysregulated miRNAs in my study, only miR-495 has been 
demonstrated to inhibit the growth of gliomas by downregulating CDK6 in human brain 
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tissue (Chen et al., 2013). Although there may be different growth conditions involved in 
cancerous tissue, this finding provides an insight into the functional role of miR-495 in 
preventing cell proliferation, as well as supporting my mass spectrometry and western blot 
results.  
CDK6 has also been found to regulate the proliferation of HSCs. Scheicher and colleagues 
demonstrated that CDK6 is essential for the suppression of early growth response protein 1 
(EGR1), a transcriptional activator of HSCs (Scheicher et al., 2015). EGR1 was also found to 
be highly expressed in quiescent, as well as CDK6 knock-out cells (Min et al., 2008). This 
indicates that high levels of CDK6 in HSCs promotes proliferation by downregulating EGR1. 
CDK6 has been shown to have binding sites for miR-183 in tumour cell lines, thus indicating 
that miR-183 may regulate HSC proliferation, if it targets CDK6 within these cells (Kim et 
al., 2017). 
 
5.4.5 Effect of diabetes on VDAC1 and CDK6 expression and function 
The effect of diabetes on VDAC1 and CDK6 function in mouse CSCs remains unclear. 
However, few evidence suggest that diabetes can alter the expression of both proteins in other 
cell types. Coronary endothelial cells isolated from diabetic mice showed an upregulation of 
VDAC1 compared to those isolated from non-diabetic mice (Sasaki et al., 2012). 
Furthermore, hyperglycemia has been shown to increase VDAC1 expression in pancreatic β-
cells (Ahmed et al., 2010). This correlates with my observation of VDAC1 upregulation in 
diabetic mouse CSCs. There is relatively less understood about the association between 
diabetes and CDK6 expression. Kushner and coauthors discovered that the knockdown of 
cyclin D2, an activator for CDK6, caused glucose intolerance in mice which then progressed 
to diabetes (Kushner et al., 2005). This indicates lower levels of CDK6 expression in the 
diabetic mice, which was supported in my study by the reduced expression of CDK6 in the 
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diabetoic mouse CSCs. Based on these findings, the next aim of my project was therefore to 
investigate the functional role for the target proteins in the diabetic heart and their effect on 
the candidate miRNAs. Western blot analyses showed that the expression of VDAC1 was 
more significantly and substantially altered compared to the expression of CDK6 in the 
diabetic CSCs. In addition, there are no published studies describing the roles of miR-30c in 
mouse CSCs. Furthermore, VDAC1 is a pro-apoptotic gene, and it is known that diabetes 
promotes intracellular pathways that lead to apoptosis (Krijnen et al., 2009). This motivated 
me to focus on conducting a more detailed examination of the functional effect of miR-30c 
and its target protein, VDAC1. Therefore, functional assays were performed in the next 
Chapter to determine the roles of miR-30c in mouse CSCs, as well as to provide evidence for 




CHAPTER 6: FUNCTIONAL STUDIES TO 




I previously showed that miR-30c expression was significantly downregulated in diabetic 
mouse CSCs (Chapter 4, section 4.3.1) and confirmed VDAC1 as the direct target for miR-
30c (Chapter 5, section 5.3.2). However, it is important to understand the functional 
importance of miR-30c downregulation in diabetic CSCs. In this Chapter, I will therefore 
answer the second objective of my PhD project by outlining the procedures and techniques 
that were performed to understand the function of miR-30c in CSCs. The experiments 
performed in this chapter will also address the significance of VDAC1 as a direct target for 
miR-30c and its association with the pathophysiological role of miR-30c. I will provide a 
brief overview of the rationale and methodology for the functional assays, followed by a 
discussion of my findings and how it can be used to answer my objective. 
 
6.1.1 Aims and objectives 
The first aim of this chapter is to confirm that miR-30c directly alters the expression of 
VDAC1 within diabetic and non-diabetic CSCs. The second aim is to determine the 
pathophysiological role of miR-30c by performing functional studies on both diabetic and 





6.1.2 Structure and functions of miR-30c 
MiR-30c is one of the five members of the highly conserved miR-30 family (miR-30a-e) that 
share 85% sequence similarity. It is derived from the miR-30c-1 and miR-30c-2 genes that 
originate from intronic sequences in both humans and mice (Li et al., 2007). Despite being 
discovered as early as 2002 (Lagos-Quintana et al., 2002), there is only a limited amount of 
information available on the functional role of miR-30c. As with a number of other miRNAs, 
miR-30c has been implicated to play a role as a tumour suppressor due to its ability to target 
genes involved with promoting uncontrolled proliferation and invasion. It has also been found 
to be downregulated in cancerous tissue compared to non-cancerous tissue. Furthermore, the 
growth of an oncogene promoting cell line was found to be reduced after transfection with a 
miR-30c precursor mimic compared to those transfected with a scrambled mimic (Tanic et al., 
2012). This indicates that miR-30c may indirectly reduce tumorogenesis by limiting the 
proliferation of cancerous cells. 
MiR-30c has also been indicated to have a role in lipid metabolism. It was observed to be 
significantly upregulated during cellular adipogenesis and also promote adipogenesis after 
overexpression in adipose-derived stem cells (Karbiener et al., 2011).  In mice, 
overexpression of miR-30c also reduces hyperlipidemia by inhibiting apolipoprotein B, which 
transports lipids and cholesterol to various tissues in the body. Hyperlipidemia is a major risk 
factor for atherosclerosis, which indicates miR-30c may be protective against heart disease. 
This notion was further strengthened after smaller atherosclerotic plaques were observed in 






6.1.3 Role of miR-30c in cardiovascular disease 
MiR-30c has been shown to be highly expressed in cardiac tissue and cardiomyocytes (Soh et 
al., 2013; Duisters et al., 2009). Moreover, it has been found to be downregulated in mouse 
cardiac tissue after pathological cardiac remodelling following MI and ischemia/reperfusion 
(Gambacciani et al., 2013; Duisters et al., 2009). This downregulation was associated with an 
increased expression of connective tissue growth factor (CTGF), which has been 
demonstrated to increase in cardiac fibrosis and heart failure (Gambacciani et al., 2013). 
However, the protective role of miR-30c in preventing cardiac dysfunction has not yet been 
replicated in in vivo studies.  
As discussed earlier (Chapter 1, section 1.1.2), diabetes may lead to the development of DCM 
which is commonly associated with diastolic dysfunction and cardiac hypertrophy in the 
absence of hypertension or coronary artery disease. MiR-30c has been found to mediate the 
effects of DCM by inhibiting the cardiac hypertrophy promoter genes, cell division control 
protein 42 (CDC42) and serine/threonine-protein kinase (PAK1) in cardiomyocytes of 
diabetic rats (Raut et al., 2015). Furthermore, miR-30c overexpression reduced the expression 
of the tumor protein p53 (p53) and cyclin-dependent kinase inhibitor 1 (p21) genes in high 
glucose-treated rat cardiomyocytes, as well as in cardiac tissue samples taken from the 
autopsies of diabetic patients. These genes are known to cause cardiomyocyte apoptosis and 
cell cycle arrest, which can then lead to compensatory hypertrophy in the remaining viable 
cardiomyocytes (Raut et al., 2016; Letonja and Petrovič, 2014; Fiordaliso et al., 2001). This 
suggests that overexpression of miR-30c can reduce the pro-hypertrophic effects of DCM, 





6.1.4 Rationale for determining role of miR-30c in diabetic CSCs 
Although miR-30c has been characterized in a number of different tissues including the heart, 
there is a limited understanding of its function in stem/progenitor cells. My study has 
identified a downregulation of miR-30c in diabetic mouse CSCs, as well as confirming 
VDAC1 as the direct target of miR-30c. VDAC1 is generally known to promote apoptosis; 
however this function has never been documented within CSCs. This chapter will therefore 
determine the functional implications of miR-30c in regulating the apoptosis of CSCs through 
the inhibition of VDAC1. In an effort to uncover novel insights of this role, miR-30c was 
overexpressed in the diabetic and non-diabetic CSCs and western blot analyses were 
subsequently performed to determine the expression of VDAC1. Moreover, a caspase and 
proliferation assay were performed on the transfected CSCs to determine the direct effect of 
miR-30c on apoptosis and cell proliferation, respectively. The results of these experiments 
will not only further verify miR-30c as an inhibitor of VDAC1, but also shed light on a 
pathophysiological role for miR-30c in CSCs. This may lead to a better understanding as to 
why diabetes causes a reduced expression of miR-30c in the CSCs.   
 
6.2 Methods: 
6.2.1 Re-initiating CSCs for functional experiments 
In preparation for the functional experiments described in this chapter, four diabetic and four 
non-diabetic CSC samples were thawed and re-initiated at P6 in T25 flasks. After scaling up 
to T75 flasks at P7, each CSC sample was plated into two T25 flasks as well as three wells of 
a 12-well plate at P8. During this process, the CSCs were lysed, pelleted and then counted 
using a hemocytometer (Appendix 5). The CSCs were then seeded into the T25 flasks at 1 x 
106 cells per flask, and seeded into the 12-well plates at 1 x 105 cells per well. The CSCs in the 
T25 flasks were grown for the purposes of extracting transfected protein for western blot 
120 
 
analyses. Moreover, the CSCs in the 12-well plates were grown for the purposes of extracting 
transfected RNA for q-PCR analyses. CSCs were incubated at 37 °C until 70% confluent 
before transfection.  
 
6.2.2 Transfecting CSCs with miR-30c precursor mimic 
Transfection is the process of introducing purified nucleic acids into eukaryotic cells. It can be 
used in preparation for functional assays by introducing precursor mimics associated with the 
simulated expression of a specific miRNA (Chen et al., 2006). For this reason, diabetic and 
non-diabetic CSCs were transfected with a precursor mimic for miR-30c to simulate miR-30c 
overexpression within these cells.  
Diabetic (n=4) and non-diabetic CSCs (n=4) grown in T25 flasks and 12-well plates were 
initially transfected with 10 µM of either  miR-30c precursor mimic or scrambled sequence 
(control) following the standardized RNAiMAX transfection procedure (Life Technologies, 
USA). The reagent volumes were customized for each transfection experiment depending on 
the number of CSCs required for the corresponding functional assays (Table A9 in Appendix 
9). To obtain the appropriate concentrations for optimal transfection of each well, 180 uL of 
the lipofectamine RNAiMAX reagent (Life technologies, USA) and 60 uL of the miR-30c 
precursor mimic (Thermofisher, USA) were diluted in 3.5 mL serum-free DMEM/F12 media. 
The reagents were mixed together at a 1:1 ratio and incubated for 5 minutes at RT. A 150 uL 
volume of diluted miR-30c precursor mimic/lipofectamine mixture was added to each well of 
the 12-well plate containing the diabetic and non-diabetic mouse CSCs. Similarly, 650 uL of 
the diluted miR-30c precursor mimic/lipofectamine mixture was added to each T25 flask. The 
transfected cells were then incubated at 37 °C for 72 hours before being analysed.  
The transfectional efficiency of these cells was also measured by q-PCR analysis. Total RNA 
was first extracted from each CSC sample and quantified as described in Chapter 2, section 
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2.5. The concentrations and purity of these total RNA samples are described in Table A3.1 in 
Appendix 3. The q-PCR data was analysed using the ΔΔCt method and samples were 
normalized to a U6 endogenous control. Fold changes were then calculated to determine the 
difference in miR-30c expression in total RNA derived from miR-30c-transfected CSCs 
compared to the scrambled controls. These fold changes were normalized to scrambled 
controls for both diabetic and non-diabetic samples to show the difference in miR-30c 
expression. A two-tailed t-test was also performed to determine the statistical significance (P 
< 0.01) of the fold changes in each condition.  
 
6.2.3 Western blot analyses for VDAC1 and cleaved caspase-3 in transfected diabetic 
CSCs 
A western blot analyses of VDAC1 was previously performed in Chapter 5, section 5.3.3 to 
validate the downregulated Nanostring expression profile of miR-30c in the diabetic CSCs. In 
this chapter, diabetic and non-diabetic mouse CSCs were overexpressed with miR-30c and 
western blot analyses were performed to confirm the direct inhibitory effect of miR-30c on 
the VDAC1 protein. Total protein was extracted from the T25 flasks containing diabetic (n=4) 
and non-diabetic CSCs (n=4) transfected with miR-30c precursor or scrambled control. The 
protein samples were quantified (concentrations described in Table A3.2 in Appendix 3) and 
western blot analyses were performed and analysed using the general protocol described in 
Chapter 2, section 2.8. The rabbit, polyclonal anti-VDAC1 (abcam, Australia) and rabbit, 
polyclonal anti-α-tubulin (abcam, Australia) were used as primary antibodies for the VDAC1 
and α-tubulin antigens, respectively. The mouse anti-rabbit IgG (Sigma-Aldrich, NZ) was 
used as the secondary antibody. In this chapter, α-tubulin (50kDa) was used as an endogenous 
control instead of β-actin as used in the earlier chapter due to technical difficulties with the 
new β-actin antibody. The blots were repeated three independent times and the relative 
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expression of VDAC1 (31kDa) was determined for all samples by calculating the mean 
VDAC1/α-tubulin ratio. The data was expressed as a fold change by normalising the mean 
VDAC1 expression in miR-30c-transfected samples to the scrambled controls. The statistical 
significance (P < 0.05) of the data was then determined by a two-tailed unpaired t-test. A one-
way ANOVA was also performed to determine the consistency of the results between 
repetitions. 
Next, to determine the anti-apoptotic effect of miR-30c through repression of VDAC1, 
western blots were performed to measure the level of apoptotic marker cleaved caspase-3 
(19kDa). A rabbit, polyclonal anti-Cleaved caspase-3 (Cell Signaling Technology, USA) and 
rabbit, polyclonal anti-α-tubulin (abcam, Australia) were used as primary antibodies for the 
Cleaved caspase-3 and α-tubulin antigens, respectively. The mouse anti-rabbit IgG (Sigma-
Aldrich, NZ) was used again as the secondary antibody. The blots were repeated three times 
and α-tubulin was used as the endogenous control. The data was expressed as a fold change 
by normalising the mean cleaved caspase-3 expression in miR-30c-transfected samples to the 
scrambled controls.  
 
6.2.4 Caspase 3/7 assay protocol 
A caspase 3/7 assay was performed using the total protein extracted from the miR-30c or 
scrambled control transfected diabetic and non-diabetic CSCs (n=4 each). This assay allows 
for the detection of caspase-3 and -7 activity which is directly proportional to the amount of 
apoptosis within the cells (O’brien et al., 2005). A caspase-Glo 3/7 reagent (Promega, USA) 
was prepared by adding the Caspase-Glo 3/7 buffer to the Caspase-Glo 3/7 substrate and 
mixing well as outlined in the standardized protocol (Promega, 2018). The extracted total 
protein samples were quantified and added to a white, transparent 96-well plate at a 
concentration of 100 µg per well. The Caspase-Glo reagent was then added at a 1:1 ratio to 
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the volume of protein in each well and mixed with pipetting. Wells with RIPA (lysis) buffer 
alone were used as a blank measurement. The plate was then incubated in the dark at RT for 1 
hour to allow for cell lysis and caspase cleavage. The luminescence of each well was finally 
measured using a luminometer to determine the caspase 3/7 activity. This caspase assay was 
repeated three times, and mean percentage fold changes were calculated from the relative 
differences in caspase activity in the diabetic and non-diabetic CSCs transfected with either 
miR-30c or scrambled control. A two-tailed t-test was then performed to determine the 
statistical significance (P < 0.05) of the fold changes. A one-way ANOVA was also 
performed to determine the consistency of the results between repetitions. 
 
6.2.5 q-PCR for proliferation markers 
Finally, to determine whether miR-30c enhances the proliferation capacity of the CSCs, a q-
PCR was performed to determine the mRNA expression levels of common proliferation 
markers, Ki-67 and Topoisomerase-2α (Topo-2α). Both Ki-67 and Topo-2α are known to be 
highly expressed in all active phases (G1, S, and G2) of the cell cycle and for this reason were 
chosen as suitable markers for the purposes of this study (Ladsetin et al., 2010; Holden, 
1999).  
Forward and reverse (3’ and 5’) Taqman primers for Ki-67 and Topo-2α (Sigma-Aldrich, NZ) 
(Sequences in Appendix 7) were incorporated in the standard q-PCR procedure described in 
Chapter 2, section 2.6. Ribosomal protein L13A (Rpl-13a) was also used as an endogenous 
control due to its high level of expression in genes derived from mouse cardiac tissue 
(Everaert et al., 2011). The mRNA expression of these genes were thus determined from the 
total RNA derived from non-diabetic (n=4) and diabetic CSC samples (n=4). The q-PCR was 
repeated twice and mean fold changes of Ki-67 and Topo-2α were calculated across all 
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6.3.1 Diabetic CSCs can be successfully transfected with miR-30c precursor mimic 
After transfecting the diabetic and non-diabetic CSCs with the miR-30c and scrambled 
controls, the transfection efficiency was determined by performing q-PCR analysis. The q-
PCR data showed that there was a significant and substantial increase in the expression of 
miR-30c in both diabetic (fold change of 1809, n=4, P < 0.01) and non-diabetic CSCs (fold 
change of 2332, n=4, P < 0.01) transfected with the miR-30c precursor mimic compared to 
the scrambled control for each condition (Fig. 6.1). There was also a reduction in miR-30c 
expression between diabetic and non-diabetic CSCs transfected with scrambled mimic (fold 
change of 0.71, n=4, P < 0.01). These results indicate that the transfection procedure was 
successful and that the concentration of miR-30c precursor mimic used (10 µM) is 
appropriate to elicit the overexpression of miR-30c in the CSCs. There was also a reduced 
expression of miR-30c in transfected diabetic CSCs compared to transfected non-diabetic 














































Figure 6.1. Quantitative bar graph data showing transfectional efficiency of the miR-30c mimic 
after its transfection into diabetic (n=4) and non-diabetic (n=4) CSCs. Performed in diabetic and 
non-diabetic samples to compare the stability of the mimic in both conditions. Data are means ± 
SEM. Significance (** = P<0.01) determined from two-tailed t-test. 
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6.3.2 VDAC1 was downregulated in the transfected diabetic CSCs  
 
Western blot analyses were performed to determine the protein expression of the miR-30c 
target gene, VDAC1 (Fig. 6.2) and pro-apoptotic cleaved caspase-3 (Fig. 6.3) in both diabetic 
and non-diabetic CSCs (Fig. A8.2 in Appendix 8). A two-tailed unpaired t-test showed that 
miR-30c overexpression significantly reduced the expression of VDAC1 in miR-30c-
transfected non-diabetic CSCs (0.75 ± 0.05, n=4, P = 0.04) and diabetic CSCs (0.71 ± 0.06, 
n=4, P = 0.03) compared to scrambled-transfected CSCs (Fig. 6.2). Furthermore, a one-way 
ANOVA showed no significant differences between repetitions in non-diabetic CSCs 
transfected with scrambled or miR-30 mimic (F = 0.07 and 1.12, respectively compared to 
Fcrit = 4.26, P > 0.05), and similarly no significant differences between repititions in non-
diabetic CSCs transfected with scrambled (P > 0.05, F = 0.37, Fcrit = 4.26). However, there 
was a significant difference observed between repititions in the diabetic CSCs transfected 
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Figure 6.2. Representative immunoblots and quantitative data showing the 
protein expression of VDAC1 in non-diabetic (ND, n=4) and diabetic (D, n=4) 
CSCs transfected with either miR-30c mimic (30c) or scrambled control (Scr). 
Samples transfected with miR-30c mimic (ND30c or D30c) were normalized to 
either NDScr or DScr, respectively, and blots repeated three times. Data are means 
± SEM. Significance (* = P<0.05) was determined by a two-tailed t-test. 
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6.3.3 Caspase-3 was downregulated in the transfected diabetic CSCs 
The western blot analyses for cleaved caspase-3 expression exhibited a similar trend to 
VDAC1 expression in response to miR-30c overexpression in the diabetic CSCs (Fig. 6.3). 
The two-tailed unpaired t-test showed a significant reduction in the expression of cleaved 
caspase-3 in miR-30c-transfected diabetic CSCs (0.64 ± 0.10, n=4, P = 0.04) compared to 
scrambled-transfected diabetic CSCs (1.00 ± 0.14, n=4). However, despite significantly 
reducing VDAC1 expression, miR-30c transfection did not produce a similar reduction in 
cleaved caspase-3 expression in miR-30c-transfected non-diabetic CSCs (0.81 ± 0.17, n=4, 
P=0.40) compared to scrambled-transfected non-diabetic CSCs (1.00 ± 0.14, n=4) (Fig. 6.3). 
A one-way ANOVA showed no significant difference between repetitions in non-diabetic 
CSCs transfected with scrambled (P > 0.05, F = 0.89, Fcrit = 4.26), however there was a 
substantially significant difference in non-diabetic CSCs transfected with the miR-30 mimic 
(P < 0.05, F = 8.27, Fcrit = 4.26) which may have contributed to the non-significant t-test. 
There was no significant differences between repititions in the diabetic CSCs transfected with 










Protein expression of Cleaved Caspase-3


































Figure 6.3. Representative immunoblots and quantiative data showing protein 
expression of Cleaved Caspase-3 in non-diabetic (ND, n=4) and diabetic (D, 
n=4) CSCs transfected with either miR-30c mimic (30c) or scrambled control 
(Scr). Samples transfected with miR-30c mimic (ND30c or D30c) were noramlized 
to either NDScr or DScr respectively, and blots repeated three times. Data are 
means ± SEM. Significance (* = P<0.05) determined by a two-tailed t-test. n.s. = 
non-significant. 
 








As with the western blot analysis, the two-tailed unpaired t-test showed a significant reduction 
in the relative caspase 3/7 activity in the diabetic CSCs (0.62 ± 0.07, n=4, P < 0.001) that 
were transfected with the miR-30c precursor mimic compared to the scrambled control (1.00 
± 0.07, n=4) (Fig. 6.4). In the non-diabetic CSCs, although there was a reduction in caspase 
3/7 activity in the CSCs transfected with the miR-30c precursor mimic (0.81 ± 0.10, n=4, this 
was not statistically significant (P > 0.05) (Fig. 6.4). A one-way ANOVA showed no 
significant differences between repititions in the non-diabetic CSCs transfected with 
scrambled or miR-30c mimic (F = 0.92 and 2.94, respectively compared to Fcrit = 4.26, P > 
0.05), and similarly no significant differences between repititions in the diabetic CSCs 
transfected with scrambled or miR-30c mimic (F = 2.50 and 2.95, respectively compared to 
Fcrit = 4.26, P > 0.05). This data further supported the effect of miR-30c on caspase 
expression in the diabetic CSCs. 
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Figure 6.4. Quantitative data showing caspase 3/7 activity in total protein 
transfected from non-diabetic (ND) (n=4) and diabetic (D) CSCs (n=4) 
transfected with either miR-30c (30c) or scrambled control (Scr). Samples 
transfected with miR-30c mimic (ND30c or D30c) were normalized to either 
NDScr or DScr, respectively, and the assay was repeated three times. Data are 
means ± SEM. Significance (** = P<0.01) determined by a two-tailed t-
test. n.s. = non-significant. 
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6.3.4 MiR-30c does not regulate CSC proliferation 
The q-PCR to determine differential expression of proliferation markers (Ki-67 and Topo-2α) 
showed no statistically significant differences (P > 0.05) between diabetic or non-diabetic 
CSCs transfected with the miR-30c precursor mimic. Although not significant, a small 
increase in Ki-67 expression was found in miR-30c-transfected diabetic CSCs (1.12 ± 0.23, 
n=4, P=0.62) compared to scrambled-transfected diabetic CSCs (1.00 ± 0.03, n=4). There was 
also similar increase in Ki-67 expression in the non-diabetic CSCs (1.28 ± 0.34, n=4, P=0.66) 
compared to scrambled-transfected non-diabetic CSCs (1.11 ± 0.20, n=4) (Fig. 6.5). There 
was no substantial difference in Topo-2α expression in miR-30c-transfected diabetic (1.03 ± 
0.09, n=4, P=0.99) and non-diabetic (1.07 ± 0.14, n=4, P=0.79) CSCs compared to the 
scrambled-transfected control (Fig. 6.5). Taken together, these results suggest that miR-30c 
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Figure 6.5. Quantitative data (bar graph and representative scatter plot) showing no significant change in 
expression of Ki-67 and TOP2A proliferation markers in non-diabetic (n=4) and diabetic CSCs (n=4) 
transfected with either miR-30c (ND30c, D30c) or scrambled control (NDScr, DScr). Data are means ± SEM. 




6.4.1 Summary of results 
The findings of this chapter have shown the first pieces of evidence that miR-30c has a 
functional role in diabetic CSCs. This was determined from a series of mechanistic 
experiments in which diabetic and non-diabetic CSCs were initially transfected with a miR-
30c precursor mimic and compared to a scrambled control. Western blot analyses revealed 
VDAC1 total protein to be significantly downregulated in miR-30c-transfected diabetic and 
non-diabetic CSCs compared to the control. Due to the fact that VDAC1 is a pro-apoptotic 
gene, this finding was further supported by a downregulation in Cleaved caspase-3 total 
protein, as well as a reduction in caspase 3/7 activity in miR-30c-transfected diabetic CSCs. 
These results suggest that overexpression of miR-30c has a role in reducing the apoptosis of 
diabetic CSCs, which may be mediated by the targeted-inhibition of the VDAC1 gene. My 
results also showed that miR-30c is not involved in regulating CSC proliferation as there were 
no significant differences in the expression of proliferation markers, Ki-67 and Topo-2α in the 
transfected CSCs. 
 
6.4.2 MiR-30c overexpression in diabetic and non-diabetic CSCs 
The initial q-PCR results showed a significantly large increase in the expression of miR-30c 
in CSCs transfected with the miR-30c precursor mimic compared to scrambled controls. This 
result therefore validated the transfection procedure used for overexpressing miR-30c in the 
CSCs. Moreover, it confirmed that the concentration of the mimic used (10 µM) was 
appropriate to establish the overexpression of miR-30c in mouse CSCs. This correlates with 
the work of other studies that have used miR-30c precursor mimics for transfection 
experiments (Kong et al., 2014). Interestingly, the relative miR-30c expression in the miR-
30c-transfected CSCs was also lower in the diabetic CSCs than the non-diabetic CSCs. This 
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therefore indirectly supports the original Nanostring microarray data which showed reduced 
expression of miR-30c in the diabetic CSCs compared to the non-diabetic CSCs. 
 
6.4.3 MiR-30c downregulates VDAC1 in diabetic and non-diabetic CSCs 
In both diabetic and non-diabetic conditions, VDAC1 total protein expression was 
significantly reduced in the CSCs transfected with the miR-30c precursor mimic compared to 
the scrambled controls. This result supported the results of the luciferase assay, indicating 
VDAC1 as a direct target of miR-30c. It also strengthens the mass spectrometry and western 
blot data (Chapter 5, section 5.3.1 and 5.3.3) suggesting that miR-30c regulates the translation 
of VDAC1. VDAC1 triggers apoptosis by causing the release of cyctochrome C in the 
mitochondria and subsequent accumulation of ROS (Baumgartner et al., 2009). Based on my 
results, I can infer that if miR-30c downregulates VDAC1 expression, it may also limit 
apoptosis in the CSCs, providing the first indications that miR-30c has a pathophysiological 
role in the CSCs.  
The majority of the research conducted on VDAC1 as a viable miRNA target has been 
associated with neuronal development. Chaudhuri et al. showed that miR-7, which has been 
found to be protective in cellular models of Parkinson’s disease, also reduces 
neurodegeneration by targeting VDAC1 in human neuroblastoma cells. The overexpression of 
miR-7 in these cells also caused a reduction in cytochrome C release and ROS generation, 
which is consistent with the apoptotic function of VDAC1 (Chaudhuri et al., 2016). In 
another study, Roshan et al. showed that the brain-specific miR-29a targets VDAC1 in the 
hippocampus and cerebellum of mice. Knocking down miR-29a in mouse brains causes a 
large increase in cell death that has been attributed to the elevated levels of VDAC1 (Roshan 
et al., 2014). These studies support the notion that the apoptotic function of VDAC1 can be 
regulated by miRNAs.  
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6.4.4 MiR-30c inhibits apoptosis in diabetic CSCs by downregulating VDAC1 
Transfection of the CSCs with the miR-30c precursor mimic significantly reduced the 
expression of cleaved caspase-3 in diabetic CSCs. This reduced caspase-3 expression also 
correlated with the reduction of VDAC1 previously observed in the miR-30c-transfected 
diabetic CSCs. The relative difference in caspase-3 expression between the CSCs transfected 
with miR-30c and scrambled controls was less in the non-diabetic CSCs than in the diabetic 
CSCs. This may be due to the VDAC1 channel being more active in the diabetic state, 
although further experiments are required to confirm this notion. The caspase 3/7 assay 
exhibited a similar trend to the western blots for cleaved caspase-3 in terms of the ability of 
miR-30c to regulate apoptosis. There was a significant reduction in caspase 3/7 activity in 
diabetic CSCs transfected with the miR-30c precursor mimic compared to the scrambled 
controls. Cleaved caspase-3 protein and caspase 3/7 activity were also reduced in the miR-
30c-transfected non-diabetic CSCs, although in both cases the data was not significant. These 
findings strongly suggest that not only does miR-30c reduce the apoptosis of diabetic CSCs, 
but that the mechanism behind it involves the targeted inhibition of VDAC1. 
The effect of miR-30c on apoptosis has previously been investigated in other cell lines 
showing differential regulation depending on the cell type. For instance, Du and co-workers 
added cisplatin to the renal tubular cell lines, HK-2 and NRK-52E. They observed a 
subsequent reduction in miR-30c expression in response to the drug. Manipulating the 
expression of miR-30c in these cells using miR-30c precursor mimics and inhibitors caused a 
miR-30c-dependent change in apoptosis. The mechanism behind this was attributed to the 
targeted-inhibition of the pro-apoptotic genes, HSPA5 and BNIP3L. The expression of both 
target genes were reduced after miR-30c overexpression, while the expression of the genes 
were increased after knocking down miR-30c in the cells (Du et al., 2017). This suggested 
that miR-30c is able to regulate renal tubular cell apoptosis; a finding that could potentially be 
used in the treatment of cisplatin-induced nephrotoxicity. However, despite a clear indication 
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that miR-30c regulates apoptosis in many cell lines, contradicting evidence has been noted in 
several cancer studies. Knock down of miR-30c in a human ovarian cancer cell line (A2780) 
suppressed cisplatin-induced apoptosis, while miR-30c was also found to induce apoptosis in 
a human myeloma cell line (H929) (Han et al., 2017; Zhao et al., 2014). These results support 
the reputation of miR-30c as a tumour suppressor, however there is no clear understanding as 
to why cancer reverses its effect on apoptosis.  
Although the role of miR-30c has not yet been characterized within CSCs, seminal evidence 
indicate that miR-30c may have a pro-survival effect in the heart. In a recent study, Liu and 
co-authors showed an increase in apoptosis after knocking down miR-30c in myocardial P19 
cells. In contrast, miR-30c overexpression caused a subsequent increase in the proportion of 
P19 cells despite using the same serum starvation treatment to stimulate apoptosis (Liu et al., 
2016). This indicates that miR-30c can also inhibit other proteins in myocardial cells that 
regulate apoptosis.   
 
6.4.5 MiR-30c does not regulate CSC proliferation  
Several studies have suggested a regulatory role of miR-30c in cell proliferation. These 
studies have shown that miR-30c promotes the proliferation of myocardial cells in in vivo rat 
models of MI and heart failure, indicating the potential of miR-30c to prevent cardiac 
dysfunction (Gambacciani et al., 2013; Duisters et al., 2009). This was supported by Liu and 
co-authors who showed that miR-30c overexpression in myocardial P19 cells increased cell 
growth, whereas downregulation of miR-30c had the opposite effect. The authors also 
discovered that an elevated proportion of miR-30c-overexpressing cells were in the S phase of 
the cell cycle, indicating that miR-30c is involved in promoting cell cycle progression. (Liu et 
al., 2016). Similar effects were documented in other stem cell subtypes. For instance, 
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overexpressing mouse neural stem cells (NSC) with miR-30c was found to promote 
proliferation and neural sphere formation (Sun et al., 2016; Chao et al., 2015).  
However, in contrast with these findings, the results of my study failed to show any 
significant change in the expression of proliferation markers, Ki-67 and Topo-2α after miR-
30c overexpression in both diabetic and non-diabetic CSCs. This may be due to the difference 
in stem cell type (NSCs vs CSCs) as miRNAs have been found to have opposing effects on 
proliferation in other stem cells. This is evident for miR-378 which promotes proliferation 
when overexpressed in mesenchymal cells, but suppresses proliferation when overexpressed 
in NSCs (Huang et al., 2015; Xing et al., 2014). Furthermore, other studies have not yet 
shown miR-30c to regulate the proliferation of primary mouse CSCs. This is an important 
distinction as primary cells can differ genetically and phenotypically to cell lines derived from 
a homogenous tissue source (Unger et al., 2002).  
 
6.4.6 The effect of diabetes on miR-30c apoptotic function 
Diabetes is commonly known to promote apoptosis of pancreatic β-cells, leading to the 
development of insulin deficiency (Lee and Parvaiz, 2006). However, it also promotes the 
apoptosis of CSCs and cardiomyocytes, triggering the development of DCM (Ouyang et al., 
2014). My results suggested that miR-30c may inhibit the apoptosis of diabetic CSCs by 
targeting VDAC1. This indicates that genetic manipulation of miR-30c may be a viable 
strategy to regulate CSC survival in the diabetic heart. It was also noted that miR-30c did not 
cause a significant change in the apoptosis of non-diabetic CSCs. The reason for this may be 
that there is a greater proportion of VDAC1 channels in the diabetic CSCs as observed from 
the western blot in Chapter 5, section 5.3.3. This would mean that miR-30c may have a 
greater impact on the functionality of VDAC1 in the diabetic state, as the inhibition of more 
channels would exponentially reduce the release of cytochrome C and ROS and hence 
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apoptosis. Another theory is that hyperglycemia may increase the opening of the VDAC1 
channel in the diabetic CSCs. There have indeed been reports indicating that the high glucose 
treatment of endothelial cells ex vivo increases the opening time of the mitochondrial 
permeability transition pore, which comprises the VDAC1 channel (Detaille et al., 2005). The 
opening time of the mitochondrial permeability transition pore is directly correlated with the 
apoptotic potential of the channel (Pangare and Makino, 2012).  
 
6.4.7 Summary 
In this chapter, I have shown that miR-30c overexpression reduces apoptosis in diabetic 
mouse CSCs by downregulating VDAC1. This answers my second overall objective that 
certain miRNAs can exhibit a pathophysiological role that relates to their differential 
expression in diabetic CSCs. It also suggests that the genetic modification of miR-30c may be 
a potential therapeutic strategy to improve diabetic CSC survival. However, these results need 
to be replicated in the human CSCs to understand the clinical translation of these findings. 






CHAPTER 7: TRANSLATION INTO HUMAN 
CSCS 
 
7.1 Introduction  
Thus far I have shown that diabetes alters the expression of miR-329, -376c, -495 and -30c 
(candidate miRNAs) in CSCs in mice. I have also demonstrated the functional consequences 
for miR-30c dysregulation in diabetes, suggesting that miR-30c could be a potential target to 
improve the functional efficacy of diabetic CSCs. The next important question is whether this 
altered expression in mice can be translated to human CSCs. In this chapter, I will therefore 
describe how the expression of the candidate miRNAs were determined in human CSCs. I 
will describe the differences in the isolation procedure of the CSCs from human heart tissue, 
followed by FACS characterization and qPCR analysis to determine miRNA expression in the 
human CSCs.  
 
7.1.1 Aims and objectives 
The aim for this chapter is to determine the expression of miR-329, -376c, -495 and -30c in 
diabetic and non-diabetic human CSCs, and observe whether these results correlate with their 
expression in the mouse CSCs. 
 
7.1.2 Comparisons between mouse and human CSCs 
As in the mouse heart, a population of resident CSCs also exists in the human heart with self-
renewing capabilities (Yadav and Mishra., 2018). Studies have indicated that human CSCs 
are functionally identical to those found in mice in that they have the potential to differentiate 
into adult cardiomyocytes (Ching et al., 2011; Bearzi et al., 2007; Oh et al., 2003). This 
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function can also contribute towards the regeneration of myocardial tissue. In response to 
myocardial injury, the CSCs migrate to the damaged site where they promote tissue repair by 
replacing the dead cardiomyocytes (Bearzi et al., 2007). Unlike the Sca-1+ CSCs that were 
characterized in mice, the primary marker for identifying human CSCs was originally c-kit 
until one study disproved this marker as being purely specific for CSCs (Sultana et al., 2015). 
More recently, human CSCs have been found to express high levels of the MSC surface 
markers such as CD105, CD90, CD29, CD73 and CD71. This may be due to the fact that the 
CSCs exhibit a mesenchymal cell-like phenotype, despite being specifically programmed to 
differentiate into cells of cardiovascular lineage (Tateishi et al., 2007). Stromal cells that are 
phenotypically similar to Sca-1 were also found to express CD105 and CD90 in the human 
heart (Ryzhov et al., 2012). For this reason, the identity of human CSCs in this project was 
determined using specific antibodies that bind to the CD105 and CD90 antigen. There has not 
been much documented on the difference in CSC growth between human and mouse origins. 
However, previous experiments in the Katare lab have revealed a similar morphology and 
growth rate for the human and mouse CSCs (Katare et al., 2013). 
 
7.1.3 Therapeutic implications of miRNA expression in human CSCs 
A variety of different miRNA subtypes have been identified within human CSCs. These 
miRNAs target the genes within signaling pathways that regulate CSC proliferation, 
differentiation and survival. Genetic manipulation of such miRNAs may therefore have 
therapeutic implications in regenerating cardiac tissue in response to ischemic injury. My 
results have thus far shown that diabetes induces alterations in the expression profiles of the 
candidate miRNAs in mouse CSCs. Furthermore, miR-329, -376c and -495 are known to be 
functionally conserved across mouse and human species (Wang et al., 2017; Clark and Naya, 
2015; Piriyapongsa et al., 2014). It is therefore plausible that the altered expression pattern of 
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the candidate miRNAs may be similar in diabetic human CSCs; and if so, it would take us one 
step closer to understanding the therapeutic potential of the candidate miRNAs in a clinical 
setting. The aim of this Chapter was therefore to replicate the altered expression of miR-329, -
376c, -495 and -30c in diabetic human CSCs. 
 
7.2 Methods 
7.2.1 Collection of human heart tissue  
Right atrial appendage (RAA) biopsies were obtained from six patients (three diabetic, three 
non-diabetic) undergoing on-pump coronary artery bypass surgery at the Dunedin Hospital. 
Full written and verbal consent was given by the patients to donate the RAA tissue for 
research purposes. The age of the patients was between 54 and 75 years old (patient 
information described in Table A10 in Appendix 10). The biopsies were collected from the 
hospital in vials containing sterile Krebs Ringer HEPES buffer solution (KRH) (Table A1.1 in 
Appendix 1) and kept at 4 °C. The samples were then taken to the Katare laboratory for 
processing. The RAA biopsies were 100-300 mg in weight and 1-2 inches in length.  
 
7.2.2 Isolation procedure for human CSCs 
Once the RAA biopsies were collected, they were cut into small pieces with surgical scissors 
after trimming away any epicardial fat tissue. To keep the tissues fresh as well as to increase 
the viability of the cells, all human CSC samples were processed within 1 hour of tissue 
collection. The same isolation procedure that was used to isolate mouse CSCs in Chapter 2, 
section 2.3.1 was also used to isolate the human CSCs from the RAA tissue. After digesting 
the CSCs chemically with the collagenase solution and mechanically with repeat-pipetting, 
the cell suspension was centrifuged at 1400 rpm for 5 minutes and re-suspended in 1 mL 
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DMEM/F12 media in T25 flasks. The human CSCs were passaged to P5 in T75 flasks. One 
T75 flask was then split into two T25 flasks at P6. The T25 flasks was frozen, until re-
initiated for FACS (described below). The other T75 flask was plated into three wells of a six-
well plate and grown to confluency, after which the total RNA was extracted from each well 
for q-PCR. 
 
7.2.3 Flow cytometry protocol 
FACS was performed to characterize the isolated human CSCs. Using the protocol from 
Chapter 2, section 2.4, three human diabetic and three human non-diabetic CSC samples were 
re-initiated at P6 and grown until confluent. CD105 and CD90 MSC markers were used as the 
primary expression markers to validate the cells as CSCs. The common HSC marker, CD34 
was also included to eliminate circulating stem cells from the cell population. Circulating 
stem cells are those which migrate to the heart and are functionally different to the resident 
stem cells (Dominici et al., 2006). Fluorophore-conjugated anti-human monoclonal antibodies 
(eBiosciences, USA) specific for CD105, CD90 and CD34 were diluted to 1:50 concentration 
with FACS buffer, as indicated in Table A1.2 in Appendix 1. The CSCs were trypsinized and 
prepared (1 x 106 cells/mL) as described in Chapter 2, section 2.4.1. Following acquisition, 
the FACS data was analysed using FlowJo 10.0 software to determine the proportions of 
CD105, CD90 and CD34 in the stained and unstained samples. The CSC samples were 
quantified (2.8 - 4.2 x 106 cells/mL) using a hemacytometer and further analysed to determine 
the proportion of cells that stained positive for both CD105 and CD90 within the CD34 




7.2.4 q-PCR protocol 
A q-PCR was performed to determine the expression of the miRNAs in the diabetic (n=3) and 
non-diabetic CSCs (n=3) using the protocol described in Chapter 2, section 2.6. After 
quantifying total RNA from each sample, the qPCR was performed in triplicate using 
miRNA-specific R.T and PCR primers for miR-329, -376c, -495 and -30c. The raw PCR data 
was then analysed by determining the mean fold change of the miRNA expression in the 
diabetic CSCs (using the 2ΔΔCq method) after normalising the data to the non-diabetic CSCs. 
The q-PCR was repeated three times using the same samples and a two-tailed t-test was used 
to determine the statistical significance (P < 0.05 or P < 0.01) of the mean fold changes 
between diabetic and non-diabetic CSCs. A one-way ANOVA and Kruskal Wallis H t-test 
were performed to determine the consistency of the results between the repetitions. 
 
7.3 Results 
7.3.1 Human CSCs exhibited similar morphology to mouse CSCs 
The human CSCs exhibited the same elongated, spindle shaped morphology as the mouse 
CSCs. However, they grow faster as they took only 2-3 days to reach P1 after their initial 
isolation compared to the mouse CSCs which took one week to reach the P1 stage. There was 
no observable change in the growth rate of the diabetic and non-diabetic human CSCs. 
Moreover, the number of human CSCs in each sample were similar to the mouse CSCs once 
confluency was achieved.  
 
7.3.2 Human CSCs exhibited MSC markers 
The FACS data showed that both diabetic (98 ± 1%) and non-diabetic CSCs (98 ± 2%) 
expressed a very high level of CD105. CD90 was moderately expressed in both diabetic (64 ± 
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10%) and non-diabetic CSCs (67 ± 8%). Moreover, further analysis showed that CSCs 
positive for both CD90 and CD105 were highly expressed in the diabetic population (80 ± 
10%), as well as the non-diabetic (80 ± 9%) population (Figs. 7.1 and 7.2). Finally, the CD34 
expression was extremely low with only 11 ± 7% in the diabetic CSCs and 14 ± 8% in the 
non-diabetic CSCs, confirming that the majority of cells isolated from the heart tissue were 
resident CSCs. The high expression of CD105, along with the low expression of CD34 in the 















Figure 7.1. Flow cytometric scatter data showing the expression of CD105 and CD90 MSC markers (conjugated to PE-Cy7 
and FITC fluorophores, respectively) among CD34
- 
CSCs in one representative human non-diabetic CSC sample. CD34 
(conjugated to APC fluorophore) was included to exclude the circulating stem cells. The expression of each marker is 
presented as a percentage within the CSC population of each sample. The proportion of CSCs that express CD34 is shown 
on the left panel (A), while the proportion of CSCs that express both CD105 and CD90 is shown on the upper right quadrant 
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Figure 7.2. Quantitative bar graph and scatter plot showing 
the relative distribution of CD105, CD90 human CSC 
markers, as well as the CD34 marker (negative control) in 
human diabetic (n=3) and non-diabetic CSCs (n=3). The 
proportion of CSCs expressing both CD105 and CD90 are 
also shown in the graph. Data are means ± SEM. 
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7.3.3 Diabetes induced similar alterations to target miRNAs in human CSCs 
After analysing the q-PCR data with a two-tailed unpaired t-test, the results showed a 
significant alteration in the expression of miR-376c, -495 and -30c in diabetic CSCs 
compared to the non-diabetic CSCs, while miR-329 expression remained unaltered (Fig. 7.3). 
MiR-376c (1.65 ± 0.03 in diabetic vs. 1.00 ± 0.03 in non-diabetic, P < 0.05) and -495 (1.43 ± 
0.19 in diabetic vs. 1.01 ± 0.03 in non-diabetic, P < 0.05) expression was upregulated in the 
diabetic CSCs compared to their expression in the non-diabetic CSCs. MiR-329 exhibited a 
similar level of expression in both diabetic (1.07 ± 0.23) and non-diabetic CSCs (1.00 ± 0.04). 
Similar to its expression in mouse CSCs, miR-30c was significantly downregulated in the 
diabetic CSCs (0.84 ± 0.03) compared to the non-diabetic CSCs (1.00 ± 0.03). The mean fold 
change of miR-30c was also statistically more significant among the four miRNAs.  
A one-way ANOVA showed no significant differences between the repetitions of each q-PCR 
for miR-329, miR-376c, miR-495 and miR-30c expression in either non-diabetic (F = 1.25, 
0.07, 0.47 and 0.03, respectively compared to Fcrit = 5.14, P > 0.05) or diabetic groups (F = 
1.16, 1.51, 1.07 and 1.70, respectively compared to Fcrit = 5.14, P > 0.05). This consistency 
was also confirmed by the Kruskal Wallis H test which showed no significant differences 
between the repetitions for miR-329, miR-376c, miR-495 and miR-30c expression in either 
non-diabetic (H = 1.87, 0.09, 0.27 and 0.09, respectively compared to Hcrit = 5.99) and 
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Figure 7.3. Quantitative data depicting the significantly altered expression of miRs -329, -376c, -495 and -30c in human diabetic (n=3) and non-diabetic CSCs 
(n=3). The q-PCR was performed three times using the same samples and a mean fold change was subsequently calculated for each miRNA. Data are means ± 






























7.4.1 Summary of results 
In this chapter, I examined the differential expression of the candidate miRNAs (miR-329, -
376c, -495 and -30c) in diabetic human CSCs. Using FACS, I first showed that the human 
CSCs that were used in these experiments were pure and expressed high levels of the well-
accepted MSC markers. I then demonstrated that the expression profiles of three out of the 
four candidate miRNAs were altered in the diabetic human CSCs. While more experiments 
are required with a larger number of samples, the results from this chapter indicate the 
translational potential of my mouse CSC data. These results also provide a solid foundation 
for future studies to determine the functional implications for miRNAs in diabetic CSCs. 
Moreover, they indicate whether miR-30c may be a potential target in a clinical setting. 
 
7.4.2 Human CSC validation 
The diabetic and non-diabetic human CSC populations contained a very high proportion of 
cells positive for both CD105 and CD90 markers, as well as a very low proportion of cells 
positive for the CD34 marker. The relative distribution of these markers suggest that the 
population of cells isolated from the RAA tissue are mainly resident CSCs. The expression of 
individual markers within the diabetic and non-diabetic CSCs were also consistent with other 
studies that have used CD105 and CD90 to characterise human CSCs and CPCs (Gambini et 
al., 2011; Mishra et al., 2011; Tateishi et al., 2007). For instance, Gambini et al. found a 
similar distribution of high CD105 (98%) expression in human CPCs (Gambini et al., 2011), 
while Tateishi et al. found that mouse CPCs also exhibited a moderate expression (68%) of 
CD90 (Tateishi et al., 2007). These studies correlated with the relative distribution of the 
markers in this study, as CD105 was expressed in 98% of CSCs in both diabetic and non-
diabetic CSC populations, while CD90 was expressed in moderate proportions of 64% and 
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67% in the diabetic and non-diabetic CSC population, respectively. Other studies reported an 
absence of the CD34 marker in human CSCs, which correlated with the extremely low 
proportions of CD34 in the diabetic and non-diabetic CSCs (Oh et al., 2003). Nonetheless, the 
presence of a CD34 positive population in my cell preparation is inevitable as the heart tissue 
was donated from patients who previously had ischemic heart disease, and it is well known 
that circulating stem cells migrate to the site of injury (Xu and Li, 2014; Rennert et al., 2013). 
 
7.4.3 Differential miRNA expression in human CSCs 
The q-PCR results showed that the expression profiles of miR-376c, -495 and -30c were 
significantly altered in the diabetic human CSCs. Notably, the expression patterns of these 
miRNAs were also similar to their differential expression in the diabetic mouse CSCs, as 
observed from the original Nanostring microarray and subsequent q-PCR analysis in Chapter 
4, section 4.3.1 and 4.3.3. This indicates that diabetes affects the expression of the candidate 
miRNAs in a similar way in both human and mouse CSCs. Interestingly, among the three 
differentially expressed miRNAs, miR-376c was the most substantially upregulated in the 
diabetic CSCs, while miR-30c was the only miRNA that was downregulated. Unlike the other 
miRNAs, miR-329 showed no significant change in expression in the diabetic human CSCs. 
This greatly contrasted with the significant and substantial upregulation that was observed for 
this miRNA in the diabetic mouse CSCs from both the Nanostring microarray and subsequent 
q-PCR. Although, there is no other evidence for its role in CSCs, miR-329 is known to inhibit 
cell proliferation in other human cell types, as indicated by the targeted inhibition of cell cycle 
promoters such as E2F1 (Xiao et al., 2013). This supports the upregulation of this miRNA in 
the diabetic mouse CSCs, but not the unaltered expression in the diabetic human CSCs. Due 
to the extremely limited amount of literature concerning the expression of miR-329 in human 
cells, the reason for this contrasting result remains unclear. A possible explanation could be 
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due to the lack of glucose control in diabetic mice. The diabetic mice used in this study had a 
consistently elevated glucose concentration, while all the diabetic human participants 
involved were on glucose-lowering drugs. However, more studies need to be performed to 
validate this theory. 
As previously stated, an upregulated miRNA expression in the diabetic CSCs suggests that it 
may possess a pathological function. As such, miR-495 is known to target genes that inhibit 
the cell cycle, as well as inhibiting the differentiation of human ESCs and MSCs (Lee et al., 
2014; Yang et al., 2013; Chen et al., 2013). Despite the fact that there is no evidence for such 
a role in CSCs, the successful translation of an upregulated expression profile from mouse to 
human CSCs in the diabetic condition suggests that miR-495 may also target human genes 
that promote CSC function. The functional nature of miR-376c remains unclear as it has been 
shown to promote the proliferation of human trophoblasts and neural differentiation of human 
pluripotent stem cells (Liu et al., 2014; Fu et al., 2013). Although this suggests a beneficial 
role for this miRNA, it contradicts the impact of the upregulated expression of miR-376c 
observed in the human CSCs in this study. Furthermore, the cell-cycle promoter, CDK6 was 
found as a target for miR-376c in the mouse CSCs, providing further evidence for a role in 
reducing CSC proliferation.  
Among the three miRNAs that were previously upregulated in the diabetic mouse CSCs, miR-
495 was the only one that was suggested to exhibit this upregulation in diabetic human CSCs. 
Evidently, it is clear that more expression studies must be performed to validate the 
upregulated expression of miR-376c, and the unaltered expression of miR-329 in the diabetic 
human CSCs.  
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7.4.4 Functional and therapeutic implications for miR-30c in human CSCs  
MiR-30c was significantly reduced in the diabetic human CSCs; a finding which correlated 
with the changes observed in the diabetic mouse CSCs. This indicates that miR-30c has 
functional and therapeutic implications in the diabetic heart. As the pathophysiological role of 
miR-30c has already been characterized in the mouse CSCs, its translated expression profile 
indicates that it may exhibit the same role in the human CSCs. MiR-30c may therefore 
promote the survival of human CSCs by directly inhibiting pro-apoptotic genes such as 
VDAC1. This has therapeutic implications in reducing the effect of diabetes on the heart by 
preventing CSC apoptosis, leading to an enhanced cardiomyocyte replacement after injury. 
Myocardial cell death also plays a pivotal role in the development of DCM, leading to MI, 
arrhythmias and endothelial dysfunction (Cai and Kang, 2003). A strategy involving genetic 
manipulation of miR-30c may therefore prevent or limit this pathological development for 
such patients. Moreover, the potential of stem cell transplantation yields many more 
therapeutic opportunities. Cardiosphere derived stem cells have been shown to increase 
functional cardiomyocytes and reduce scarring after transplantation in the infarcted heart 
(Makkar et al., 2012). The overexpression of miR-30c in transplanted CSCs may therefore 
increase their ability to improve cardiac function by promoting CSC survival in the heart.  
Altogether, the results from this chapter provide the first evidence that the expression of miR-
495, -376c and -30c are not only altered in diabetic mouse CSCs, but also in diabetic human 
CSCs. Importantly, this indicates that miR-30c may exhibit the same pathophysiological role 
in human CSCs that was discovered in the mouse CSCs in the diabetic condition. In the next 
chapter, I will discuss my findings from all previous chapters, and determine whether I have 




CHAPTER 8: SUMMARY AND CONCLUSIONS 
 
8.1 Summary and interpretation of results 
In this final chapter, I will provide a complete summary of my project and discuss whether the 
aims and hypothesis were addressed. I will also outline the primary limitations and challenges 
that I faced throughout the project, as well as ways that they could have been overcome. 
Finally, I will discuss future work and experiments that could be implemented to advance our 
understanding of how miRNAs can affect CSC function. 
 
8.1.1 Summary of mouse CSC study 
In the mouse study, I first established a culture of diabetic (n=6) and non-diabetic mouse 
CSCs (n=6) that formed the framework for the functional experiments involving miRNAs. I 
isolated the CSCs from diabetic db/db mouse heart tissue and confirmed their identity by 
performing a MACS purification technique (targeting the Sca-1 marker); which was later 
analysed by FACS. Once enough of the CSCs were grown in vitro, I performed a Nanostring 
microarray using RNA extracted from the diabetic and non-diabetic CSC samples to 
determine the differential expression of miRNAs between the two conditions. I found that out 
of 598 randomly selected miRNAs, 16 miRNAs exhibited a significantly altered expression 
profile in the diabetic CSCs. Furthermore, seven of these 16 miRNAs were predicted to target 
genes that are involved in regulating stem cell self-renewal. The altered expression of four of 
these seven miRNAs (miR-329, -495, -376c and -30c) were then validated by q-PCR at the 
molecular level. The GSK3-β and MEF2C genes were predicted to be targets for these 
miRNAs based on bioinformatic prediction tools and relevant literature. However, 
preliminary western blot analysis showed no change in their expression between the diabetic 
and non-diabetic CSCs.  
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Mass spectrometry was thus implemented to produce more reliable targets for the miRNAs 
using protein derived from the diabetic (n=5) and non-diabetic CSCs (n=5). The mass 
spectrometry analysis revealed VDAC1 to be a target for miR-30c, and CDK6 to be a target 
for miR-329, -495, and -376c. Western blot analyses then showed VDAC1 to be significantly 
upregulated and CDK6 to be significantly downregulated in the diabetic CSCs, validating the 
differential expression of the candidate miRNAs. VDAC1 was confirmed as a direct target for 
miR-30c by performing a luciferase assay. Diabetic (n=4) and non-diabetic CSCs (n=4) were 
then transfected with a miR-30c precursor mimic to determine the functional characteristics of 
the miRNA. Western blot analyses showed that the presence of the miR-30c precursor mimic 
caused direct downregulation of VDAC1 in the transfected diabetic and non-diabetic CSCs 
compared to control. Additional western blots revealed that cleaved Caspase-3 was also 
downregulated in diabetic CSCs transfected with the miR-30c precursor mimic compared to 
control; a finding which was observed to directly correlate with the downregulated VDAC1 in 
the same condition. This indicated that miR-30c exhibits an anti-apoptotic role in the diabetic 
mouse CSCs by inhibiting VDAC1 (Fig. 8.1). A Caspase 3/7 assay also supported this 
conclusion as there was a significant reduction in caspase 3/7 activity in protein derived from 




























Figure 8.1. A flow chart diagram depicting the potential molecular pathway of miR-30c reducing 
apoptosis. My findings suggest that miR-30c inhibits the expression of pro-apoptotic VDAC1 in the 
mitochondrial membrane of CSCs, and in doing so prevents the facilitated transport of apoptotic 
molecules such as cytochrome C. This also inhibits the entry of calcium ions (Ca2+) into the 
mitochondria, thereby preventing the accumulation of ROS in the cell. Ultimately, this means that 












8.1.2 Summary of human CSC study 
The human CSC study was performed to determine if the altered expression of miR-329, -
495, -376c and -30c observed in diabetic mouse CSCs can be translated to human diabetic 
CSCs with the aim to demonstrate the possible clinical implication of the target miRNAs. I 
isolated human CSCs from RAA biopsies collected from patients undergoing coronary artery 
bypass surgery. The diabetic (n=3) and non-diabetic human CSCs (n=3) were grown in vitro 
to expand the cell population. Their identity was then confirmed from FACS by targeting the 
CD105 and CD90 markers. A q-PCR provided evidence to suggest that diabetes affected the 
expression profiles of miR-376c, -495 and -30c in the human CSCs in a similar manner to 
how they were affected in the mouse CSCs. MiR-329 was the only miRNA that could not be 
translated from mouse to human CSCs. This indicated that miR-376c, -495 and -30c had 
pathophysiological roles in diabetic human CSCs. Moreover, the anti-apoptotic role of miR-
30c that was suggested in the diabetic mouse CSCs may also be present in the diabetic human 
CSCs. This is because the reduced expression of miR-30c that was observed in diabetic 
human CSCs aligns with previous studies from the Katare laboratory that have demonstrated 
that diabetes increases apoptosis in human CSCs (Fomison-Nurse et al., 2018; Katare et al., 
2013). 
 
8.2 Addressing aims and hypothesis of project 
The first aim for this project was to determine whether diabetes affects the expression of 
miRNAs within mouse and human CSCs. I have addressed this aim by giving preliminary 
evidence that miR-329, -495, -376c and -30c exhibit significantly altered expression profiles 
in the diabetic mouse CSCs. I also showed that this change in expression translated to human 
CSCs for miR-495, -376c and -30c. This indicates that diabetes may effect the expression of 
these miRNAs in both mouse and human CSCs. 
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The second aim was to demonstrate the pathophysiological role of the differentially expressed 
miRNAs in the diabetic CSCs. From the four miRNAs that were altered in the mouse study, I 
chose to focus on the role of miR-30c. This was due to the relative lack of understanding of 
the functional characteristics of miR-30c, as well as the extent to which miR-30c impacted its 
predicted target gene, compared to the other miRNAs. I addressed this aim by providing 
evidence to suggest that miR-30c promotes the survival of CSCs in the diabetic condition by 
regulating the pro-apoptotic VDAC1 gene. This indicates that miR-30c may have a 
pathophysiological role in the diabetic CSCs, and also provides more evidence for a 
therapeutic application in CSC transplantation. Altogether, I have addressed both objectives 
of my PhD thesis. 
 
8.3 Limitations 
8.3.1 Markers for CSC identification 
There are a number of limitations of this project, as listed below. Firstly, although specific 
markers were used such as Sca-1, CD105 and CD90 for the identification of mouse and 
human CSCs, there is no guarantee that these markers do not also bind to other cells besides 
CSCs. This is because unlike other stem cell subtypes, CSCs have not been characterized to 
the extent to which a specific marker has been identified purely for CSC identification. 
Nevertheless, the rationale for using these markers was based on previous published studies in 
which a similar population of resident stem cells was identified in the heart. Even so, the 
FACS data in both mouse and human CSCs did not show that the markers were bound to 
100% of the cells tested for. This indicates that there were some cells in the population that 
could not be considered CSCs based on the method used to characterise them as such. 
Although the percentage of these cells was small, they may have affected the changes 
observed in the downstream functional results. One possible method for overcoming this in a 
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future study is to use FACS to purify the CD34 negative population consisting of CSCs 
positive for both CD90 and CD105, although, as discussed earlier, the CSCs are more 
effective as a heterogenous population than a specific single cell population (Li et al., 2010). 
 
8.3.2 Simulating diabetes in vitro 
The growth conditions of the CSCs may have also been a limiting factor. The cells were 
grown in vitro using DMEM/F12 media. This media contains a fixed 17.5 mM concentration 
of glucose. This is much higher than the normal physiological concentration for blood glucose 
in humans (4-6 mM), as well as the normal concentration for people with diabetes (7-10 mM) 
(American Diabetes Association, 2006). It is also higher than the normal physiological blood 
glucose levels for non-diabetic mice (2.8-5.6 mM). It is however, roughly equivalent to the 
normal concentration of the diabetic mice (>16.7 mM) (King et al., 2012). Therefore, 
although it can be presumed that the DMEM/F12 media was beneficial to simulate diabetic 
conditions for the diabetic mouse CSCs, it may not be suitable for culturing non-diabetic 
mouse or human CSCs. Due to the complexity of such diseases, it is very difficult to simulate 
diabetic conditions in vitro. For this reason, the glucose levels may not be the only parameter 
that should be regulated during the growth of the CSCs. Diabetes is also known to promote 
insulin deficiency, as well as the build-up of oxidative stress, leading to cell death (Ouyang et 
al., 2014; Lee and Parvaiz, 2006). To better simulate diabetic conditions, the growth 
conditions should therefore exhibit insulin deficiency and a hypoxic microenvironment. 
Furthermore, although the diabetic mice were confirmed as hyperglycemic, the impact of 
obesity as a complication of type-2 diabetes was not measured. The fact that these parameters 
were not accounted for during the culturing of diabetic CSCs may therefore reflect the fact 
that the statistical significant results purely indicate that effects are unlikely to have occurred 
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by chance, and do not necessarily confirm biological significance. More reliable techniques 
need to be optimized to better simulate the pathological nature of diabetes in vitro. 
Other limitations arose from comparing the diabetic mouse and human CSCs. The type-2 
diabetic patients that donated heart tissue were treated with glucose-lowering drugs, while the 
diabetic mice did not undergo such treatment. The effects of these drugs have not been 
measured; however there is a possibility that they may influence molecular events within the 
diabetic CSCs. Moreover, the age of the mice may be a limiting factor when making 
comparisons to humans. In the study, 12 week old mice were used which is equivalent to a 30 
year old human (Jackson et al., 2017). However, the diabetic and non-diabetic patients were 
considerably older than this (54-75 years old), which may have affected the results. Finally, 
due to the association between obesity and type-2 diabetes, the weights of the human patients 
were recorded. Unlike the mice, the type-2 diabetic patients were not consistently heavier than 
the non-diabetic patients (Appendix 10), suggesting a discrepancy in the nature of the diabetic 
condition between humans and mice. However, this may also indicate that diabetes was a 
greater contributing factor than weight with regards to the differential miRNA expression that 
I observed in the human CSCs. 
 
8.3.3 Bioinformatic analyses 
Another limiting factor was the method used for the identification of miRNA target genes. 
Although bioinformatic analyses is accepted in the field, the miRNA-target prediction 
databases associated with this method (eg. TargetScan, miRanda) are often not experimentally 
validated, therefore showing low precision and sensitivity (Witkos et al., 2011; Alexiou et al., 
2009). This was addressed in Chapter 5 by implementing mass spectrometry to identify more 
reliable targets in the experimental samples.  
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Bioinformatic pathways were also used to predict that 7 out of the 16 significantly regulated 
miRNAs were associated with regulating stem cell proliferation and self-renewal. However, if 
the bioinformatic pathways were unreliable, this may suggest that the other 9 miRNAs may 
also be involved in regulating stem cell proliferation or apoptosis. 
 
8.3.4 Low sample size 
Finally, there were instances where a larger sample size may have increased the statistical 
power of some of the findings in my project. This was particularly notable in two 
experiments. In the caspase 3/7 assay in Chapter 6, section 6.3.3, total protein derived from 
non-diabetic CSCs transfected with miR-30c precursor mimic was found to exhibit reduced 
caspase activity compared to the non-diabetic control. This change was not significant; 
however the P value was extremely close to being so at 0.06. A large number of samples may 
have reduced this P value to significant levels. Also, in the q-PCR performed in Chapter 7, 
section 3.3, the expression profiles of all four miRNAs were able to be translated from mouse 
to human CSCs in the diabetic condition, except for miR-329. However, due to time 
constraints and other difficulties in obtaining the RAA biopsies, only three diabetic and three 
non-diabetic samples were used in my project. A larger sample size may have impacted these 
results such that the change in expression of miR-329 may have translated better from 
diabetic mouse to human CSCs. Although the data was statistically significant, a larger 
sample size may have also reduced the variability in miR-376c and miR-495 expression 






8.3.5 Passaged and cryopreserved CSCs 
There is evidence to suggest that primary cells that are passaged and/or cryopreserved exhibit 
substantial changes in their morphology, gene expression and differentiation potential (Nam 
et al., 2014). Although passaging and cryopreservation can be used as tools to generate cell 
numbers and store these cells, respectively, they may therefore also have led to a change in 
the functional nature of the CSCs.  
One example of the effect of passaging may be the inconsistent VDAC1 expression observed 
in the study. In Chapter 5, I showed that the expression of VDAC1 was substantially and 
significantly increased in the diabetic CSCs. However, despite not being the main focus, this 
increased expression was not found in the CSCs transfected with the scrambled mimic during 
the transfection experiment in Chapter 6. This change in expression may be due to the effects 
of passaging or cryopreservation. Passaging may also be a contributing factor for the lack of 
consistency in miRNA expression in the human study. If the human CSCs were processed at 
the same passage, there may be less variation in miR-376c expression between each q-PCR 
repetition. Therefore, reducing the number of passages and freeze-thaw cycles, and keeping 
these parameters consistent may have increased the reliability of my results. 
 
8.3.6 Luciferase assay 
The luciferase assay performed in the study has a number of limitations. Firstly, a larger 
sample size may have altered the suggested outcome that VDAC1 is a direct target for miR-
30c. Also, neither the 3’UTR construct of VDAC1 or the Lipofectamine transfection reagent 
were tested for their individual effects alongside the co-transfected data set. They could have 




8.3.7 Consequences of mimic overexpression 
Although the study was focused on demonstrating the possible role of miR-30c in CSCs, 
physiological conditions are not easily attained. For this reason, the substantial increase in 
miR-30c expression as a result of transfecting the CSCs with the miR-30c precursor mimic 
may have consequences when considered in a clinical setting. However, more experiments are 
needed to understand the specific concentration of miR-30c mimic required to induce the 
molecular changes, while limiting any harmful side-effects as a result of the overexpression. 
 
8.3.8 Increased scar formation 
Sca-1 has been identified as a suitable marker for the identification of CSC. However, studies 
have shown that Sca-1+ cells may differentiate into adipocytes or fibroblasts upon myocardial 
degeneration (Paylor et al., 2013). This can therefore lead to scar formation and other 
cardiomyopathies when these cells are transplated into tissue. This may therefore be a 
potential side-effect of transplanting Sca-1+ CSCs into the human heart, and one that must be 
carefully addressed and remedied before considering a clinical application of miR-30c within 
the Sca-1+ CSCs. However, it is possible that the cells can be genetically engineered with a 
cocktail of miRNAs which have the potential to reduce fibrotic differentiation. Future studies 
could focus on using the miRNA cocktail to improve the efficacy of stem cells. 
 
8.4 Future work 
8.4.1 Understanding mode of inhibition of miR-30c 
My findings suggest that VDAC1 may be a functional target for miR-30c. It would be 
interesting to further understand the mode of inhibitory action associated with this interaction. 
As previously stated, miRNAs can either bind to the mRNA of the target gene, causing its 
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degradation; or alternatively, they can repress the translation of the mRNA into protein. The 
western blots in Chapter 5, section 5.3.3 and Chapter 6, section 6.3 indicated that miR-30c 
causes translational repression of the VDAC1 total protein. However, whether miR-30c also 
degrades the mRNA of VDAC1 has yet to be determined. A q-PCR can be performed using 
RNA extracted from diabetic and non-diabetic CSCs transfected with a miR-30c precursor 
mimic to determine the expression of the VDAC1 mRNA. This would provide an indication 
as to whether the mRNA of VDAC1 is repressed in the presence of the miR-30c precursor 
mimic. If the mRNA is repressed, it would suggest that a proportion of miR-30c binds to the 
VDAC1 mRNA to confer its inhibitory action. 
 
8.4.2 Effect of miR-30c on VDAC1 in human CSCs 
My findings suggest that miR-30c was similarly dysregulated in mouse and human CSCs. The 
suggested molecular mechanism associated with this dysregulation involves inhibition of pro-
apoptotic VDAC1 and caspase-3. However, this mechanism has not yet been investigated in 
the human CSCs. Therefore, the next step is to determine if VDAC1 and caspase-3 proteins 
are similarly reduced in human CSCs transfected with the miR-30c mimic. Western blot and 
q-PCR analysis may be performed to demonstrate this, and the results of these studies can be 
compared to the mouse data. Furthermore, apoptosis functional assays may be performed to 
confirm the suggested role of miR-30c in regulating the apoptosis of CSCs in mice and 
human tissue.  
 
8.4.3 Loss of function experiments 
Loss of function (‘silencing’) experiments may also strengthen the findings of my thesis. In 
this context, an anti-miRNA specific for miR-30c may be transfected into the CSCs to inhibit 
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the expression of any existing miR-30c. As my results suggest, I would expect to observe an 
increased expression of VDAC1 in mouse CSCs transfected with the anti-miRNA for miR-
30c. These experiments, in combination with the results of my thesis, may provide much 
stronger evidence to suggest that VDAC1 is not only inhibited by miR-30c, but that this 
interaction is directly linked to a potential role of miR-30c in regulating apoptosis. 
 
8.4.4 Determining whether miR-30c can regulate CSC membrane potential 
While my study has suggested the pro-apoptotic role of VDAC1, this gene is also known to 
regulate mitochondrial membrane potential. Therefore, a secondary role of miR-30c may be 
to regulate mitochondrial membrane potential of CSCs. In support of this, studies have shown 
diabetes to adversely affect mitochondrial membrane potential in a number of different tissues 
(Sivitz and Yorek, 2010; Widlansky et al., 2010). The mitochondrial membrane potential can 
be measured by performing a cobalt-calcein assay in the diabetic and non-diabetic CSCs 
transfected with the miR-30c precursor mimic. The calcein dye passively diffuses into the 
mitochondria, allowing the CSCs to be fluorescently labelled. The opening of the 
mitochondrial permeability transition pore (mPTP) leads to the exit of calcein and entry of 
cobalt ions into the mitochondrial compartment, manifesting as a reduction of fluorescence 
intensity (Lee et al., 2013). The loss of fluorescence is also proportional to the membrane 
potential of the cell. Opening of the mPTP is also associated with the onset of apoptosis. 
Determining the membrane potential would therefore directly parallel the results of this thesis, 
and improve our understanding of the pathophysiological role of miR-30c within the CSCs. It 
would also be interesting to determine whether diabetes affects the ability of miR-30c to 
regulate membrane potential of CSCs, and if it does so in a similar manner as the ability of 
miR-30c to regulate apoptosis.  
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Although from the MS results, GSK3-β was not found to be a target for miR-30c, the 
phosphorylation and subsequent inactivation of this gene is also known to induce opening of 
the mPTP and therefore membrane potential (Juhaszova et al., 2004). This indicates that there 
are other genes which may be involved in regulating the mPTP, but may not be direct targets 
of miR-30c. Therefore future experiments must be performed to uncover the complex 
molecular pathways leading to this function. 
 
8.4.5 Functional studies on other candidate miRNAs  
In this project, I have shown that diabetes causes dysregulation of miR-329, -376c, -495 and -
30c in CSCs. Moreover, while my project focused on demonstrating the functional 
significance of only miR-30c, it would be interesting to perform similar experiments on other 
dysregulated miRNAs. Thus far, the general function of these miRNAs seems to involve the 
regulation of cell proliferation. Proliferation assays could therefore be performed on CSCs 
transfected with corresponding mimics to provide new insights into their anti-proliferative 
role in the CSCs. Moreover, because the target protein that was identified for these miRNAs 
was the cell-cycle regulator, CDK6, western blots could be performed on the transfected cells 
to determine the involvement of CDK6 in regulating proliferation. This would provide a 
better understanding of the roles of miR-329, -376c and -495 in mouse CSCs, and might also 
reveal the therapeutic potential of miR-376c and miR-495 in human CSCs. Finally, it would 
be interesting to determine if using precursor mimics or anti-miRNAs to overexpress or 
knockdown the miRNAs, respectively, will provide novel information on the synergistic 





8.4.6 Testing the functional efficacy of miR-30c in an in vivo mouse model of myocardial 
infarction 
All the results presented in my thesis were using an in vitro model. While these results 
provided the first pieces of evidence for the ability of diabetes to induce dysregulation of 
miRNA expression in mouse and human CSCs, as well as laying down the foundation for a 
potential therapeutic role of miR-30c, it is also important to test the beneficial effects of miR-
30c expression in an in vivo model. Stem cell therapy plays a major role in improving the 
functional recovery of patients after a MI, whereby millions of cells are lost due to apoptotic 
cell death. Therefore, a mouse model of MI can also be used to demonstrate the anti-apoptotic 
function of miR-30c in vivo. Genetically engineered diabetic and non-diabetic CSCs that 
overexpress miR-30c can thus be injected along the border zone of the left ventricle after MI 
is induced. Alterations in cardiac function as a result of either miR-30c overexpression can 
then be observed and compared to the sham (placebo surgery) control. The parameters 
measured may include the functional recovery of the heart using echocardiography, or 
angiogenesis by performing histological analyses. This would provide a greater indication of 
the benefits of miR-30c in an animal model, as well as insight into its therapeutic application 
in treating the infarcted heart.  
 
8.5 Concluding remarks 
Diabetes is a growing epidemic that greatly reduces quality of life and damages different 
tissues, including the heart. It is therefore imperative to research and develop new ways of 
treating this disease. In this thesis, I have shown evidence to suggest that miR-30c may have 
an anti-apoptotic role in diabetic mouse CSCs. In particular, I have shown that miR-30c may 
be genetically manipulated in vitro to improve CSC survival, which indicates its therapeutic 
potential in CSC transplantation. This is an important step to understanding how miRNAs can 
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enhance stem cell therapy and therefore have a beneficial impact on human health, especially 
in pathologies such as diabetes. I have also shown that miR-495, -376c and -30c are 
differentially expressed in diabetic CSCs. These miRNAs may be further investigated to 
determine whether they have potential role within diabetic CSCs, which may lead to a 
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APPENDIX 1: LIST OF REAGENTS 
 
Table A1.1 List of buffers used and their composition 
No.  Solution Reagents 
1 Phosphate Buffer Saline (PBS) 10 mM Sodium Phosphate Monobasic 
1.8 mM Potassium Phosphate Dibasic 
137 mM Sodium Chloride 
2.7 mM Potassium Chloride 
2 Hank’s Balanced Salt Solution 
(HBSS) 
1.26 mM Calcium Chloride Dihydrate 
0.49 mM Magnesium Chloride Hexahydrate 
0.41 mM Magnesium Sulphate Heptahydrate 
5.3 mM Potassium Chloride 
0.22 mM Potassium Phosphate 
4.17 mM Sodium Bicarbonate 
138 mM Sodium Chloride 
0.34 mM Sodium Phosphate Dibasic 
5.55 D-Glucose 
3 Kreb’s Ringer Hienslet Buffer 
(KRH) 
116 mM Sodium Chloride 
4 mM Potassium Chloride 
1 mM Magnesium Chloride 
1.8 mM Calcium Chloride 
25 mM Glucose 
10 nM HEPES Acid (adjusted to pH 7.4) 
4 Collagenase type II and IV 0.02g/mL collagenase type II and IV (1357 
Unit)  
5 SDS-Page gel solution 12% Resolving gel (per gel):  
5.3 mL dH2O 
4 mL Lower Tris (adjusted to pH 8.8) 
160 µL 10% SDS 
6.4 mL 30% Acrylamide/Bis-acrylamide 
160 µL 10% Ammonium persulfate 
10 µL TEMED 
4% Stacking gel (per gel): 
4.2 mL dH2O 
1.75 mL Upper Tris (adjusted to pH 6.8) 
70 µL 10% SDS 
0.931 mL 30% Acrylamide/Bis-acrylamide 
70 µL 10% Ammonium persulfate 
7 µL TEMED 
6 TBS-T 0.05% TBS-T in dH2O: 
8g Sodium Chloride 
0.2g Potassium Chloride 
3g Tris 
1L dH2O 
80 mL Tween20 
7 FACS buffer 3 mM HEPES in HBSS buffer 
1% Fetal Bovine Serum 
8 Loading buffer 2X Loading buffer: 
4.165 mL Upper Tris 
10 mL 20% SDS 
20 mL 50% glycerol 
5 mL 30% mercaptoethanol 
500 µL EDTA (200mM) 
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10.38 mL dH2O 
0.05% bromophenol blue 
9 RIPA lysis buffer 50 mM Tris-HCl: 
0.6057g Tris 
100 mL dH2O (adjusted tp pH 7.4) 
8.766g Sodium Chloride 
0.0292g EDTA 
1mL SDS (0.1% normally, 0.02% for MS) 




Table A1.2 List of antibodies used 







1 Monoclonal  Anti-Sca-1-
FITC 
Mouse 1:100 Miltenyl Biotenic 
2 Polyclonal  Anti-VDAC1 Rabbit 1:1000 abcam 
3 Monoclonal  Anti-CDK6 Mouse 1:1000 Cell Signaling 
Technology 
4 Polyclonal  Anti-α-
tubulin 
Rabbit 1:1000 abcam 
5 Secondary Anti-mouse 
IgG 
Goat 1:3000 ThermoFisher 
6 Secondary Anti-rabbit 
IgG 
Mouse 1:3000 ThermoFisher 
7 Monoclonal  Anti-CD34-
APC 
Human 1:50 eBiosciences 
8 Monoclonal Anti-CD90-
FITC 
Human 1:50 eBiosciences 
9 Monoclonal  Anti-CD105-
PE-Cy7 





APPENDIX 2: FLUOROPHORES AND TUBE 









Tube number Solution/sample Compensation Beads/PI 
1 FITC-CD90 Yes Beads 
2 PE-Cy7-CD105/Sca-1 Yes Beads 
3 APC-CD34 Yes Beads 
4 PI-Live Yes PI 
5 PI-Dead Yes PI 
6 Unstained CSC sample No - 
















APC 660 640 (red) FL6 CD34 
PE-Cy7 774 496, 565 (blue) FL5 CD105, Sca-1 
PI 620 488 (blue) FL3  
FITC 525 488 (blue) FL1 CD90 
Table A2.1 Fluorophores and their conjugated antibodies that were used in FACS experiments. 
APC = Allophycocyanin, PE-Cy7 = Phycoerythrin–Cyanin 7, PI = Propidium Iodide, FITC = 
Fluorescein isothiocyanate. 
Table A2.2 Tube set up for FACS experiment. The table shows the antibody (with conjugated 
fluorophore) solutions, as well as the CSC samples included in the reaction. It also shows whether 
the samples were used for compensation, and whether they were stained with the AbC Capture 
beads or PI. 
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APPENDIX 3: RNA AND PROTEIN 
QUANTIFICATION 
 
I extracted RNA from the diabetic and non-diabetic CSCs in order to measure the 
transfectional efficiency of the miR-30c precursor mimic. The concentrations and purity of 
this RNA is shown below. 
 
Sample Concentration (ng/µL) Purity (260/280) 
Non-diabetic #1 scr A 14.76 1.768 
Non-diabetic #1 scr B 14.44 1.799 
Non-diabetic #1 scr C 7.41 1.860 
Non-diabetic #1 30c A 11.38 2.030 
Non-diabetic #1 30c B 9.42 1.845 
Non-diabetic #1 30c C 8.37 1.847 
Non-diabetic #2 scr A 5.96 2.050 
Non-diabetic #2 scr B 12.58 1.767 
Non-diabetic #2 scr C 9.38 1.894 
Non-diabetic #2 30c A 8.09 2.100 
Non-diabetic #2 30c B 8.25 2.095 
Non-diabetic #2 30c C 6.54 2.083 
Non-diabetic #3 scr A 7.52 1.928 
Non-diabetic #3 scr B 8.98 1.923 
Non-diabetic #3 scr C 34.85 1.820 
Non-diabetic #3 30c A 11.41 1.821 
Non-diabetic #3 30c B 9.26 1.792 
Non-diabetic #3 30c C 11.30 1.893 
Non-diabetic #4 scr A 12.42 1.997 
Non-diabetic #4 scr B 14.54 1.812 
Non-diabetic #4 scr C 15.86 2.026 
Non-diabetic #4 30c A 22.11 1.849 
Non-diabetic #4 30c B 26.15 1.971 
Non-diabetic #4 30c C 20.20 1.860 
Diabetic #1 scr A 13.65 1.940 
Diabetic #1 scr B 9.22 2.089 
Diabetic #1 scr C 9.73 2.084 
Diabetic #1 30c A 9.23 2.084 
Diabetic #1 30c B 14.90 2.117 
Diabetic #1 30c C 11.19 1.912 
Diabetic #2 scr A 8.84 1.860 
Diabetic #2 scr B 14.50 1.989 
Diabetic #2 scr C 15.34 1.921 
Diabetic #2 30c A 14.34 2.008 
Diabetic #2 30c B 15.97 1.978 
Diabetic #2 30c C 13.08 1.875 
Diabetic #3 scr A 7.07 2.032 
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Diabetic #3 scr B 11.59 1.884 
Diabetic #3 scr C 10.27 2.038 
Diabetic #3 30c A 9.25 2.035 
Diabetic #3 30c B 10.07 1.856 
Diabetic #3 30c C 10.10 1.925 
Diabetic #4 scr A 5.24 2.068 
Diabetic #4 scr B 5.58 2.073 
Diabetic #4 scr C 4.83 1.881 
Diabetic #4 30c A 7.91 1.878 
Diabetic #4 30c B 9.51 2.102 






Table A3.1 The table shows concentrations (ng/µL) of total RNA extracted from diabetic (n=4) 
and non-diabetic CSCs (n=4), transfected with either miR-30c precursor mimic (30c) or scrambled 
mimic (scr). Each transfected sample was extracted in triplicate (A, B and C) and analysed by a 




I quantified total protein extracted from the diabetic (n=4) and non-diabetic CSCs (n=4) using 
the Bradford method. The optical density of each protein sample was first calculated by 
comparing their absorbance with the BSA reference standard curve. The following figure 
shows the reference standard curve, along with graph equation that can be used to calculate 
the optical density (x in the equation) of the protein samples, as well as the R-squared (line of 
best fit) measure of statistical regression. In this case, an R-squared value of 0.9604 ( ̴ 1.0) 




































Figure A3. Reference standard curve graph for Bradford method of protein quantification. 
The graph shows a standard curve of BSA concentration relative to optical density, which 
can be used to determine the optical density (x) of the protein samples. The R-squared value 
is also included to show the statistical regression of the standard curve. 
210 
 
The optical density of each protein sample can then be used to calculate the protein 
concentrations as shown in example below. 
 




Non-diabetic #1 scr 0.34 0.52 2.59 
Non-diabetic #1 30c 0.50 0.83 4.15 
Non-diabetic #2 scr 0.62 1.06 5.41 
Non-diabetic #2 30c 0.53 0.89 4.45 
Non-diabetic #3 scr 0.49 0.83 4.15 
Non-diabetic #3 30c 0.31 0.48 2.39 
Non-diabetic #4 scr 0.30 0.44 2.21 
Non-diabetic #4 30c 0.46 0.76 3.82 
Diabetic #1 scr 0.31 0.48 2.38 
Diabetic #1 30c 0.37 0.59 2.95 
Diabetic #2 scr 0.52 0.89 4.43 
Diabetic #2 30c 0.45 0.76 3.79 
Diabetic #3 scr 0.42 0.68 3.42 
Diabetic #3 30c 0.41 0.65 3.23 
Diabetic #4 scr 0.60 1.03 5.18 








Table A3.2 The table shows how the protein concentration was calculated from the optical density 
of each diabetic (n=4) and non-diabetic sample (n=4) transfected with either miR-30c precursor 
mimic (30c) or scrambled mimic (scr). The samples used in the Bradford assay were diluted (1 in 5) 
to obtain working solutions. Using the graph equation of the reference standard curve, the 
concentration of protein in the assay, as well as the concentration of the sample can be calculated.  
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Figure A4. Ponceau stain of total protein derived from non-diabetic (n=4) and 
diabetic (n=4) mouse CSCs. The blot was performed to determine CDK6 
expression in the non-diabetic and diabetic CSCs. The image was taken using 
the Syngene PXi gel imaging system (Atkinson, USA) and the proteins bands 







APPENDIX 5: COUNTING CSCS USING 
HEMOCYTOMETER 
 
In this project, a hemocytometer was used to count the CSCs. The following procedure was 
used to determine the appropriate number of CSCs to seed into flasks, as well as for 
experiments that required a cell count (eg. MACS purification).  
The CSCs were trypsinized and pelleted, before re-suspension in 1 mL DMEM/F21 media.. 
After gently mixing the cell suspension, 10 µL of the cell suspension was added onto the 
hemocytometer grid, as well as an additional 10 µL to the opposite grid. A flat cover slip was 
placed on top of both grids (without air bubbles) and the cells visualized under a light 
microscope. The CSCs were counted in each of the four corner squares, as well as in the 
centre square of the grid, and divided by five. The cell counts from each grid were averaged to 
give the number of CSCs (x 104/mL) in each sample. This was used to calculate the volume of 
cell suspension required by dividing the desired cell number by the CSC count, as shown in 
the table below. 
Eg. After the diabetic and non-diabetic CSCs were cultured to P3 in T75 flasks, the CSCs 
were counted to achieve the desired number for MACS purification (1 x 107). 
  
Sample CSC count      
(per mL) 
Number of CSCs needed 
for MACS 
Volume of cell suspension 
required (mL) 
Diabetic #1 1.9 x 107 1 x 107 526 
Diabetic #2 2.4 x 107 1 x 107 417 
Diabetic #3 1.3 x 107 1 x 107 769 
Diabetic #4 2.8 x 107 1 x 107 357 
Non-diabetic #1 1.5 x 107 1 x 107 667 
Non-diabetic #2 2.6 x 107 1 x 107 385 
Non-diabetic #3 1.9 x 107 1 x 107 526 
Non-diabetic #4 1.4 x 107 1 x 107 714 
Table A5. Volumes of diabetic and non-diabetic CSC cell suspensions required from MACS 
purification based on cell count. 
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Figure A6. Phase contrast image taken from observing purified CSCs under a light 
microscope. The cells are shown at 10 weeks following initial isolation from diabetic 
mouse heart tissue. Cells appear similar to senescent cell morphology, with large, flat 








APPENDIX 7: SEQUENCES FOR PRIMERS 
 
 
Primer name Sequence of primer 
 Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 














Table A7. Sequences of proliferation primers (Ki-67, Topo-2α) used in the q-PCR to determine the 
proliferation of miR-30c-transfected diabetic and non-diabetic CSCs, as well as the sequence of the 
miR-30c precursor mimic used for all transfection experiments. 
215 
 






































N1       N2        N3       N4        D1       D2        D3      D4 
N1        N2        N3       N4        D1       D2        D3       D4 
N1        N2        N3        N4         D1        D2        D3       D4 
N1        N2        N3        N4         D1        D2        D3       D4 
VDAC1 blot #2 
VDAC1 blot #3 
CDK6 blot #2 
































Nscr   N30c    Nscr     N30c   Dscr    D30c    Dscr   D30c 
Nscr   N30c   Nscr   N30c   Dscr    D30c     Dscr   D30c 
Nscr    N30c    Nscr     N30c    Dscr    D30c     Dscr   D30c 










Figure A8. Additional immunoblots for determining expression of VDAC1, CDK6 and 
cleaved caspase-3 in transfected (A8.2) and non-transfected (A8.1) diabetic (n=4) and non-
diabetic CSCs (n=4). N = Non-diabetic, D = Diabetic, Nscr = Non-diabetic transfected with 
scrambled mimic, N30c = Non-diabetic transfected with miR-30c mimic, Dscr = Diabetic 
transfected with scrambled mimic, D30c = Diabetic transfected with miR-30c mimic. 
217 
 




To measure the transfectional efficiency of the miR-30c precursor mimic, 6 x 105 diabetic 
(n=4) and non-diabetic CSCs (n=4) were initially seeded into 12-well plates in triplicate. 
Meanwhile, 1x 106 CSCs from the same samples were seeded into T25 flasks for western blot 
analysis. The reagents used in the transfection experiment are shown in the table below. 
 
Flask/Plate Number of 













6 x 105 4  4  12  400 








Table A9. Table showing the volumes of miR-30c/scrambled mimic, lipofectamine reagent, and 
DMEM/F12 required for transfecting CSCs depending on the number of CSCs required for each flask/plate. 
Numbers are shown for either one well of the 12-well plate or one T25 flask.  
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Case No.  Date 
collected 
Sex Type Age (years) Weight (kg) 
293  26/02/15 Male Diabetic-type 
2 
54 132 
290 19/02/15 Male Non-diabetic  58 106 
322 28/04/15 Male Diabetic-type 
2 
59 101 
284 29/01/15 Male Non-diabetic 61 115 
308 26/03/15 Male Non-diabetic 64 87 
326 21/04/15 Male Diabetic-type 
2 
75 81 
Table A10. Patient information for three type-2 diabetic and three non-diabetic human patients. This 
includes the date collected, sex and age of the patients 
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APPENDIX 11: Top 40 significantly upregulated 
and top 40 significantly downregulated MS peptides 
 
Peptide/gene name  Fold change  Significance (P 
value) 
Downregulated 
Signal transducer and activator 1 (STAT1) 
0.375819 2.75E-12 
UDP-N-acetylhexosamine pyrophosphorylase (UAP1) 0.207817 2.35E-09 
Cyclin-dependent kinase 6 (CDK6) 0.439827 4.40E-07 
Translationally-controlled tumor protein (TPT1) 0.753579 3.92E-05 
Rab3 GTPase-activating protein catalytic subunit 
(RAB3GAP1) 0.544419 0.00012 
Heparin Binding Growth Factor (HDGF) 0.654617 0.00012 
1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
beta-3 (PLCB3) 0.598453 0.00017 
GRIP And Coiled-Coil Domain-Containing Protein 2 
(GCC2) 0.53808 0.00055 
Crk-like protein (CRKL) 0.670665 0.00021 
Nexilin (NEXN) 0.663014 0.0007 
UMP-CMP kinase (CMPK1) 0.776847 0.00088 
Vamp6/Vps39-like protein (VPS39) 0.476113 0.00098 
SAP Domain Containing Ribonucleoprotein (SARNP) 0.595147 0.00143 
Mannosidase Alpha Class 1A Member 1 (MAN1A1) 0.607646 0.00776 
Guanylate cyclase soluble subunit beta-1 (GUCY1B1) 0.62574 0.01368 
40S ribosomal protein S7 (RPS7) 0.695617 0.01734 
Protein disulfide-isomerase (P4HB) 0.632183 0.01768 
Family With Sequence Similarity 129 Member A 
(FAM129A) 0.883568 0.0178 
Constitutive coactivator of PPAR-gamma-like protein 1 
(FAM120A) 0.736727 0.01813 
Metaxin 2 (MTX2) 0.690314 0.01845 
Erythrocyte Membrane Protein Band 4.1 Like 2 (EPB41L2) 0.688939 0.01846 
RAB11-binding protein (RELCH) 0.631278 0.01951 
Tripeptidyl-peptidase 1 (TPP1) 0.801314 0.01975 
Integrin Linked Kinase (ILK) 0.74826 0.02101 
Guanine nucleotide-binding protein Gq (GNAQ) 0.746936 0.02103 
Uveal autoantigen with coiled-coil domains and ankyrin 
repeats (UACA) 0.602769 0.02138 
Sorting nexin 7 (SNX7) 0.841615 0.02145 
Glutathione reductase (GSR) 0.6343 0.02157 
Pirin (PIR) 0.657804 0.02172 
Ubiquitin carboxyl-terminal hydrolase 14 (USP14) 0.888771 0.02186 
Flotillin-2 (FLOT2) 0.77797 0.02326 
V-type proton ATPase subunit D (ATP6V1D) 0.792766 0.02369 
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) 0.849724 0.03291 
Dehydrogenase/reductase (SDR family) X-linked protein 
(DHRSX) 0.724815 0.03292 
Milk fat globule-EGF factor 8 protein (MFGE8) 0.571682 0.03295 
WD Repeat Domain 11 (WDR11) 0.68289 0.03341 
220 
 
Vacuolar protein sorting-associated protein 26A (VPS26A) 0.710931 0.03354 
Phosphoribosyl Pyrophosphate Synthetase Associated 
Protein 1 (PRPSAP1) 0.721211 0.03624 
ATPase H+ Transporting V0 Subunit A2 (ATP6V0A2) 0.741759 0.0369 
Copper transport protein (ATOX1) 0.911446 0.03914 
Upregulated 
Cartilage-associated protein precursor (CRTAP) 1.778638 8.88E-09 
Myosin-10 (MYO10) 1.707861 2.45E-06 
Spectrin alpha chain, non-erythrocytic 1 (SPTAN1) 1.62398 6.24E-06 
Dihydrolipoyllysine-residue succinyltransferase component 
of 2-oxoglutarate dehydrogenase complex (DIST) 1.864016 0.00014 
26S proteasome non-ATPase regulatory subunit 13 
(PSMD13) 1.789953 0.00024 
Transmembrane and TPR repeat-containing protein 3 
(TMTC3) 1.867017 0.00036 
Pyruvate carboxylase (PCX) 2.582412 0.00038 
NAD-dependent protein deacetylase sirtuin-2 (SIRT2) 1.506322 0.00107 
Rab GTPase-binding effector protein 2 (RABEP2) 1.993037 0.00163 
NAD(P)H dehydrogenase [quinone] 1 (NQO1) 2.117885 0.00188 
Peptidyl-prolyl cis-trans isomerase A (PPIA) 2.129923 0.00193 
Voltage-dependent anion-selective channel protein 1 
(VDAC1) 1.668126 0.00214 
Lysosome-associated membrane glycoprotein 1 (LAMP1) 2.234822 0.00385 
RNA polymerase II-associated protein 1 (RPAP1) 1.982721 0.00613 
Collagen alpha-2(I) chain precursor (COL1A2) 1.31064 0.00729 
Nuclear pore complex protein Nup153 (NUP153) 1.713274 0.01164 
Adenosine deaminase (ADA) 1.292302 0.00041 
DnaJ homolog subfamily B member 11 precursor 
(DNAJB11) 1.356682 0.00053 
Dihydropyrimidinase-related protein 3 CRMP4b (DPYSL3) 1.392175 0.00054 
Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating (NSDHL) 1.397111 0.00075 
Importin subunit alpha-4 (KPNA3) 1.138781 0.0008 
Tubulin beta-6 chain (TUBB6) 1.31872 0.00091 
Peptidyl-prolyl cis-trans isomerase B precursor (PPIB) 1.240009 0.00105 
Actin, cytoplasmic 1 (ACTB) 1.582567 0.00118 
Aspartate aminotransferase, cytoplasmic (GOT1) 1.337512 0.00136 
Carboxypeptidase E precursor (CPE) 1.614357 0.00146 
Cathepsin D precursor (CTSD) 1.29219 0.00151 
Cytoplasmic dynein 1 light intermediate chain 1 
(DYNC1LI1) 1.254479 0.00178 
AP-3 complex subunit mu-1 (AP1M1) 1.549883 0.00201 
Aspartate aminotransferase, mitochondrial (GOT2) 1.234478 0.00216 
Protein ERGIC-53 precursor (LMAN1) 1.638345 0.00249 
Ubiquitin-40S ribosomal protein S27a precursor (RPS27A) 1.239542 0.00262 
Tricarboxylate transport protein, mitochondrial (SLC25A1) 1.244248 0.00341 
Target of Myb protein 1 (TOM1) 1.204444 0.00856 
Amine oxidase [flavin-containing] B (MAOB) 1.240643 0.00994 
Collagen alpha-1(I) chain preproprotein (COL1A1) 1.137343 0.01514 
Filamin-C isoform 2 (FLNC) 1.154882 0.01587 
26S protease regulatory subunit 10B (PSMC6) 1.803936 0.01715 
Prostaglandin reductase 1 (PTGR1) 1.265975 0.01813 
Annexin A1 (ANXA1) 1.141198 0.01956 
Acyl-coenzyme A thioesterase 9 (ACOT9) 1.143652 0.02172 
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Signal transducing adapter molecule 2 (STAM2) 1.40476 0.02202 
Proteasome subunit beta type-5 (PSMB5) 1.142082 0.02283 
COP9 signalosome complex subunit 5 (COPS5) 1.261288 0.02389 
Elongation factor 1-beta (EEF1B) 1.152118 0.02649 
Muscleblind-like protein 2 (MBNL2) 1.691183 0.02738 
Secretory carrier-associated membrane protein 1 (SCAMP1) 1.248962 0.02804 
Cytosolic non-specific dipeptidase (CNDP2) 1.225636 0.02967 
Voltage-dependent anion-selective channel protein 2 
(VDAC2) 1.204845 0.03108 
Vacuolar protein sorting-associated protein 35 (VPS35) 1.091945 0.03126 
Actin, aortic smooth muscle (ACTA2) 1.412265 0.03331 
Cytochrome b5 (CYB5A) 1.227659 0.03435 
Proteasome subunit beta type-6 precursor (PSMB6) 1.149633 0.03725 
Elongation factor 1-gamma (EEF1G) 1.145832 0.03845 
Coronin-1C (CORO1C) 1.207869 0.03855 
Proteasome subunit alpha type-7 (PSMA7) 1.192553 0.03971 
 
 
Table A11. Table showing the top 40 peptides that were upregulated and top 40 peptides that were 
downregulated from mass spectrometry. Potential gene targets were selected from this group on the 
basis of statistical significance and fold change. 
